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Zusammenfassung   1 
ZUSAMMENFASSUNG 
Typische Merkmale von Krebserkrankungen sind unkontrolliertes Wachstum, 
Streuung der Tumorzellen in umliegende Gewebe und letztlich auch die Resistenz 
gegen verschiedene Therapieansätze. Besonders letzteres zeigt den Bedarf an 
neuen, innovativen Behandlungsmöglichkeiten wie die adenovirale Onkolyse. Dabei 
werden Tumorzellen mit tumorspezifisch replikationsfähigen oder onkolytischen 
Adenoviren (Ad) infiziert und durch deren lytischen Replikationszyklus zerstört.  
Die Expression therapeutischer Gene mit Hilfe von onkolytischen Ad ist ein neues 
und vielversprechendes Konzept zur Behandlung von Krebs. Neben der Art des 
Transgens ist die Effizienz und Kinetik der Transgenexpression entscheidend. Das 
Ziel des Projektes war es das Transgen so in das virale Genom zu inserieren, dass 
seine Expression nach der viralen Replikation erfolgt. Diesbezüglich habe ich das 
Reportergen Luziferase mit Hilfe einer Internen Ribosomen Bindungssequenz, einer 
selbst spaltenden 2A-Sequenz oder einer zusätzlichen Spleiß-Akzeptor Sequenz in 
die späte Transkriptionseinheit des adenoviralen Genoms eingefügt. Für eine 
Melanom-spezifische, virale Replikation ersetzte ich den Promotor des essentiellen 
viralen Gens E1A durch den Melanom-spezifischen Tyrosinase Promotor. Während 
alle onkolytischen Ad dieselbe Zytotoxizität in Melanomzellen zeigten, war der 
lytische Effekt der Melanom-spezifischen Viren in nicht melanotischem Gewebe um 
den Faktor 10 – 1000 reduziert. Meine Ergebnisse zeigten, dass die Spezifität der 
Transgenexpression von der Strategie der Transgeninsertion im Virusgenom 
abhängt. Die höchste Spezifität der Luziferasexpression konnte für die Kombination 
von transkriptionellem Targeting und Transgenexpression mittels alternativen 
Spleißens gezeigt werden. Zur Verknüpfung von Virustherapie und molekularer 
Chemotherapie inserierte ich ein Prodrug-aktivierendes Gen mittels optimierter 
Spleiß-Akzeptor Sequenz in das virale Genom. Dieser Ansatz resultierte in 
indirektem, transkriptionellem Targeting der genetischen Prodrug-Aktivierung und 
zeigte eine verbesserte Effizienz der Onkolyse in der Kombinationstherapie.  
Die therapeutische Anwendung von onkolytischen Ad würde deutlich von einem 
gerichteten Tumorzelleintritt profitieren, der durch den natürlichen Ad Tropismus 
nicht gegeben ist. Dies erfordert die Ablation des nativen Ad Tropismus und den 
Einbau Zell-bindender Liganden. Die kurzen Fiberproteine des Ad41 (Ad41s) 
Kapsids konnten bereits aufgrund ihrer reduzierten Lebertransduktion erfolgreich als 
Ausgangsformat für die Tropismusablation eingesetzt werden. Basierend auf Studien 
bezüglich Insertionspositionen für Peptidliganden im Ad41s Fiberprotein war mein 
Ziel den Replikationszyklus von Ad mit derartigen Kapsidmodifikationen zu 
untersuchen. Mittels des Modellpeptides RGD konnte die Produktion der 
onkolytischen Ad, welche eine interne RGD Insertion in unterschiedlichen Loops des 
Fiberproteins aufweisen, gezeigt werden. Abhängig von der Insertionsposition hat 
sich die Genexpression der frühe und späte viralen Gene der Fiber-Chimären Ad 
deutlich unterschieden. Die Viren wiesen im Vergleich zum Wildtyp Ad5 eine 
reduzierte Zytotoxizität auf, welche unabhängig von der Insertionsposition des 
Peptids war. Die Ergebnisse deuten auf eine reduzierte oder verspätete 
Viruszusammensetzung hin. Für den gerichteten Krebszelleintritt wurde ein kürzlich 
beschriebenes, EphA2-bindendes Peptid in eine definierte Position des Ad41s 
Fiberproteins eingebaut. Das resultierende Virus konnte spezifisch EphA2-positive 
Zellen infizieren, aber es wies im Vergleich zur entsprechenden Kontrolle ein deutlich 
geringeres lytisches Potential auf.  
Die Kombination von effektiver Onkolyse mit einer gerichteten Gentherapie konnte in 
dieser Arbeit eindrucksvoll gezeigt werden. Des Weiteren liefert diese Studie wichtige 
Grundlagen für die Entwicklung von Peptid-abhängigem Zelleintritt onkolytischer Ad. 
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1. SUMMARY 
Cancer is characterized by growing incidence, early metastasis, and resistance 
against effective treatment for advanced disease, suggesting a pressing need for 
novel therapeutic approaches. Recombinant adenoviruses (Ad) have emerged as 
promising agents in therapeutic gene transfer, genetic vaccination and virotherapy. 
Virotherapy is defined as killing of cancer cells by specific virus infection, replication, 
cell lysis and virus spread by so called oncolytic viruses.  
“Armed” oncolytic Ad in which a therapeutic gene is genetically engineered into the 
virus and dependent on the tumour-selective replication of the virus for expression, 
represent a new and promising strategy for cancer treatment. This was achieved by 
using either an internal ribosomal entry site, a ‘self-cleaving’ 2A peptide or by an 
additional splice acceptor site to insert the reporter gene luciferase into the late 
transcription unit. In addition, I engineered novel melanoma-targeted, conditionally 
replicative Ad by replacing the promoter of the essential viral gene E1A with a 
cassette containing a human tyrosinase enhancer/promoter construct. While all 
oncolytic adenoviruses showed nearly similar cytotoxicity in melanoma cells, the 
melanoma specific Ads had a 10 – 1000 fold lower cytopathic effect in cell lines 
derived from various nonmelanocytic tissues. I showed that the mode of transgene 
expression and the locale of transgene insertion into the virus genome critically 
determine the efficacy of this approach. The most specific transgene expression (up 
to 1500 fold) was observed for an Ad which combines the tyrosinase promoter and 
the transgene expression by alternative splicing. In summary, I could show that 
transcriptional targeting combined with splice acceptor site mediated transgene 
expression is feasible and results in the highest levels of selectivity for replication and 
transgene expression. To combine the benefit of viral oncolysis with molecular 
chemotherapy, I inserted a suicide gene for gene directed enzyme prodrug therapy 
via optimized splice acceptor site into the virus genome. This approach resulted in 
indirect transcriptional targeting of genetic prodrug activation by the “armed”, 
melanoma specific Ad as well as in increased therapeutic effect of the oncolytic Ad.  
Therapeutic applications of Ad would benefit form a targeted virus cell entry into 
cancer cells. Such tropism-modification of Ad requires the ablation of their natural cell 
binding properties and the incorporation of cell-binding peptides. The short capsid 
fiber proteins of Ad subgroup F has recently been suggested as a tool for genetic Ad 
detargeting based on the reduced liver infectivity of corresponding fiber chimeric Ad-
vectors in vitro and in vivo. Based on previous studies to determine functional 
insertion sites for peptide ligands into the Ad41 short fiber of Ad-vectors, I 
investigated the lytic potency of oncolytic Ad engineered with peptide ligands inserted 
in the Ad41 fiber. With the RGD model peptide I could demonstrate that the 
production of oncolytic Ad with ligands inserted into different loops of the fiber is 
feasible. Depending on the insertion site, viral replication, early and late viral gene 
expressions of the fiber-chimeric Ad differs in comparison to matching control 
viruses, carrying the same ligand in the HI loop of Ad5 fiber. The cytotoxicity of fiber-
chimeric viruses is reduced irrespective of the insertion site. The results indicate that 
a decreased or delayed virus assembly could be a reason for my observation. 
Furthermore, I used fiber-chimeric virus as a novel platform for genetic targeting of 
Ad cell entry. I generated an ablated virus which targets EphA2 receptor expressing 
melanoma cells via inserted EphA2 peptide ligand. However, the lytic potency of the 
chimeric fiber Ad was significantly reduced compared to the matching control virus.  
Summarized, I developed an oncolytic Ad which combined effective oncolysis with 
targeted prodrug activation therapy of melanoma and I generated an oncolytic Ad 
showing peptide-dependent cell entry for targeted oncolysis of melanoma. 
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2. INTRODUCTION 
2.1. Cancer and cancer therapies 
Cancer is a disease of chaos, a breakdown of existing biological order within the 
body. More specifically, the disorder seen in cancer appears to derive from a 
population of cells, which display uncontrolled growth, invasion of adjacent tissues 
and metastasis (spread to other location in the body via lymph or blood). Most of the 
1013 cells in our body can cross over the border from normalcy to malignancy and 
transform into a cancer cell. This explains why cancer can affect all tissues. 
Depending on their origin they are classified as carcinoma (malignant tumours 
derived from epithelia), sarcoma (tumours derived from a variety of mesenchymal cell 
types), lymphoma (malignancies derived from hematopoietic tissues, including the 
cells of the immune system), blastoma (tumours caused by malignancies in precursor 
cells) and melanoma (tumours of melanocytes). These observations about the origin 
of cancer force us to consider our thinking about how cancers are formed or what 
can trigger a cell to transform into a cancer cell. Is it an inherent risk of incessant cell 
divisions during normal biological processes or are there some factors, which 
increase the risk of cancer?  
In 1915, Katsusaburo Yamagiwa published the first experimental induction of 
tumours by treatment of rabbit skin with a chemical carcinogen (coal tar condensate). 
Together with Peyton Rous’s observation, that tumour formation can be induced by a 
chicken sarcoma virus, the first evidences that some types of cancer are associated 
with specific exposures, virus infection or lifestyle, were given.  
These days, much more is known about the cause of cancer and the state of 
knowledge is that cancer is a genetic disease. Heredity and environment (chemical 
carcinogens, ionizing radiation, viral or bacterial infection) are the two factors, which 
mainly determine the risk of cancer. The avoidance of certain cancer causing factors 
in diet and lifestyle is associated by up to 50% reduction in the risk of dying from 
cancer in the West. For example, tobacco smoking is associated with many types of 
cancers, and causes 90% of all lung cancers. Hepatitis B and C viruses and human 
papillomaviruses play key roles in development of different cancer types such as 
cervical cancer, as well. Furthermore, laboratory research supported that only 1 in 
1017 cell divisions lead to a clinically detectable cancer, so that the risk to develop 
cancer caused on an error during the cell cycle is less than the epidemiologically 
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observed risk. However, there are still open questions in the process of cancer 
pathogenesis, which need to be explained and understood.  
In the eighteenth century, the first cancer therapy was described by John Hunter 
(1728-1793). He suggested that surgery could be a method to remove the tumour 
and cure cancer. The first non-surgical treatment came up with the discovery of X-
rays by Wilhelm Conrad Roentgen and with the discovery of natural radioactivity by 
Henry Becquerel. Most of the anticancer treatments used today were developed in 
the period before 1975. In this time the knowledge about the genetic and biochemical 
mechanisms of cancer pathogenesis was marginal. This could be one explanation 
why most approaches for cancer therapy have been not so successful. For example, 
in 1970 in the United States, the 5 years survival rate of patients diagnosed with lung 
cancer was 7%. Three decades later, this number had risen to 14%, a relatively 
minor enhancement. However, a few types of cancer could be already cured such as 
testicular cancer. 
Hence, one of the most difficult questions often posed to cancer researchers still is: 
How is cancer going to be cured? In regard of the today’s knowledge it doesn’t exist 
a simple answer, which advises a single therapy that will cure all cancers, because 
cancer is not a single disease. Instead, there will several individual anti-cancer 
therapies, which are targeted specific ally to one or a small group of cancer types. In 
2001 the first company came out with a targeted cancer therapy: Trastuzumab 
(Herceptin).It blocks human epidermal growth receptor 2, which is overexpressed in 
25% of all breast cancers and in almost half of glioblastomas. Furthermore Gleevec, 
Avastin and Rituxan come to mind here. Gleevec was developed to block the 
tyrosine kinase activity of Bcr-Abl fusion protein, which is constantly active in chronic 
myelogenous leukaemia (CML). Rituxan can be used for the treatment of B-cell 
tumours. But there are still a high number of research projects on going to develop 
new anti-cancer therapies. These therapeutic agents included small-molecular-
weight drugs, proteins, monoclonal antibodies, immunotherapy, gene therapy and 
virotherapy.  
 
2.2. Gene therapy for cancer treatment 
The term gene therapy originally encompasses a range of treatments that use 
correction of a defective gene function as the solution to cure genetic disorders. 
Defective genes, which are the reason for the disease, are mostly replaced with the 
intact genes for restoring the lost gene function in the patient. This should result into 
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an elimination of the disease. For that purpose, DNA segments of the gene of 
interest are cloned into so called vectors, which are able to deliver the healthy gene 
into the target cells. A wide range of these vectors were investigated either ex vivo or 
in vivo and shown remarkable efficacy. A variety of different methods has been 
developed for transferring the therapeutic gene into the cell such as microinjection, 
electroporation, liposome formulations, gene gun and the use of viral vectors. 
Meanwhile, viral vectors have evolved to become the most common gene delivery 
system based on their high efficiency. Several types of viral vectors, including 
retrovirus, adenovirus, adeno-associated virus (AAV), and herpes virus, have been 
used for gene therapeutic applications. 
In 1990, the first person was successfully treated with viral gene therapy. W.F. 
Anderson could cure severe combined immune deficiency (SCID) by delivering the 
adenosine-deaminase (ADA) gene via a retrovirus into the stem cells of a four year 
old girl (Beardsley et al. 1990; Culver, Anderson et al. 1991). In the mean time, only 
one mutation which causes SCID is curable by gene therapy. Furthermore, gene 
therapies are still aimed to hereditary genetic diseases, as cystic fibrosis, duchenne 
muscular dystrophy, arthritis and lysosomal storage diseases. However, the most 
clinical treatments involving gene therapy are directed against cancer. Many 
approaches for cancer gene therapy try to compensate mutations of either tumour 
suppressor genes or oncogenes. The tumour suppressor genes retinoblastoma (RB), 
p53, adenomatous polyposis coli (APC), Breast Cancer 1 (BRCA 1) and p16INK4a are 
often mutated and become inactive in many tumour types. A promising viral vector is 
a replication-incompetent adenovirus transferring the p53 gene to cancer cells 
resulting in inhibition of angiogenesis and tumour cell invasion as well as apoptosis 
through induction of Fas/CD95-mediated cell death (Merritt, Roth et al. 2001; 
Swisher, Roth et al. 2003).  
An additional and innovative approach for cancer gene therapy is the concept of 
boosting the immune system in order to target and destroy cancer cells. Therefore, 
the anti-tumour immune response is augmented by delivering immunostimulatory 
genes into cancer cells. These transgenes are often cytokines that produce further 
pro-inflammatory immune stimulating molecules and encourage the development of 
an anti-tumour immune response, mainly cytotoxic T-lymphocytes (CTLs), which are 
able to kill the cancer cells (Nawrocki, Wysocki et al. 2001; Handerson, Mossman et 
al. 2005). For example, in a phase I trial an adenovirus was used to transfer the 
cytokine IL-2 into high-risk localized prostate cancer to augment an inflammatory 
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response (Trudel, Trachtenberg et al. 2003). Another very promising immunotherapy 
based on viral vectors resulted in the successfully treatment of metastatic melanoma 
in 2006. A retrovirus-mediated delivery of a melanoma-specific T-cell receptor for an 
adoptive T-cell therapy demonstrated to cause tumour recognition by autologous 
lymphocytes from peripheral blood (Morgan, Dudley, Wunderlich et al. 2006). 
Gene-directed enzyme-prodrug therapy (GDEPT) is also another promising approach 
for gene therapy. This prodrug based cancer therapy consists of two components: a 
nontoxic prodrug, which can be applicated systemically at high doses, and a prodrug 
activating enzyme. Whereas the dose dependent side effect limited the traditional 
chemotherapy, the prodrug therapy tries to minimize this toxicity by selectively 
converting the chemotherapeutic agent by the enzyme at the target tumour site. 
Ideally, surrounding tumour cells are also killed by the activated chemotherapeutic 
drug (local bystander effect). Predominantly adenoviral and retroviral vectors have 
been used in GDEPT clinical trials. Thymidine kinase (TK) and cytosine deaminase 
(CD) and their respective prodrugs ganciclovir (GCV) and 5-flourocytosine (5-FC) are 
the most advanced prodrug based therapies, which have shown increased 
therapeutic potency (Kirn, Niculescu-Duvaz et al. 2002; van Dillen, Mulder et al. 
2002). In this regard, Immonen et al. engineered an adenoviral vector coding for the 
thymidine kinase (HSV-TK), which improves in combination with the prodrug 
ganciclovir survival of patients with malignant glioma (Immonen et al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1: Prodrug activation system FCU-1 / 5-FC. Schematic outline of the mechanism of prodrug 5-
fluorocytosine (5-FC) activation by the suicide gene FCU-1, which encodes a fusion protein derived 
from the yeast cytosine deaminase (FCY-1) and uracil phosphoribosyltransferase genes (FUR-1) 
(Erbs et al. 2000). 5-FUMP, 5-fluoro-UMP  
 
 
Of note, a new and highly potent suicide gene is FCU-1, which encodes a fusion 
protein derived from the yeast cytosine deaminase (FCY-1) and uracil 
phosphoribosyltransferase genes (FUR-1) (Erbs et al. 2000; Fig. 1). The FCY-1 
domain deaminates the nontoxic prodrug 5-fluorocytosine (5-FC) to its highly toxic 
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derivative 5-fluorouracil (5-FU). Its active metabolite is 5-FUTP, which can either be 
incorporated into RNA resulting in the inhibition of the mRNA processing or can be 
converted to 5-FUMP by FUR1. The toxic 5-FUMP inhibits the cellular enzyme 
thymidylate synthases which is required for DNA synthesis. Erbs et al. have 
suggested that the insertion of the fusion gene FCU-1 in cancer cell significantly 
increases cancer cell death after 5-FC application. Interestingly, and in contrast to 
GCV and its toxic metabolites, 5-FC and 5-FU can penetrate cells by passive 
diffusion and expand the local toxic effects to neighbouring, uninfected cells, 
irrespective of the presence of specific cellular connexins. The second advantage of 
the FCU-1/5-FC system is the more effective prodrug activation in vitro and in vivo in 
comparison to TK/GCV and CD/5-FC (Erbs et al. 2000). Other enzyme/pro-drug 
combinations are Nitroreductase and CB1954 (Braybrooke et al. 2005) as well as 
CYP2B6 and Cyclophosphamide (Barzon et al. 2004; Singh et al. 2001). 
Meanwhile, viral vectors have been evaluated as a promising new tool for the 
development of novel cancer gene therapies. The key requirement of this approach 
is the stringent delivery of the appropriate gene into tumour cells without harming 
healthy cells. Therefore, the therapeutic genes have to be expressed only in cancer 
cells in order to act in a specific and safe manner. The main approaches by which 
viral vectors and thus transgene expression can be made tumour selective are by 
modification of viral cell binding and entry (= transductional targeting), by specific 
regulation of gene expression (= transcriptional targeting) and especially by the 
combination of both targeting strategies. Transductional targeting has been realised 
by modification of the viral tropism from the native receptor to a surface protein 
preferentially expressed on cancer cells through genetic engineering of the virus 
capsid (Glasgow, Everts et al. 2006) or by conjunction with bispecific adapters 
(Haisma et al. 2000). Transcriptional targeting has been achieved by insertion of a 
tissue/tumour-selective promoter driving the expression of therapeutic genes 
(Nettelbeck, Jerome et al. 2000). For cancer therapy, a few promoters have already 
been used, such as the ErbB-2 promoter (Pandha et al. 1999) and human alpha-
lactalbumin promoter (Anderson et al. 1999) for breast cancer and the prostate-
specific-antigen (PSA) promoter for prostate cancer (Pang, Taneja et al. 1995; 
Lee,Liu et al. 1996; Martiniello-Wilks, Garcia-Aragon et al. 1998). In this regard, the 
tyrosinase promoter (Vile and Hart 1993; Hughes, Wells et al. 1995) is a promising 
candidate for targeting malignant melanoma. Tyrosinase is a pigment cell-restricted 
enzyme that catalyzes the rate limiting step in melanin synthesis. Mechanisms of 
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tissue-specific transcriptional control were intensively explored beginning in the 
1980s, resulting in promoter studies as exemplified for genes associated with 
pigmentation pathways in melanocytes (Kluppel et al. 1991; Shibata et al. 1992; 
Lowings et al. 1992; Yavuzer and Goding, 1993; Ganss et al. 1994; Bentley et al. 
1994). Subsequently, tissue specific promoters were optimized for gene therapy 
applications, thus as the tyrosinase promoter (Vile and Hart 1993; Siders et al. 1996). 
The study of Siders et al. describes optimized regulatory sequences of enhancer and 
promoter derived from human tyrosinase promoter region that is sufficient for high-
level, tissue-specific transcription in pigment lineage cells. However, these targeting 
strategies imply that the expression of the therapeutic gene is highly specific and 
efficient expressed at high level in the tumour cells. 
 
2.3. Virotherapy for cancer treatment 
In the quest to develop novel cancer therapies, virotherapy, or viral oncolysis, has 
recently emerged as a promising new modality to specifically kill tumour cells. It is 
defined as killing of cancer cells by tumour-selective virus infection, replication and 
concomitant cell lysis. The newly synthesized oncolytic viruses are able to spread 
through tumour mass and start a new therapeutic cycle by virtue of viral replication 
and cell lysis. Key advantage of viral oncolysis is the amplification of the therapeutic 
agent in the patients’ tumour. 
Already in the beginning of the last century, a first case of viral anti-tumour activity 
was reported where a patient with cervical carcinoma showed significant tumour 
regression after rabbies vaccination (de Pace et al. 1912). More recent clinical 
reports have described the remission of Burkitt’s and Hodgkin’ lymphomas following 
natural infection with measles virus (Bluming and Ziegler et al. 1971; Taqi, 
Abdurrahman et al. 1981). The mechanisms of naturally occurring oncotropismus of 
some viruses are poorly understood but are likely to be found in the genetic and 
cellular changes acquired during carcinogenesis. For example, mouse fibroblasts are 
normally resistant to reovirus infection but become susceptible to virus infection 
following transformation of the ras-pathway, which is often constitutively activated in 
tumours (Coffey, Strong et al. 1998; Strong and Lee, 1996). Additional strategies are 
used for genetic engineering that facilitates targeting oncolytic viruses to tumour 
cells. On the one hand, tumour selectivity can be achieved by deleting of viral gene 
that are essential for viral replication in healthy tissue but are dispensable upon 
infection of transformed cells, or on the other hand by placement of a tumour-specific 
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promoter upstream of a viral gene, which is a key player of the viral replication (see 
chapter 2.4.3.1). The first viral gene deletion mutant was reported in 1991. In this 
herpes simplex virus I (HSV-I) the thymidine kinase gene was deleted, which is 
needed for nucleic acid metabolism and only produced at high concentration in 
proliferating cells, thus as tumour cells (Martuza et al. 1991). 
This knowledge provides the basis for clinical trials with potentially oncolytic viruses. 
In most studies oncolytic viruses have not been very successful in destroying 
tumours, yet. Several factors have been identified that could explain the marginal 
therapeutic benefit of previously investigated oncolytic viruses. In most cases the 
virus is neutralized by the host immune system and failed to impact tumour growth. 
Furthermore, efficient viral cell entry and spread within the tumour mass as well as 
potential cell killing are also an important requirement for a successful tumour 
remission. To overcome these hurdles, intensive research has aimed to genetically 
engineer viruses in order to optimize tumour specificity without harming their 
oncolytic potency. These days, optimized adenovirus (Hecht, Bedford, Abbruzzese et 
al. 2003), herpes simplex virus I (Markert, Medlock, Rabkin et al. 2000), Vaccinia 
virus (Wallack, Sivanandham, Balch et al. 1998) and Newcastle disease virus 
(Batliwalla, Bateman, Serrano et al. 1998) are tested in phase II and phase III trials. 
 
2.4. Adenovirus and their use as gene therapy vector or oncolytic 
virus 
Several biological features have made adenovirus (Ad) a promising tool for anti-
cancer therapy. It is endemic in human population and its natural pathogenicity is 
related only with mild respiratory infection (Shenk et al. 1996). Also the adenoviral 
double stranded DNA genome exists only in episomal form in infected cells, thus 
avoiding the risk of insertion mutagenesis. Furthermore, Ads are highly stable and 
have the ability to infect a wide variety of dividing and non-dividing cells, as well as 
possessing established procedures for manufacturing and production of high viral 
titers, which is essential for clinical utility. Beside these features, Ads own the 
capacity of transgene insertion (up to 8kb) without loss of replication potential and 
importantly, the technology and genetic knowledge to manipulate the viral genome is 
also already available so that Ads can be modified to become tumour selective. 
Consequently, Ads have already been used in clinical trails and in regard to these 
studies Ads offer a powerful, attractive therapeutic for cancer. 
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2.4.1. Adenoviruses: Virion Structure, Cell Entry and Genome 
Organization 
2.4.1.1. Serotypes and Virus Structure 
Since the first isolation of Ad from adenoid tissue by Rowe and colleagues (Rowe, 
Huebner et al. 1953) a large number of different species, and more than 100 different 
serotypes have been reported, among of these 52 in humans. The human Ad 
serotypes have been sub grouped from A to F based on genome size, organization, 
homology, nucleotide composition, oncogenicity and hemagglutination properties 
(Fields, Knipe et al. 1996). The most well studied serotypes are the group C viruses, 
which consist of the Ad serotypes 1, 2, 5, and 6. So far, the most gene therapy and 
virotherapy studies have been carried out using the serotypes 2 and 5 (Ad2 and 
Ad5). Since the discovery of Adenovirus (Ad) rapid advances have been made in the 
understanding of molecular virology. The genome structure and organization, capsid 
configuration and lytic replication cycle of adenoviruses are exceptionally well 
described in detail (Zhang 1999; Russel 2009) 
 
 
Fig.2: Schematic diagram of the Ad5 virion. 
Adenoviruses are non-enveloped particles of 70-90nm in 
diameter with an inner nucleoprotein core. The double 
stranded DNA is packaged within an icosahedral protein 
capsid. The major protein of the capsid is the trimeric 
hexon that constitutes the 20 triangular faces of the 
icosahedron. The penton base and fiber proteins are 
localized at each of the 12 vertices of the Ad capsid. 
(origin: http://biomarker.cdc.go.kr:8080/index.jsp) 
 
 
 
 
 
Adenoviruses are non-enveloped, icosahedra particles of 70-90nm in diameter with 
an inner nucleoprotein core containing the Ad genome, which is encased in a protein 
shell, the so-called capsid (Fig. 2). The capsid is comprised of three major protein 
components: hexon, penton, and fiber. Hexon, a stable trimer, is the most abundant 
structural component and constitutes the 20 triangular faces of the icosahedron. The 
pentons contain a pentameric penton base, which associate with trimeric fiber 
proteins to form penton capsomer complexes. The penton acts as an anchor for the 
fiber protein, which extends outward from the virion like an antenna (Philipson 1984; 
Rux and Burnett 2004). 
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The fiber is a homotrimer in which three identical polypeptides are arranged in 
parallel orientation (Stouten, Sander et al. 1992). Each of these polypeptides consists 
of three distinct domains: tail, shaft, and knob. The tail domain non-covalently binds 
fiber to the penton base, whereas the shaft domain extends away from the virion 
surface. The C-terminus of the trimer forms a propeller-like knob (Xia, Henry et al. 
1994), which is responsible for binding to the host’s primary cellular virus receptor. 
Furthermore, the knob domain is essential for trimerization and stabilizing the trimeric 
configuration of the fiber, which has been shown to be crucial for association of the 
fiber with the penton base in the assembly of native virions (Novelli and Boulanger 
1991).  
 
2.4.1.2. Cell Binding and Entry 
The primary receptor for many human Ad serotypes, including the subgroup C 
serotype 2 and 5 viruses, is the coxsackie- and adenovirus-receptor (CAR) 
(Bergelson, Cunningham et al. 1997; Tomko, Xu et al. 1997; Roelvink, Mi Lee et al. 
1999). CAR is a transmembrane protein and is present in many human tissues 
including heart, lung, liver, and brain (Howitt, Anderson et al. 2003). Recent research 
has shown that besides CAR Ads can use other molecules as receptors as well. The 
coagulation factor X is discussed to mediate liver transduction via the viral hexon 
protein in vivo (Waddington et al. 2006).  
 
 
Fig.3: Cell binding mechanism of Ad5 
virion. Ad5 binds to its receptor CAR 
through the fiber. The Fiber protein 
consists of a tail, shaft and knob domain. 
Subsequently, integrins interact with the 
RGD peptide motif in the penton base and 
facilitate cell entry by endocytosis. 
 
 
 
 
 
 
 
Introduction   12 
The best known are major histocompatibility complex I (MHCI) and heparan sulfate 
glycosaminoglycans (Hong, Karayan et al. 1997; Dechecchi, Melotti et al. 2001). 
In contrast, most subgroup B viruses (particularly serotypes 3, 11, 14, 16, 21, 35, 50) 
seem to bind to the plasma membrane protein CD46 ubiquitously expressed (Zhang 
and Bergelson 2005). 
Cell infection for most non-group B viruses starts with high-affinity binding to CAR via 
the fiber knob domain (Fig. 3). Following attachment, the Arg-Gly-Asp (RGD) motifs 
of the penton base interact with cellular integrins αvβ3 and αvβ5, which initiates viral 
endocytosis within a clathrin-coated vesicle (Wickham, Mathias et al. 1993). The 
acidic environment of the endosome alters the topology of the virus as capsid 
components dissociate, which ultimately induces escape of the virions into the 
cytoplasm. With the help of microtubules the virions translocate toward the nucleus 
pore complex. Meanwhile, the viral particle disassembles and viral DNA enters the 
nucleus via the nuclear pore where it associates with histone molecules (Meier and 
Greber 2003) and activates viral gene expression and genome replication. 
 
2.4.1.3. Genome Organization and Viral Replication 
The Ad genome itself is a linear, double-stranded DNA that is approximately 36kb in 
length with inverted terminal repeats (ITRs) at both ends. Both ITRs in company with 
the encapsidation signal on the left end, act as cis elements, which are necessary for 
viral DNA replication and packaging. The genome is subdivided in five early (E1A, 
E1B, E2, E3 and E4), four intermediate (IVa2, IX, VAI, and VAII) and one late 
transcription units (Fig. 4).  
 
 
 
Fig.4: Schematic representation of adenovirus genome and transcription units. The central solid 
line represents the viral genome. Positions of the left and right ITR (inverted terminal repeats), the 
packaging sequence (ψ), the early transcription units (E1A, E1B, E2, E3 and E4), and the major late 
transcription unit (major late promoter (MLP), L1-L5) are shown. Arrows indicate the direction of 
transcription (McConnell and Imperiale 2004). 
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The first viral protein to be expressed is E1A, which activates transcription of the 
early transcription units and induce the host cell to enter S phase by interfering with 
proteins of the retinoblastoma (Rb) pathway, thereby providing an optimal 
environment for virus replication. Rb acts as a tumour suppressor by inhibiting cell 
cycle progression via binding to E2F, a transcriptional activator that promotes 
expression of genes necessary for driving cells into S phase. E1A proteins are able 
to sequester Rb, which releases E2F, allowing it to drive the expression of cellular 
genes involved in cell cycle entry and DNA replication. Such a cell cycle deregulation 
would normally lead to the accumulation of the tumour suppressor p53, followed by 
apoptosis. Expression of the adenoviral E1B genes prevents premature cell death, 
thus allowing viral replication to occur unimpeded. The E1B55K protein directly binds 
to p53, induces its degradation and inhibits its ability to induce expression of pro-
apoptotic genes (Sarnow, Ho et al. 1982; Ben-Israel and Kleinberger 2002). 
However, adenovirus infection also stimulates apoptosis by a p53-independent 
mechanism, which is blocked by the E1B19K protein. The E1B19K protein shares 
structural and sequence homology with cellular Bcl-2 proteins. Proteasomal 
degradation of the critical anti-apoptotic Bcl-2 family member Mcl-1 by E1A 
expression results in the release and activation of the pro-apoptotic Bcl-2 family 
member BAK, normally bound by Mcl-1 in uninfected cells. E1B19K directly binds to 
BAK and another pro-apoptotic protein, BAX, inhibiting their co-oligomerization and 
forming pores in the outer mitochondrial membrane, allowing survival of infected cells 
(White, Cipriani et al. 1991; Han, Sabbatini et al. 1996; Han, Modha et al. 1998; 
Sundararajan, Cuconati et al. 2001; McNees and Gooding 2002). In Ad-E1B19K 
mutants, formation of such BAK-BAX heterocomplexes correlate with the release of 
cytochrome c and Smac/DIABOLO from the intermembrane space of mitochondria, 
resulting in activation of the downstream caspases 9 and 3 and the ensuing 
apoptosis program (Cuconati, Degenhardt et al. 2002).  
Further, the E2 region encodes for proteins needed for viral DNA replication: DNA 
polymerase, preterminal protein and single-stranded DNA binding protein (de Jong, 
van der Vliet et al. 2003). Even though adenovirus replication takes place in the 
nucleus, it requires its own enzymatic machinery because of its chromosomal 
structure. The viral genome does not have telomeres, so the integrity of the DNA 
ends is ensured by the preterminal protein (pTP), which is covalently linked to the 5´ 
end of each genome strand and acts as a primer for the viral DNA polymerase. 
Additional, the DNA-binding protein (DBP) is encoded in early region E2a. It is a 
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multifunctional protein involved in several aspects of the adenovirus life cycle, 
including an ability to modulate transcription. 
The proteins of the E3 unit subvert the host immune response and allow persistence 
of infected cells by reducing the presentation of viral antigens of major 
histocompatibility complex (MHC) class I determinants (Bennett, Bennink et al. 
1999). Furthermore these proteins protect the infected cell from lysis by TNF-α and 
Fas by clearing their receptors from the cell surface (Gooding, Ranheim et al. 1991; 
Shisler, Yang et al. 1997). In contrast to the immunomodulatory functions of all other 
E3 genes the E3 11.6kd protein, which is also referred to as the adenovirus death 
protein (ADP), increases the efficiency of lysis and release of progeny virus from the 
infected cell and accumulates mainly during the late stage of infection (Tollefson, 
Ryerse et al. 1996; Tollefson, Scaria et al. 1996). Of note, it is not necessary for 
adenoviral replication in vitro. 
The E4 proteins are known to play a role in DNA replication, late gene expression, 
and splicing (Tauber and Dobner 2001); together with other early proteins they also 
mediate the inhibition of the production, maturation, or stability of host cellular DNA, 
RNA and/or proteins. 
Among the intermediate transcription unit the IX gene acts as a transcriptional 
transactivator as well as a minor component of the viral capsid that increases virus 
stability (Sargent, Meulenbroek et al. 2004). The IVa2 protein is crucial for assembly 
of adenoviruses and packaging of viral DNA (Zhang and Imperiale 2003). The VA 
(VA I and VA II) genes encode for short stretches of RNA (approx. 200 bases), which 
form double-stranded hairpin-loop structures that are essential for maintaining 
translation of adenoviral genes by inhibiting the cellular protein kinase R (PKR) 
pathway, which otherwise would block protein translation and finally trigger apoptosis 
in order to prevent further viral spread.  
The adenoviral late genes are divided into five subunits, L1-L5, and are transcribed 
from one promoter, the major late promoter (MLP) that is particularly efficient during 
late infection, which starts with replication of the virus genome. The major late 
transcription unit encodes up to 20 different mRNAs, all of which are derived from a 
long precursor transcript by differential splicing and polyadenylation. These 
transcripts primarily encode structural proteins of the virus and other proteins 
involved in virion assembly. Viral particle assembly in the nucleus starts about 8h 
post-infection (dependent on the cell type) and results in the production of 
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approximately 104 new viral particles per cell. At approximately 30 – 40 h after virus 
entry the new virus generation is released by cell lysis (Büchen-Osmond, 2003). One 
protein that facilitates the spread of progeny virus involves ADP that localizes to the 
nuclear membrane, endoplasmatic reticulum and golgi apparatus where it interacts 
with a protein called MAD2B. However, how this interaction leads to cell death and 
by which mechanism the cell dies still remains uncertain. Adenovirus-induced cell 
death was long presumed to be apoptotic (Hall et al., 1998) but recent studies either 
suggest a “necrosis-like programmed cell death” (Abou El Hassan, van der Meulen-
Muileman et al. 2004) or autophagy to be involved in the death of adenovirus-
infected cells (Ito, Aoki et al. 2006). 
2.4.2. Adenoviral vectors 
In the last two decades, adenoviral vectors have received much attention as gene 
transfer agents and offer a wide variety of gene therapeutic applications. In the so 
called first generation of adenoviral vectors, the viral early region 1 (E1), and less 
often the early region 3 (E3), were substituted by transgenes. The E1 region encodes 
proteins necessary for the activation of viral promoters and for the expression of 
further early and late genes. Hence the E1 proteins are key regulators of viral 
replication and the removal of this region renders the vectors replication-defective. 
For the viral growth of E1 deleted adenoviruses helper cell lines are necessary to 
complement the E1 functions in trans. By transforming a human embryonic kidney 
cell line with sheared fragments of adenovirus type 5 DNA, which also includes the 
E1 region, the Ad producer cell line 293 was established (Graham, Smiley et al. 
1977; Fallaux, Bout et al. 1998; Schiedner, Hertel et al. 2000). The E3 region-
encoded proteins are not essential for the viral replication in vitro, and therefore, no 
helper cell lines are needed for the production of an E3 deleted adenoviral vector 
(Wold, Tollefson, Hermiston et al. 1995). The benefit of E1 / E3 double deleted 
vectors is a higher capacity for foreign DNA. Since adenovirus can package 
approximately 38 kb without affecting growth rate and viral titer (Bett, Prevec, 
Graham et al. 1993), E1 deleted virus can accept insertion up to 5.1 kb, while E1 / E3 
deleted adenoviruses can accommodate about 8.2 kb of transgene DNA.  
First generation adenovirus causes strong systemic immune response in vivo, chiefly 
due to the de novo synthesis of viral proteins at very low levels (Gilgenkrantz et al. 
1995; Yang, Su, Wilson et al. 1996). To avoid this significant immunogenicity, 
additional viral genes responsible for viral replication have been deleted, giving rise 
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to the second generation of adenoviral vectors. These are characterized by deletion 
of E1, E2 (Amalfitano, Hauser et al. 1998; Lusky, Christ et al. 1998) and E4 
(Armentano, Sookdeo et al. 1995) genes. A positive effect in regard to a reduction of 
an inflammatory response could be demonstrated only in some studies, however, 
others failed (Gao, Yang et al. 1996; Lusky, Christ et al. 1998).  
To further enhance the transgene capacity of adenoviruses, a third generation of 
vectors has been established. These so called “high capacity” or “helper-dependent” 
vectors (Kochanek et al. 1996; Parks et al. 1996; Fisher et al. 1996; Kumar-Singh) 
are deleted for all viral genes, but retain the two ITRs and the Ψ, as cis-acting signal 
required for viral replication and packaging, which allows up to 36kb transgene 
insertion. However, their viral replication, growth and purification turned out to be 
difficult due to complementation of viral protein functions by helper cell lines or helper 
viruses and need to be optimized. 
 
2.4.3. Oncolytic adenoviruses 
In the last two decades, genetically engineered oncolytic adenoviruses (OAds) that 
specifically target and destroy tumour cells by viral lysis, offer more and more the 
opportunity for the development of promising cancer therapies.  
 
 
 
 
 
 
 
 
 
 
 
Fig.5: Concept of adenoviral oncolysis. Oncolytic adenoviruses are derived from human 
adenoviruses via genetic modifications. Such modifications include the mutation or deletion of viral 
genes, or the insertion of tumour-specific promoters. Oncolytic adenoviruses infect tumour cells, 
replicate their genome, assemble new viral particles and kill the host tumour cell by lysis, resulting in 
the release of the progeny viruses. This new virus generation spreads, and starts a new cycle of virus 
replication and tumour cell killing. Genetic modifications of adenoviruses allow for efficacy 
enhancement and/or tumour cell restriction at various steps of the viral life cycle, such as viral 
infection, viral replication and/or virus release/tumour cell lysis. As a consequence, infection of normal 
cells by oncolytic adenoviruses and/or replication within these cells is impaired. Thus, the ideal 
oncolytic adenovirus represents an efficient and specific anti-cancer agent. 
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This strategy exploits their highly evolved quality of efficient cell entry and lytic 
property during virus replication to destroy tumour cells. The viral mediated tumour 
regression is propagated through the specific infection of adjacent tumour cells by 
the newly released progeny virus particles (Fig. 5).  
2.4.3.1. Strategies for restricting Ad replication to tumour cells 
The key requirement for adenoviral oncolysis is safety. This can be achieved through 
restriction of viral replication to cancer cells. Therefore, different approaches have 
been established. On the one hand, deletion (fully or in part) of early viral genes 
which are critical for viral replication in healthy cells but dispensable upon infection in 
cancer cells has been one strategy. Otherwise, the replacement of viral promoters 
with tissue or tumour-specific promoters has also successfully targeted viral 
replication to tumour cells. Of note, both mechanisms of transcritptional control are 
cellular genetic tools, which operate post entry.  
Most approaches for the development of oncolytic adenoviruses have focused on the 
genetic engineering of their early E1 genes. The E1 genes are the first genes 
expressed after viral cell entry and are the key regulator for viral replication. The two 
E1 genes E1A and E1B (E1B55K) have been mostly modified in order to achieve 
tumour selective replication. Normally, their proteins force the host cell to enter the S 
phase, an assumption for viral replication. A 24pb deletion in the E1A region avoids 
that the E1A protein is able to bind and inactivate the retinoblastoma protein (see 
chapter 2.4.1.3). In this regard, S phase induction by the OAds is ablated, which is 
dispensable in proliferating cells lacking a functional RB pathway. An example of an 
E1A mutated OAds is Ad5∆24 (dl992-947), which has a deletion of 24bp in the pRb-
binding domain of E1A (Fueyo et al. 2000, Heise et al. 2000). Efficiency of Ad∆24 
was shown in several tumour types, such as lung adenocarcinoma, prostate cancer 
and ovarian cancer (Bauerschmitz et al. 2002, Fueyo et al. 2000, Suzuki et al. 2001) 
and it also has been demonstrated that Ad∆24 replicates in cancer cells as efficient 
as wild type adenovirus, because other E1A functions that are mandatory for viral 
replication are retained. Another OAd, called dl1520 or ONYX-015 was derived by 
deletion of E1B55K (Bischoff et al. 1996). Since the tumour suppressor protein p53 
cannot be inactivated by binding E1B55K, apoptosis is induced in infected cells, 
aborting replication and spread of the virus (Bischoff, Kirn et al. 1996). Thus, the 
presumption was that ONYX-015 can only replicate in p53-deficient tumour cells. 
However, many approaches indicated that the proposed basis for selective 
replication is far more complex and not solely determined by p53 deficiency 
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(Geoerger et al. 2002, Kirn et al. 2001). In summary, these virus mutants revealed a 
proof of principle for tumour selectivity of adenoviral replication, a favourable safety 
profile in clinical trails and offer a basis for on-going research efforts. 
To achieve specificity of adenoviral replication, investigators have also used a 
second strategy based on exploiting transcriptional control regions. This so called 
“transcriptional targeting” deals mostly with placing the essential viral gene E1A 
under the control of tissue or tumour-specific promoters, which are preferentially 
active in tumour cells and inactive in normal cells. The first approach of a tissue-
specific OAd has been used for prostate cancer. The OAd Calydon CV706 was 
limited to prostate-specific antigen (PSA) -producing tissues, such as human prostate 
cancer cells, by insertion of the PSA gene promoter-enhancer element upstream of 
the E1A gene, which is needed to induce the viral replication cycle. This study 
showed, that CV706 was able to specifically destroy prostate tumours in xenograft 
mouse models (Rodriguez, Schuur et al. 1997) and demonstrated a high safety index 
in a phase I trail (Deweese, Vander, Li et al. 2001).  
Fig.6:  Transcriptional targeting by an optimized human tyrosinase enhancer / promoter 
construct (Nettelbeck et al. 2002). A schematic outline of modifications introduced into the 
adenovirus serotype 5 genome is shown. The optimized tyrosinase enhancer / promoter construct 
consists out of two tandem enhancers and the core promoter (-209/+51) of the humane tyrosinase 
genes; LITR, left inverted terminal repeat; Ψ, packaging signal; pA, polyadenylation signal. 
 
Another promising OAd, which embodies this principle and is of special interest for 
malignant melanoma, use the optimized tyrosinase enhancer/promoter, TyrE/P 
(Nettelbeck et al. 1999), to drive expression of E1A (Fig. 6) or E4 gene (see also 
chapter 2.2). In this regard, a highly melanoma-selective expression of E1 or E4 was 
shown. Importantly, specific expression of E1 or E4 from TyrE/P resulted in reduced 
virus progeny production and cytotoxicity in non-melanoma cells, whereas replication 
and cytotoxicity were similar to wildtype adenovirus in melanoma cells (Nettelbeck et 
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al. 2002; Banerjee et al. 2004). Furthermore, the selectivity of TyrE/P was confirmed 
in a co-culture system and in three-dimensional organotypic cultures, a mixed 
population of melanoma cells and primary human keratinocytes (Nettelbeck et al. 
2002; Banerjee et al. 2004). Based on these results, TyrE/P is a prominent candidate 
for tissue-selective targeting of OAds to malignant melanoma. However, this principle 
of tissue targeting implies that the OAds can also replicate in healthy tissues from 
which the tumours originate. In the case of OAds targeted by PSA promoter or 
TyrE/P, harming of prostate epithelium or pigmented cells of the skin might be 
tolerable. 
In addition to tissue-specific regulatory elements, many other tumour selective 
promoters have been characterized and tested to target adenoviruses to 
hepatocellular carcinoma, using AFP promoter (Hallenbeck, Chang et al. 1999; Li, Yu 
et al. 2001; Ohashi, Kanai et al. 2001); to breast carcinomas, using DF3/MUCI gene 
promoter (Kurihara, Brough, Kovesdi et al. 2000); to ovarian carcinoma, using a 
secretory leukoprotease inhibitor promoter (Barker, Dmitriev, Nettelbeck et al. 2003); 
and neuroblastoma, using the midkine differentiation factor promoter (Adachi, 
Reynolds, Yamamoto et al. 2001). 
 
2.4.3.2. Strategies for tropism modification of adenoviruses 
Currently, ONYX-015 has been tested in phase I and II clinical trials for head and 
neck-, pancreatic-, ovarian-, colorectal-, lung-cancer and oral carcinoma. Despite of a 
high titer application systemically or locally, no statistic significant tumour regression 
was observed. Toxicity and intratumoral spread of this first generation adenovirus 
seem to be the limitation in vivo. One explanation has been shown to result from a 
deficiency of the primary receptor CAR on tumour cells. Accordingly, most tumour 
cells freshly purified form tumour biopsies have been revealed to be resistant to 
adenovirus infection due to a lack of CAR expression (Hemmi, Geertsen et al. 1998; 
Miller, Buchsbaum et al. 1998; Li, Pong et al. 1999). As all present OAds are derived 
from serotype 2 or 5, which both infect cells via binding to CAR, tropism modification 
of these agents is critically required for efficient oncolysis. Moreover, tumour 
targeting could also lessen side effects, such as hepatocellular cytotoxicity 
associated with systemic adenovirus application.  
To overcome this obstacle, the cell binding domain of Ad5 was switched between 
different adenovirus serotypes. In this regard, substitution of the Ad5 fiber knob 
domain with the corresponding domain of subgroup B Ad3 implements potent cell 
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entry of the tropism-modified OAd into primary melanoma cells (Rivera et al. 2004B), 
ovarian cancer cells (Kanerva, Mikheeva et al. 2002), renal cancer cells (Haviv, 
Blackwell et al.2002), and squamous cell carcinoma (Kawakami, Li et al. 2003), 
which are all resistant to Ad5 infection. However, this strategy results rather in 
enhancing of unselective cell entry than in increased tumour specificity, potency and 
safety. To achieve tumour cell-selective entry of OAds, the ablation of the natural 
tropism and the retargeting for example by incorporation of targeting ligands into the 
virus capsid are required. Notably, all oncolytic adenoviruses described to date are 
based on post-entry restriction of the adenoviral life cycle. 
First efforts focused on insertion of candidate ligands into the HI loop or at the C-
terminus of the adenoviral fiber. The incorporation of few peptides was feasible 
without the loss of fiber stability and folding properties and furthermore, the ligands 
could retain their binding capacity. Note that the insertion of recombinant antibody 
fragments as targeting motifs into the adenoviral capsid is hampered by the 
incomplete folding of most antibodies in the cytosol, where adenoviral proteins are 
produced. Dmitriev and co-workers inserted the targeting peptide RGD-4C into the HI 
loop to broaden the viral tropism to the αv integrin-mediated entry pathways without 
harming the fiber firmness (Dmitriev, Krasnykh et al. 1998). In an Ad context, the 
placement of RGD motif in the HI loop showed increased transduction efficacy for 
primary and established cancer cells, such as squamous cell carcinoma of the head 
and neck (Kasono, Blackwell et al. 1999) and pancreatic cancer cells (Wesseling, 
Bosma et al. 2001) as well as dendritic cells (Asada-Mikami, Heike et al. 2001). 
However, only one study by Baker and colleagues could demonstrate selective 
adenoviral transduction of endothelial cells by insertion of a targeting peptide into the 
Ad5 fiber (Nicklin et al. 2001). Besides, previous reported tumour-specific peptides 
and nanobodies consisting of a single monomeric variable antibody domain (Cortez-
Retamozo et al. 2004) represent ligands with high potential for targeting of OAds cell 
binding and entry. However, efficient and selective as well as successful anti-cancer 
therapy mediated by targeting viral cell entry is not shown yet. 
 
A prerequisite for a successful Ad tumour targeting is still the ablation of the native 
tropism to avoid infection of healthy tissues and liver sequestration. Several point 
mutations of the AB (S408E) (Einfeld et al. 2001; Jakubczak et al. 2001b), DE 
(Y477A) (Alemany et al. 2001) and FG loop (Mizuguchi et al. 2002) of the Ad5 fiber 
knob domain have been analysed that successfully abolish CAR binding resulting in 
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strongly reduced viral transduction in vitro. Surprisingly, in vivo the CAR binding 
ablated vectors showed no or only minimal reduction on hepatocyte transduction in 
mice, rats and nonhuman primates (Alemany et al. 2001; Leissner et al. 2001; Nicol 
et al. 2004; Roelvink et al. 1999; Smith et al. 2002; Smith et al 2003a).  
The penton base RGD motif mediates binding to membrane integrins and stimulation 
of endocytosis. Hence, integrins can normally serve as secondary receptor of the 
entry pathway, in the absence of CAR binding, this penton base integrin interaction 
alone can also result in virus transduction (Huang et al. 1996). As the penton base 
RGD motif plays a significant role in liver transduction, the deletion of the RGD 
sequence in combination with CAR ablation leads to a detargeted Ad5 with minimal 
liver uptake and reduced macrophage stimulatory activity in some, but not in all, 
studies (Schoggins, Falck-Pederson et al. 2006). 
Although the canonical two step entry pathway via CAR and integrins is the dominant 
mechanism contributing to Ad5 transduction in vitro, interactions of the viral capsid 
with major histocompatibility complex molecules and heparin sulphate glycos-
aminoglycans (HSG) also play an important role of cell entry (Dechecchi, Melotti, 
Bonizzato et al. 2001; Hong, Karayan, Tournier, Curiel and Boulanger et al. 1997). In 
this regard, mutation of the KKTK motif, a putative HSG binding domain, in the Ad5 
shaft showed reduced liver transduction in vitro and in vivo (Nicol, Graham, Miller, 
White, Smith, Nicklin and Baker et al. 2004; Smith and Stevenson et al. 2003). 
Furthermore, replacement of the Ad5 fiber shaft with a short shaft derived from the 
Ad35 or short Ad40 fiber mediated reduced transduction of hepatic tissue (Koizumi et 
al. 2003; Nakamura et al. 2003). 
Recently, the short fiber of subgroup F adenovirus serotypes 40 and 41 has been 
suggested as a tool for genetic adenovirus detargeting. These serotypes possess 
two different fiber molecules, a long fiber with the cell binding domain and a short 
fiber. As no cellular receptor has been reported for the short fiber, it seem not to be 
involved in virus attachment (Roelvink et al. 1999; Favier et al. 2002; Nakamura et al. 
2003), but might be essential for stability of the virus capsid. Furthermore, Ad40 and 
Ad41 lack the RGD motif in their penton bases or fibers (Albinsson and Kidd 1999). 
In this regard, several studies observed that Ads with chimeric Ad40/Ad41s-derived 
fibers did not mediate efficient adenoviral gene transfer in vitro and in vivo 
(Nakamura et al. 2003; Nicol et al. 2004; Schoggins et al. 2003; Schoggins et al. 
2005). Based on these observations, the short fibers of subgroup F constitute a 
scaffold of interest for target ligand insertion into adenovirus capsid. Different 
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functional insertion sites for the model peptide RGD-4C into the Ad41 short fiber 
knob were determined (Hesse et al. 2007). In conclusion, the feasibility of ligand 
insertion into the Ad41 short fiber knob domain resulting in molecules that retain both 
fiber/capsid integrity and the potency of the inserted peptide to bind its cellular 
receptor has been shown.  
2.4.3.3. Strategy for efficient transgene expression by oncolytic 
adenoviruses 
Several OAds have entered the clinics. However, clinical experiences showed that 
these agents are safe, but not potent enough as monotherapy to effect complete 
tumour regressions or to generate sustained clinical response. A promising strategy 
to improve therapeutic efficacy of oncolytic adenoviruses is to combine viro- and 
gene therapy via “arming” of oncolytic viruses with therapeutic genes. In this regard, 
therapeutic genes could mediate killing of uninfected cancer cells by means of 
molecular chemotherapy/prodrug activation (Fig. 7), anticancer immune activation, 
apoptosis induction, angiogenesis, or other genetic effector mechanisms (bystander 
effect). 
 
 
 
 
 
 
 
 
 
 
Fig.7: Gene directed enzyme prodrug therapy in combination with viral oncolysis. An attractive 
strategy to improve therapeutic efficacy of OAds is to develop “armed” viruses by insertion of suicide 
genes into the virus genome. After converting of the prodrug into highly toxic metabolites this 
chemotherapeutic can also cross connective tissue which poses a physical barrier to viruses.  
 
Choosing the appropriate transgene, the mode of transgene expression and the 
locale of transgene insertion into the virus genome are the major questions for 
implementation of “armed” OAds. In this regard, the insertion of therapeutic genes 
into the genome of OAds has to consider the compact genome structure and the 
limited packaging capacity of the viruses in order to retain oncolytic potency. One 
strategy offered by the replicating virus is to use endogenous viral gene expression 
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control machinery (promoter/enhancer, polyadenylation, and splice signals) by 
replacing viral genes such as the non essential E3 gene. In this case, the transgene 
expression should follow the normal kinetic of the substituted endogenous gene 
(Freytag et al. 1998; Wildner et al. 1999; Van Beusechem et al. 2002; Geoerger et al. 
2004; Lamfers et al. 2005; Oosterhoff et al. 2005). A second approach is the 
transgene insertion into adenoviral transcription units, thereby exploiting the viral 
gene expression mechanism and kinetics. This has been implemented by fusion of 
the transgene by an internal ribosome entry site (IRES) to the viral genes, which 
have been successfully employed in replicating viruses (Sauthoff et al. 2002; Rivera 
et al. 2004; Sova et al. 2004). Using of viral splice acceptor sites (Fuerer and Iggo, 
2004; Jin et al. 2005; Carette et al. 2005) for splicing of transgene from viral mRNA 
could be also a possibility for transgene expression.  
Specific cellular promoters have been utilized for indirect or direct transcriptional 
targeting of transgene expression by oncolytic adenoviruses. By selective 
amplification of the transgene template, transcriptional targeting of adenoviral 
replication indirectly confers specificity to the expression of the transgene inserted 
into the virus genome. The second mechanism of indirect control is achieved when 
transgene is expressed from the major late promoter, which should be only active 
after selective replication (promoter dependent) of the viral genome. Direct targeting 
can be implemented by expression of the transgene from a selective cellular 
promoter construct (Davis et al. 2006). One problem of the indirect or direct 
transcriptional targeting of transgene expression could be that the promoters might 
loose their selectivity during virus replication (Rohmer et al. 2008). Indeed, regulation 
of therapeutic gene expression by OAds remains challenge and a highly efficient and 
selective strategy for transgene expression for an anti-cancer therapy is still missing. 
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3. OBJECTIVES OF THE STUDY 
The aim of my first project was the development of selective and efficient late 
therapeutic gene expression by transcriptionally targeted oncolytic adenoviruses. 
This study was based on previously developed adenoviruses with melanoma-
restricted replication potential via the tight tyrosinase promoter (Nettelbeck et al. 
2000). I used this strategy of transcriptional targeting of the viral replication to 
malignant melanoma cells should to indirectly control late transgene expression 
which should be replication-dependent. Specifically, it should be analyzed if the 
mode of transgene expression and the locale of transgene insertion into the virus 
genome critically determine the efficacy and specificity of the transgene expression. 
To address this issue I developed different strategies for transgene expression from 
the viral late transcription unit by either fusion the transgene to the late virus gene via 
internal ribosome entry side or a ‘self-cleaving’ 2A peptide or by inserting the 
transgene into the viral genome via an additional splice acceptor site. First, the 
selectivity and efficiency of late transgene expression should be analyzed. 
Especially, the influence of the different transgene insertion strategies on indirect 
transcriptional targeting of transgene expression was of interest, because so far it 
has not been analyzed. Importantly, viral gene expression and oncolytic potency 
should not been affected when the transgene is inserted into the late transcription 
unit downstream of the fiber gene. Finally, it should be investigated whether the 
therapeutic efficacy of oncolytic adenoviruses is improved by inserting a therapeutic 
gene via the optimized insertion strategy into the viral genome. Towards this goal, I 
planned to combine viral oncolysis with genetic prodrug activation (molecular 
chemotherapy). 
The second project was designed to develop strategies for targeting oncolytic 
adenoviruses to cancer cells by tumour-selective cell entry. Notably, all oncolytic 
adenoviruses described to date are based on post-entry restriction of the adenoviral 
life cycle. My initial work in this project was focus on the engineering of the virus 
capsid for optimal ablation of native virus tropism and insertion of targeting ligands in 
context of oncolytic viruses. Therefore, I investigated efficiency of viral replication and 
the lytic potency of oncolytic adenoviruses engineered with the model peptide RGD 
inserted in the Ad41 fiber knob. Additionally, tumour cell-binding peptides should be 
analyzed after insertion into the best suited position of my fiber formats in the context 
of oncolytic adenoviruses. 
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4. Materials and Methods 
4.1. Materials 
4.1.1. Chemicals, filters and enzymes 
The utilized chemicals such as salts, buffer substances, solvents and antibiotics were 
purchased from Roche (Mannheim), Dianova (Hamburg), Merck (Darmstadt), 
Invitrogen (Karlsruhe) and Sigma (Deisenhofen). The nutrient medium for bacteria 
derived from Roth (Karlsruhe). Filters were purchased from Schleicher and Schuell 
(Dassel), enzymes from New England Biolabs (Frankfurt/Main) and Invitrogen 
(Karlsruhe).  
 
4.1.2. Buffers and solutions 
4.1.2.1. Buffers and solutions for gel electrophoresis 
4.1.2.1.1. Electrophoresis of nucleic acids 
Agarose gel: 0.5-2% Agarose in 1x TAE buffer (addition of 10μl ethidium bromide in 
100ml Agarose) 
50x TAE buffer: 2M Tris-HCl; 1M sodium acetate; 62,5mM EDTA, pH 8.5 
10x DNA loading buffer: 0.1% bromophenol blue; 50% glycerol; 0.1M EDTA pH 8.0 
Ethidium bromide: 10mg/ml (Carl Roth, Karlsruhe) 
DNA ladder: 1kb DNA ladder (Invitrogen, Karlsruhe) 
4.1.2.1.2. Electrophoresis of proteins 
4x separating buffer: 1.5mM Tris-HCl pH 8.8; 0.04% SDS  
4x stacking buffer: 0.5M Tris-HCl pH 6.8; 0.4% SDS 
Acrylamide: 30% (Carl Roth, Karlsruhe) 
10% APS 
Temed (Promega, Mannheim) 
10x running buffer: 2M Glycine; 250mM Tris; 1% SDS 
RiPa lysis buffer: 10mM Tris-HCl pH 7.5; 150mM NaCl; 1% NP40 (Igepal) 1% 
sodium desoxycholate; 0.1% SDS; 1mM PMSF; 20mM sodium fluoride; 2mM sodium 
orthovanadate 
4x sample buffer: 200mM Tris-HCl pH 6.8; 400mM DTT; 8% SDS; 0.4% 
bromophenol blue; 40% glycerol; 10% β-Mercaptoethanol (β-Me) 
Protein gel marker: Page Ruler Prestained protein ladder (Fermentas, St. Leon-Rot) 
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4.1.2.2. Buffers and solutions for western blot analysis 
1x transfer buffer: 25mM Tris; 192mM Glycine; 20% methanol 
10x TBS: 250mM Tris-HCl pH 7.4; 1.5M NaCl 
PBS: 137mM NaCl; 2.7mM KCl; 7.3 mM Na2HPO4; 1.4mM KH2PO4; pH 7.0 
Blocking solutions: 5% BSA in TBS and 5% powdered milk in TBS; 0.02% Tween; 
0.02% NaN3 
Washing solution (TBST): 1x TBS; 0.02% Tween 
ECL Western Blotting Substrate (Pierce, USA) 
 
 
4.1.2.3. Buffers and solutions for viral lysis 
TE-buffer: 100mM Tris-HCl pH 8.0; 10mM EDTA 
VL buffer: 1M TE buffer; 10% SDS 
 
4.1.2.4. Buffers and solutions for production of transformation competent 
bacteria 
MgCl2: 0.1M, ice-cold, sterile 
CaCl2: 0.1M, ice-cold, sterile 
Glycerol: 99.9%, ice-cold, sterile 
 
4.1.2.5. Buffers and solutions for DNA precipitation 
Lithium chloride: 4M 
EtOH: 100% 
 
4.1.2.6. Buffers and solutions for caesium chloride equilibrium density 
ultracentrifugation 
CsCl 1.41: 304.6g caesium chloride in deionized water (500 ml) pH 7.8, sterile 
CsCl 1.27: 227.2g caesium chloride in deionized water (500 ml) pH 7.8, sterile 
Hepes: 5mM, sterile 
Glycerol: 99.9 %, sterile 
 
 
4.1.3. Media 
4.1.3.1. Media for bacterial culture 
LB-medium: Carl Roth LB (Luria Bertani) Broth, Miller  
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LBampAgar: LB-Agar (Lennox) with 100mg/l ampicillin  
LBkanAgar: LB-Agar (Lennox) with 50mg/l kanamycin  
SOC-medium: 2% bactotryptone pH 7.0 (NaOH); 0.5% yeast extract; 10mM NaCl; 
2.5mM KCl; 10mM MgSO4; 10mM MgCl2; 20mM glucose 
 
4.1.3.2. Media and solutions for cell culture 
DMEM: Dulbecco’s Modified Eagle Medium, 4.5g/l glucose without L-glutamine, with 
sodium pyruvate and pyridoxine (Invitrogen, Karlsruhe)  
RPMI: RPMI 1640 without L-glutamine (Invitrogen, Karlsruhe) 
OptiMEM (Invitrogen, Karlsruhe) 
FBS: foetal bovine serum (PAA, Pasching): was inactivated on 56ºC for 30 min 
before usage 
DPBS: Dulbecco’s phosphate buffered saline 0.0095M PO4 without calcium and 
magnesium (Lonza, Belgium; Invitrogen, Karlsruhe) 
Trypsin-EDTA: 500mg/l trypsin; 200mg/l Versene (EDTA) (Invitrogen, Karlsruhe) 
P/S/G: L-glutamine (200mM) with penicillin and streptomycin (100x); (PAA; 
Pasching) 
P/S: 10.000U penicillin/ml; 10.000µg streptomycin/ml (Lonza, Belgium) 
Gentamycin: 10mg/ml gentamycin (Sigma, Deisenhofen) 
L-Glutamine: 200mM in 0.85% NaCl (BioWhittaker, Verviers, Belgium) 
β-Me: 50mM (Invitrogen, Karlsruhe) 
Hepes: 1M in 0.85% sodium chloride (Lonza, Belgium) 
DMSO: Sigma, Deisenhofen 
Crystal violet: 1% crystal violet in 70% ethanol 
 
4.1.4. Cells and Bacteria Strains 
4.1.4.1. Bacteria strains 
Escherichia coli Maximum Efficiency DH5α: genotype: F-Φ80∆lacZ∆M15, rec A1, 
end A1, hsdR17 PhoA, supE44, gyrA96, relA1 (Invitrogen, Karlsruhe) 
Escherichia coli Electro Maximum DH5α: genotype: F-Φ80∆lacZ∆M15, rec A1, 
end A1, hsdR17 mcrA, mcrB, mcrC, mrr (Invitrogen, Karlsruhe) 
Escherichia coli BJ5183: genotype: endA1, sbcBC, recBC, galK, met, thi-1, bioT, 
hsdR (Stratagene, Amsterdam). 
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4.1.4.2. Human cells lines 
Table 1: Human cell lines used in this dissertation 
name cell type medium source 
A549 
Human lung 
adenocarcinoma 
epithelial cell line 
DMEM/10%FCS/1%P/S/G ATCC (Manassas, USA) 
C8161 Melanoma cell line DMEM/10%FCS/1%P/S/G (Welch et al., 1991) 
Colo829 Melanoma cell line RPMI/10%FCS/1%P/S/G 0.04% β-Me 
J. Banchereau (Texas, 
USA) 
HaCat immortalized keratinocyte cell line DMEM/10%FCS/1%P/S/G 
P. Boukamp 
(Heidelberg, Germany) 
(Boukamp, 
Petrussevska et al. 
1988) 
HFF Primary normal foreskin fibroblast 
MEM/7.5% FCS/1%G/ 
1% gentamycin 
M. Marschall (Erlangen, 
Germany) 
293 
Human embryonic kidney 
cells 
(stably transformed with sheared 
Ad5 DNA) 
DMEM/10%FCS/1%P/S/G G. Fey (Erlangen, Germany) 
Mel624 Melanoma cell line RPMI/10%FCS/1%P/S/G J. Schlom (Bethesda, USA) 
Mel888 Melanoma cell line RPMI/10%FCS/1%P/S/G J. Schlom (Bethesda, USA) 
pMelL Low passage melanoma cells 
As mentioned above for 
primary melanoma 
D.Dieckmann, M Lüftl 
(Erlangen, Germany) 
SK-Mel-28 Melanoma cell line DMEM/10%FCS/1%P/S/G ATCC (Manassas, USA) 
 
4.1.5. Adenoviruses 
Ad5 WT: Ad serotype 5 wild type; provided by D. Curiel, Birmingham, USA 
(Davydova, Le et al. 2004). 
Ad5∆24Tyr: Ad serotype 5 that expresses E1AΔ24 from an optimized human 
tyrosinase enhancer/promoter (hTyr2E/P) (Nettelbeck et al. 2002). 
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4.1.6. Nucleic acids 
4.1.6.1. Oligonucleotides 
All oligonucleotides were purchased from and were synthesized by MWG-Biotech 
(Martinsried).  
 
4.1.6.1.1. Oligonucleotides for PCR cloning 
Name Sequence Description  Fragment size 
Mlu for 5’-ACT TAC GCG TGC TAG CCC G-3’ 
mutation of  
cryptic splice 
acceptor 
sequence   
1140bp 
mut SA rev 5’-CCG AAT AAT CCG GTC GCT ATA GAA AAT GAA ATC AGG TCT AGT TG-3’ 
mut SA for 5’-ATA GCG ACC GGA TTA TTC GGT TGT TGG TTG AAG AAG GTT TG-3’ 
293bp 
Age rev 5’-CCA CCG GTG GCC AGC ATT G-3’ 
Table 2: Oligonucleotides for PCR cloning. Recognition strings for restriction enzymes are marked in 
bold. 
4.1.6.1.2. Oligonucleotides for annealing 
Oligonucleotides for insertion of a 50bp spacer between splice acceptor site and FCU gene 
Spacer_1 5’- P-CTAGCCCGGGCTCGAGATCTCTGCTAATCTTCCTTTCTCTCTTCAGGCCC-3’ 
Spacer_2 5’-P-GTCTTCCACGGGGCCTGAAGAGAGAAAGGAAGATTAGCAGAGATCTCGAGCCCGGG-3’ 
Spacer_3 5’-P-CTTCAGGCCCCGTGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCGC-3’ 
Spacer_4 5’-P-CATGGCGGATAGAATGGCGCCGGGCCTTTCTTTATGTTTTTGGCGTCTTC-3’ 
BPSA ts 5’-P-GATCTCTGCTAATCTTCCTTTCTCTCTTCAGGCCAC-3’ 
BPSA bs 5’-P-CATGGTGGCCTGAAGAGAGAAAGGAAGATTAGCAGA-3’ 
Table 3: Oligonucleotides for PCR annealing. Recognition strings for restriction enzymes are marked 
in bold. 
4.1.6.1.3. Oligonucleotides for splicing analysis 
Name Sequence 
TPL for 5’-CTG AGC GAG TCC GCA TCG-3’ 
FCU 1090-1109 rev 5’-TAT CTG TCA CCA AAG TCA-3` 
FCY 430-449 rev 5’-TGA GGT CTT TCA TCG ATA AA-3’ 
Table 4: Oligonucleotides for PCR splicing analysis of FCU.  
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4.1.6.1.4. Oligonucleotides for controlling recombinant modified Ad genomes 
Name Sequence 
SeqITR for 5’-CGG GAA AAC TGA ATA AGA GGA AGT GA-3` 
Ad1124-1100 rev 5’-ATT TTC ACT TAC TGT AGA CAA ACA T-3` 
E1A∆24 rev 5’-AAA GCC AGC CTC GTG GCA GGT AAG-3` 
pGL3-Seq3’ MCS rev 5’-TTA TGC AGT TGC TCT CCA GCG GTT C-3` 
E3 for 5`-CTG CTA GTT GAG CGG GAC AGG GGA C-3` 
E3 rev 5`-GGC AAG GAG GTG CTG CTG AAT AAA C-3` 
E4-for 5’-ATT GAA GCC AAT ATG ATA ATG AGG G-3` 
E4-rev 5’-CAC AGC GGC AGC CTA ACA GTC-3` 
5knob for 5’-AGG CAG TTT GGC TCC AAT ATC TGG-3` 
RGD Ad5 HI for 5`-TGC CGC GGA GAC TGT TTC TGC-3’ 
Seq Mfe fiber rev 5’-TGT ATA AGC TAT GTG GTG GTG GGG-3` 
FCU1_RT for 5’-GAA ACT GAC ACC AAC GAA AAC-3` 
FCU 1090-1109 rev 5’-TAT CTGTCACCAAAGTCA-3` 
Table 3: Oligonucleotides for controlling recombinant modified Ad genomes 
 
Combination of oligonucleotides Ad genome region DNA fragment size 
SeqITR for + Ad1124-1100 rev E1A-region 
Ad5 WT: 844bp 
Ad5∆24 viruses: 820bp 
Ad5Tyr∆24 viruses: 1430bp 
E1A∆24 rev + Seq ITR E1A-region Ad5 WT: 666bp Ad5∆24 viruses: - 
pGL3-Seq3’ MCS rev + 5knob for Fiber with luciferase insertion Ad5 ∆24 fiber IL / TL: 1172bp 
E3 for + E3 rev E3-region Ad5 WT: 2836bp Ad5 ∆24 E3- viruses: 206bp 
E4 for + E4 rev E4-region 
Ad5 WT: 398bp 
Ad5 ∆24 FCU viruses: 1520bp 
Ad5 ∆24 SL: 2051bp 
RGD Ad5 HI for + Seq Mfe fiber rev RGD insertion 
Insertion in:  
HI loop: 457bp 
IJ loop: 401bp 
EG loop: 538bp 
5knob for + Seq Mfe fiber rev Ad5 fiber knob domain Ad5 WT: 524bp 
FCU1_RT for + FCU1090-1109 rev FCU insertion Ad5 ∆24 FCU viruses: 455bp 
Table 4: Combination of oligonucleotides for controlling recombinant modified Ad genomes  
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4.1.6.1.5. Oligonucleotides for sequencing 
All sequences obtained from PCR and from annealing with oligonucleotides, as well 
as all cloning steps were proved by sequencing (MWG-Biotech, Martinsried) to 
exclude mutations.  
Name Sequence 
pGL3-for 5’-CTA GCA AAA TAG GCT GTC CCC TA-3` 
pGL-rev 5’-CTT TAT GTT TTT GGC GTC TTC C-3` 
SeqITR 5’-CGG GAA AAC TGA ATA AGA GGA AGT GA-3` 
Seq Mfe fiber rev 5’-TGT ATA AGC TAT GTG GTG GTG GGG-3` 
Seq Luc rev 5’-TTC ATA GCC TTA TGC AGT TGC-3’ 
RAE antisense 5’-AAC ACG TGG GTC AGA GAG GT-3’ 
Table 5: Oligonucleotides used for sequencing 
 
4.1.6.1.6. Oligonucleotides for quantitative real time PCR (qPCR) 
Human gene Orientation Sequence 
GAPDH 
sense 5’-GGT TTA CAT GTT CCA ATA TGA TTC CA-3` 
antisense 5’-ATG GGA TTT CCA TTG ATG ACA AG-3` 
β-Actin 
sense 5´-TAA GTA GGC GCA CAG TAG GTC TGA-3` 
antisense 5´-AAA GTG CAA AGA ACA CGG CTA AG-3` 
 
Adenovirus 
gene/Transgene Orientation Sequence 
E4 
sense 5`-GGT TGA TTC ATC GGT CAG TGC-3` 
antisense 5`-TAC GCC TGC GGG TAT GTA TTC-3` 
E1A 
sense 5’-AAC CAG TTG CCG TGA GAG TTG-3’ 
antisense 5’-CTC GTT AAG CAA GTC CTC GAT ACA-3’ 
Fiber 
sense 5’-TGA TGT TTG ACG CTA CAG CCA TA-3` 
antisense 5’-GAT TTG TGT TTG GTG CAT TAG GTG-3` 
Hexon 
sense 5`-ACC TGG GCC AAA ACC TTC TC-3` 
antisense 5-CGT CCA TGG GAT CCA CCT C-3` 
Luciferase 
sense 5’-TGA CCG CCT GAA GTC TCT GA-3’ 
antisense 5’-TGG AGC AAG ATG GAT TCC AAT-3’ 
FCU1 
sense 5’-GAA ACT GAC ACC AAC GAA AAC-3’ 
antisense 5’-TTT TAC CGA TAC GCA CAG AC-3’ 
Table 6: Oligonucleotides for quantitative real time PCR 
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4.1.6.2. Plasmids 
pGL3-Basic: luciferase reporter plasmid that lacks eukaryotic promoter and 
enhancer sequences (Promega, Madison, USA). 
pGL3-SV40: luciferase reporter plasmid that contains a SV40 promoter located 
upstream of the luciferase gene (Promega, Madison, USA). 
pGL3-CMV.IE: luciferase reporter plasmid that contains the CMV immediate early 
promoter upstream of the luciferase gene (Nettelbeck, unpublished). 
pShuttle: Ad transfer vector containing a multiple cloning site in which an expression 
cassette can be inserted. Upon homologous recombination in bacteria with pAdEasy-
1 or pVK500-5ts3k the expression cassette is inserted into the original E1 region of 
the Ad genome (He et al.,1998). 
pS-cs-Δ24: shuttle plasmid contains a mutant E1A gene with a 24bp deletion 
(E1A∆24) to prevent binding and inactivating pRB and upstream multiple cloning site 
(Nettelbeck et al.,2002).  
pS∆24_SA_FCU-1: FCU-1 shuttle plasmid that contains a splice acceptor sequence 
(SA) located upstream of the FCU-1 gene. Additionally, it contains the mutant E1A 
gene with a 24bp deletion (obtained from Michael Behr). 
pS-hTyr-Δ24: contains a mutated E1A gene under the control of the human Tyr 
promoter (Nettelbeck et al.,2002). 
pAdEasy-1: 33.4kb plasmid containing the Ad5 genome with deletions in the left end 
of genome including E1 region (He et al.,1998).  
pVK500fiber: plasmid containing the Ad5 genome with partial deletion of the fiber 
gene. 
 
Following plasmids were generated in this thesis by the described cloning procedure: 
pS∆24_SA_spacer_FCU-1: contains a 51bp long, non-coding sequences of the 
luciferase gene as spacer between the splice acceptor sequence and the FCU1 
gene. 
pS∆24_SA_mFCU-1: contains a SA_FCU1 cassette with a mutation of a cryptic 
acceptor sequence at position 594 of the FCU-1 gene.  
pNEB.PK.SnaBI: contains the 5 fiber gene with a partial deletion at the C-terminus 
and the restriction site SnaBI at the C-terminus. 
pNEB.5/41sHI/IJ/EG_RGD: contains the fiber chimeric 5/41s incorporated the RGD 
ligand into the HI/IJ/EG loop of the 41s knob. 
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pF5/41sHI_eph ∆E3: contains the fiber chimeric 5/41s incorporated the ephrin ligand 
into the HI loop of the 41s knob. In addition, it contains a deletion of the E3 region. 
pAd5Ssp_FCU-1: plasmid contains the Ad5 genome with the therapeutic gene FCU-
1 and 51pb long spacer.  
pAd5Ssp_mFCU-1: plasmid contains the Ad5 genome with the therapeutic gene 
FCU-1 with a mutation at position 594 and 51pb long spacer.  
pAd5/41sHI/IJ/EG_RGD: plasmid contains the Ad5 genome with the fiber chimeric 
5/41s incorporated the RGD ligand into the HI/IJ/EG loop of the 41s knob. 
pAd5/41sHI_eph ∆E3: plasmid contains the Ad5 genome with the fiber chimeric 
5/41s incorporated an EphA2 peptide ligand into the HI loop of the 41s knob and a 
deletion of the E3 gene. 
4.1.6.3. Antibodies 
4.1.6.3.1. Antibodies for western blot analysis 
Antigen Clonality Species Dilution Buffer condition Source 
Ad5 fiber tail  
(monomeric and 
trimeric) 
monoclonal 
(4D2) mouse 1:2000 TBST 
Abcam 
(Cambridge) 
Ad5 hexon polyclonal rabbit 1:2000 TBST Abcam (Cambridge) 
yeast cytosine 
deaminase polyclonal sheep 1:250 TBST 
AbD Serotec 
(Oxford) 
human β-Actin monoclonal (AC-74) mouse 1:2000 5%MMP/TBS 
Sigma 
(Deisenhofen) 
human α-tubulin monoclonal mouse 1:50000 5%MMP/TBS Sigma (Deisenhofen) 
goat IgG H&L- 
HRP  polyclonal donkey 1:5000 5%MMP/TBS 
Dianova 
(Hamburg) 
mouse IgG-HRP polyclonal goat 1:5000 5%MMP/TBS 
Cell Signaling 
Technology 
(Danvers) 
rabbit IgG H&L- 
HRP polyclonal goat 1:10000 5%MMP/TBS 
Cell Signaling 
Technology 
(Danvers) 
Table 7: Antibodies for western blot analysis 
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4.2. Methods 
 
Standard methods of molecular biology required for this dissertation were performed 
according to the laboratory manual Molecular Cloning by J. Sambrook and D. Russel 
(Sambrook and Russell 2001). 
4.2.1. Nucleic acid methods 
4.2.1.1. DNA cloning 
Plasmids or amplified PCR products were cleaved with relevant restriction 
endonucleases in buffers as described by the manufacturer to generate vector and 
insert fragments for cloning. For the conversion of DNA overhangs, i.e. filling in 
recessed 5’-overhangs or digesting protruding 3’-overhangs, DNA Polymerase I, 
Klenow Fragment (Invitrogen, Karlsruhe), was utilized following restriction digestion 
according to the manufacturer’s protocol. To prevent self-religation of cutted vector-
ends, especially when blunt ends were generated, subsequent dephosphorylation 
was accomplished with calf alkaline intestine phosphatase following the 
manufacturer’s instructions (Invitrogen, Karlsruhe). If required, DNA fragments were 
purified using Qiagen® PCR-purification kit as described by the manufacturer. 
Subsequently, digested/modified DNA fragments were separated and analyzed by 
gel electrophoresis on 1% agarose gel at 100V in 1xTAE buffer. Required DNA 
fragments for ligation were excised from gel and were prepared using QIAquick® Gel 
Extraction Kit (Qiagen, Hilden) following instructions by the manufacturer. Ligation 
was performed using Rapid Ligation Kit (Roche, Mannheim) following instruction 
manual in a total volume of 20µl with a molar ratio between linearized vector and 
DNA insert of approx. 1:3 to 1:5. Half of the ligation sample was applied for 
transformation of bacteria.  
4.2.1.1.1. Production of transformation-competent bacteria and transformation 
4.2.1.1.1.1. Production of chemical-competent bacteria and transformation by heat 
shock 
For spontaneous uptake of foreign DNA, bacteria were treated with divalent cations 
(Mg2+ and Ca2+). A single colony of DH5α was inoculated in 5ml LB-medium and 
cultivated over night at 37°C by vigorous shaking in a shaker incubator. On the next 
day overnight culture was transferred to 300ml of LB-medium and bacteria were 
grown until they reached OD600nm of 0.4-0.6. After 15 min incubation on ice, bacteria 
were collected by centrifugation at 4°C and 3000rpm for 5 min. Pellets were 
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resuspended in 150ml of ice-cold, sterile 0.1M MgCl2-solution and incubated on ice 
for 1 h. Following centrifugation (see above) bacteria were resuspended in 12ml ice-
cold, sterile 0.1M CaCl2-solution and incubated on ice for another hour. Glycerol was 
added reaching a final concentration of 20%. Chemical-competent bacteria were 
stored in 200μl aliquots at -80°C.  
For heat shock transformation, bacteria were thawed on ice. 1μg of plasmid DNA or 
10μl ligation sample was mixed with 100μl chemical-competent bacteria and 
incubated on ice for 15 min. Afterwards, a heat shock of 60 sec at 42°C was 
performed. Samples were chilled on ice for 90 sec and 1ml of SOC medium was 
added. After shaking at 37°C for 1 h, 200μl was used for plating the bacteria on LB-
agar-dishes containing amp or kan depending on the resistance gene of the 
transformed plasmid. Plates were incubated at 37°C over night. 
4.2.1.1.1.2. Production of electro-competent bacteria and transformation by 
electroporation 
For the production of electro-competent bacteria a single colony of DH5α or BJ5183 
was inoculated in 10ml LB-medium and incubated at 37°C over night by vigorous 
shaking. Four ml of the overnight culture was added to Erlenmeyer-flasks containing 
a total volume of 500ml LB-medium. Cells were cultivated until they reached OD600nm 
of 0.8, were then incubated on ice for 1 h following centrifugation at 3000rpm for 10 
min at 4°C. The pellet was resuspended in 200ml ice-cold, sterile 10% glycerol 
solution and spun down by another centrifugation step. Subsequently, washing of the 
cells was repeated and cells were resuspended in 20ml 10% glycerol following 
collection by centrifugation. Five ml of 10% glycerol was used for resuspension and 
aliquots of 50μl were stored at -80°C.  
For transformation 50μl of bacteria were thawed on ice. Electro-competent DH5α 
were mixed with 2μl Ad-genome plasmids and incubated on ice for 1 minute. 
Afterwards, this mixture was transferred into a pre-chilled electroporation cuvette. 
The cuvette was placed in the electroporator and pulse of 2.5kV was applied. 
Immediately after transformation, 1ml SOC medium was added to the cells. Following 
1 h shaking at 30°C the sample was used for plating the cells on LB-agar dishes 
containing amp or kan. Plates were incubated for at least 30 h at 30°C.  
 
4.2.1.1.1.3. Homologous recombination for the generation of recombinant 
adenoviral genomes 
2μg of pShuttle-plasmids containing modified adenoviral-regions were digested with 
Pme I for 5 h at 37°C. An aliquot was controlled for complete digestion by DNA 
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electrophoresis on 1% agarose gel at 100V and the sample was purified using 
Qiagen Quickspin Purification Kit (Qiagen, Hilden) as described by the manufacturer. 
For homologous recombination electro-competent BJ5183 bacteria were used. An 
amount of 100-200ng of backbone plasmid (pAdEasy-1 or pVK500) was mixed with 
8-10μl linearized pShuttle-plasmid and used for electroporation of 50μl BJ5183. 
Following 1 h shaking at 30°C samples were plated on LB-agar dishes with amp or 
kan and incubated for at least 30 h at 30°C.  
 
4.2.1.2. Preparation of DNA and RNA 
4.2.1.2.1. Analytical isolation of plasmid DNA (mini lysate) 
To analyze modified cloning products after transformation into bacteria, a single 
colony was inoculated into 5ml of LB-medium containing the relevant antibiotic (notes 
in parentheses refer to preparation of Ad genomes). A sample of 1.5ml (4ml) of the 
overnight culture grown at 37°C (30°C) was utilized to prepare DNA. For small 
plasmids (≤ 15kb) Qiaprep Spin Miniprep Kit (Qiagen, Hilden) was applied following 
manufacturer’s instructions. Larger plasmids (pAd plasmids) were isolated using 
200μl of P1-buffer (Qiagen) for resuspension. Cells were lysed with 400μl P2-buffer 
(Qiagen) and incubated at RT for 5 min. By adding 300μl of P3-buffer proteins, cell 
wall components and genomic DNA were precipitated and pelleted by centrifugation 
at 13.000rpm for 10 min DNA was precipitated from supernatant with 750μl 
isopropanole, spun down by centrifugation for 15 min at 13.000rpm and washed with 
70% ethanol. DNA was resuspended in 30μl TE buffer pH 8.0. For analysis of 
plasmid DNA 10μl (17μl) were used for restriction digestion and subsequently 
analyzed on a 1% (0.5%) agarose gel by electrophoresis.  
4.2.1.2.2. Quantitative isolation of plasmid DNA (midi lysate) 
For large-scale preparation of plasmid DNA required for cloning and transfection 
purposes, Qiagen Plasmid Midi Kit (Qiagen) was used according to the 
manufacturer’s protocol. DNA was isolated from 100ml bacteria culture. For midi 
preparation of pAd-plasmids 4ml P1-buffer, 8ml P2-buffer and 6ml P3-buffer was 
utilized differing from standard protocol. pAd plasmids were resuspended in 100μl TE 
buffer pH 8.0 and controlled by restriction digestion and PCR followed by agarose gel 
electrophoresis. DNA plasmids (except pAd plasmids) of all cloning steps were 
proved by sequencing at MWG Biotech to exclude mutations (see chapter 4.1.6.1.3: 
Oligonucleotides for sequencing).  
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4.2.1.2.3. DNA isolation from infected human cell cultures 
For preparation of total DNA of infected human cell cultures, Qiagen Blood Mini Kit 
(Qiagen) was used following the instruction protocol. For this purpose, cells were 
harvested by removing the medium, adding 400µl of PBS and using a cell scraper. 
Samples were then stored at -20°C. 
4.2.1.2.4. RNA isolation 
Total cellular RNA was isolated from cell cultures of 50.000 cells using Qiagen 
RNeasy Mini RNA Extraction Kit (Qiagen) according to the manufacturer’s manual. 
To avoid RNA degradation by RNases 10µl β-mercaptoethanol per 1ml Buffer RLT 
was added.  
4.2.1.2.5. RNA isolation and reverse transcription 
Total cellular RNA was isolated from cell cultures of 500.000 cells using Qiagen 
RNeasy Mini RNA Extraction Kit (Qiagen) according to the manufacturer’s manual. 
To remove cell debris and shear genomic DNA from lysate, QIAshredder columns 
were utilized. One µg of total RNA was reverse transcribed into single strand cDNA 
using SuperScript II Reverse Transcriptase Kit (Invitrogen) as described by the 
manufacturer. Specifically, the protocol for first strand synthesis using oligo TT 
primers was performed.  
4.2.1.3. PCR (poymerase chain reaction) 
For the amplification of DNA fragments from genomic DNA or plasmid DNA (also pAd 
plasmids), the PCR method (polymerase chain reaction) was carried out using Taq 
Polymerase Kit (Invitrogen, Karlsruhe) or Pfu Polymerase (Promega, Madison) as 
described by the manufacturer. Standard samples with a total volume of 100μl 
contained 30ng of DNA template, 50pmol of each oligonucleotide primer, 10μl 10x 
PCR buffer, 20mM dNTP mixture (end concentration 0.2mM each), 1.5mM MgCl2 
and 4U Taq DNA-polymerase. PCR cloning of all fiber modifications were performed 
with Pfu Polymerase (Promega, Madison) and a typical sample had a total volume of 
50μl consisting of 30ng DNA template, 10pmol of each oligonucleotide primer, 5μl 
10x PCR buffer containing MgCl2, 1μl dNTP mixture (end concentration 0.2mM each) 
and 1.25U Pfu Polymerase. If not mentioned otherwise, all PCR reactions were 
performed using Taq Polymerase Kit (Invitrogen, Karlsruhe). For the control of 
constructed recombinant Ad genomes a total PCR volume of 25μl was used. A 
typical PCR was accomplished under following conditions: 
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Denaturation   95°C   5 min 
 Amplification   
Denaturation  95°C  1 min 
  Annealing  58-62°C 1 min    
  Extension  72°C  1 min / 90 sec 
 Extension    72°C  10 min   
 
Annealing temperature, cycle number and extension time was individually defined for 
the relevant oligonucleotide-primers and fragment. Ten μl of PCR product was 
analyzed by standard agarose gel electrophoresis. PCR samples for cloning were 
purified using the Qiagen®Quickspin Purification Kit (Qiagen, Hilden). 
4.2.1.3.1. Two step PCR 
Two step PCR was performed for mutation of a cryptical splice acceptor sequence 
located at position 594 of the FCU gene. Two µl of PCR product from the first PCR 
run was applied as DNA template for the second PCR run. 
1. PCR step A: primer for: Mlu 
   primer rev: SAmut rev 
   template: pS∆24_SA_FCU1  
1. PCR step B: primer for: SAmut for 
   primer rev: Age 
   template: pS∆24_SA_FCU1 
2. PCR step:  primer for: Mlu 
   primer rev: Age 
   template: products from the 1. PCR step A and B 
4.2.1.3.2. Quantitative real time PCR (qPCR) 
To quantify either intracellular adenoviral mRNA or adenoviral genomes after 
infection, qPCR with or without reverse transcription was performed with 7300 Real 
Time PCR System (Applied Biosystems, Darmstadt) using MicroAmp® 96 Well 
Reaction Plates (Applied Biosystems) at a total volume of 25µl for each PCR 
reaction. Each probe contained 12.5µl of 2x Power SYBR Green Master Mix (Applied 
Biosystems) consisting of all components necessary for the reaction, 2µl template 
mRNA or DNA isolated either with Qiagen RNeasy Mini RNA Extraction Kit (Qiagen) 
or Qiagen Blood Mini Kit (Qiagen), and 10pmol of each oligonucleotide-primer (see 
chapter 4.1.6.1.6). For quantification of adenoviral mRNA Reverse Transcriptase and 
RNase-Inhibitor (both from Applied Biosystems) were additionally added. qPCR was 
performed with an initial denaturation step of 10 min at 95°C, followed by 50 cycles of 
15 sec denaturation at 95°C, 10 sec annealing at 60°C and 15 sec elongation time at 
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72°C. At the end of each cycle, the fluorescence emitted by the SYBR Green was 
measured. After completion of the cycling process, samples were subjected to a 
temperature ramp (from 65°C to 95°C at 0.1°C/s) with continuous fluorescence 
monitoring for melting curve analysis. Known amount of template DNA pTG3602 
(108, 106, 104 and 102 copies/µl) was amplified to generate a standard curve for 
quantification of the copy numbers of unknown samples. For calibration of cellular 
mRNA amounts, 200, 20, 2 and 0.2ng/µl human RNA isolated from A549 cells, was 
utilized for creation of standard curves and to determine the GAPDH mRNA 
concentrations of the samples. Cellular DNA was measured using β-actin 
oligonucleotides and 200, 20, 2 and 0.2ng/µl human DNA isolated from A549 cells as 
standard. Data were normalized with cellular genomic DNA or cellular RNA for each 
sample individually and were analyzed with the 7300 System SDS Software (Applied 
Biosystems). Negative controls with no template were carried out for each reaction 
series. 
4.2.1.4. Protein biochemical and immunological methods 
4.2.1.4.1. Preparation of total cell lysates 
For the preparation of total cell lysate from Ad-infected, cells were harvested using 
cell scrapers (Sarstedt, Nümbrecht). Afterwards cells were pelleted by 1100rpm. This 
was followed by two cycles of washing with 5ml ice-cold PBS. Cells were then lysed 
in 50μl RiPa-buffer containing freshly supplemented protease inhibitors. After shaking 
at 1000rpm over night in a Thermomixer at 4°C, cell debris were pelleted at 
13.000rpm at 4°C and supernatant was stored at -20°C.  
4.2.1.4.2. Determination of total protein concentration  
To determine the concentration of total protein Bio-Rad Dc Protein Assay (Biorad, 
Munich) was used according to the manufacturer’s instructions. For generation of 
standard curves, known amount (1.4μg/μl, 1.05μg/μl, 0.7μg/μl, 0.35μg/μl and 
0.175μg/μl) of BSA (NEB, Frankfurt a. Main) was applied. Samples of unknown 
protein concentration were diluted (1:4) and all samples mixed with reagent A and B. 
After 20 min incubation at RT, adsorption at 750nm was determined.  
4.2.1.4.3. Discontinous SDS-Polyacrylamidgelelectrophoresis (SDS-Page)  
For electrophoretic separation of proteins according to size, SDS-PAGE was 
performed pursuant to Laemmli’s method (Laemmli,1970). Gels were composed of a 
separating gel (8-12% acrylamide) and a stacking gel (4% acrylamide). Samples 
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were mixed with 4x sample buffer and after incubation at 95°C for 5 min loaded on 
the gel. Electrophoresis was carried out using 1x running buffer for 2 h at 100V.  
4.2.1.4.4. Western Transfer 
For the immunological identification of separated proteins, western transfer was 
carried out using Protran-Nitrocellulose-Transfer-Membrane (Schleicher & Schuell, 
Dassel) with a pore size of 0.2μm. The transfer was accomplished in a wet blot 
chamber (Biorad, Munich) for 1 h with 0.8mA/cm2. Whatman filters (Schleicher & 
Schuell, Dassel), gel and nitrocellulose membrane were wetted in transfer buffer 
before assembling in the following order starting from the anode side: 1 sponge, 1 
Whatman filter, nitrocellulose membrane, gel, 1 Whatman filter and 1 sponge. 
4.2.1.4.5. Immunoblot 
Following western transfer, the membrane was incubated on a rocking platform with 
blocking solution (5% MMP/PBS/Tween/NaN3) for 2 h at RT. Membranes were 
incubated with primary antibody diluted in 5% BSA/TBST overnight at 4°C. The next 
day the membrane was washed 3 times 15 min each with TBST. The HRP-
conjugated secondary antibody was incubated in 5% MMP/TBST for 1 h at RT and 
unbound antibody was washed away 3 times 20 min each with TBST. For 
chemiluminescent detection, Pierce ECL Western Blotting Substrate (Pierce, USA) in 
a total volume of 5ml was used according to the manufacturer’s protocol. Exposition 
of X-ray films (Fuji X-ray films RX, Kisker-Biotech, Steinfurt) was performed as 
required for individual antibody for 5 min to 45 min. 
4.2.1.5. Cell culture 
4.2.1.5.1. Passaging, freezing and thawing cell culture cells 
Cells were incubated at 37°C in a humidified atmosphere with 5% CO2. Passaging 
cell culture cells was carried out depending on their growing modality every 2 to 4 
days. Cell lines were cultivated for several weeks. For detaching, cells were washed 
with PBS and subjected to Trypsin-EDTA. After removing Trypsin-EDTA from cells, 
10ml of corresponding medium was added in order to inactivate Trypsin-EDTA. 
Splitting was performed in a ratio of 1:3 to 1:10 according to growing features of 
individual cell types. For storage, cells were collected by centrifugation at 1200rpm 
for 3 min and resuspended in 10% DMSO, 90% FCS. One ml aliquots were stored at 
-80°C for 24 h before freezing in liquid nitrogen at -140°C. To re-cultivate frozen 
samples, cells were thawed at 37°C quickly before washing with 10ml of relevant 
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growth medium. Cell pellets were resuspended in growth medium and seeded at 
appropriate density.  
4.2.1.5.2. Luciferase reporter assay 
For the determination of luciferase activity in transduced cell lysates the Promega 
Luciferase Assay System (Promega) was utilized as described by the manufacturer. 
Cells were washed with PBS and lysed in 200μl Luciferase lysis buffer. Cell culture 
plates were incubated at -80°C to freeze samples for complete cell lysis. Following 
thawing at RT, 10μl cell lysate was mixed with 50μl Luciferase reagent and 
immediately measured in a luminometer (FluoroskanAsentFL, Thermo Scientific, 
Braunschweig, Germany). For the analysis, background (only lysis buffer) values 
were subtracted.  
4.2.1.6. Recombinant adenovirus 
4.2.1.6.1. Generation of recombinant adenovirus 
The generation of plasmids containing a recombinant adenoviral genome was carried 
out using homologous recombination in BJ5183 bacteria with linearized pShuttle 
plasmids and backbone plasmid (pAdEasy-1 or pVK500). For the generation of 
replication-competent adenoviruses, either A549 or in case of the melanoma targeted 
viruses Mel888 / Colo829 cells were used, while replication-deficient adenoviruses 
were produced in E1-complementing 293 cells (Quantum, Quebec, Canada).  
For the generation of recombinant adenovirus, 6μg pAd-plasmid was linearized with 
Pac I for 5 h at 37°C and precipitated with 4M Lithium chloride and 100% ethanol. 
The DNA pellet was resuspended in 30μl H2O, whereof 8μl was controlled by 
standard gel electrophoresis in a 0.5% agarose gel. Twenty μl of linearized pAd-
plasmid diluted in 250μl OptiMEM (Invitrogen) was mixed with 20μl Lipofectamine 
(Invitrogen) solved in 250μl OptiMEM and incubated at RT for 30 min. Meanwhile 
cells were washed with PBS and 2.5ml OptiMEM was added to the cells. The 
transfection mixture was dispersed onto 50-60% confluent A549 or 293 cells seeded 
into T25-cell culture flasks one day prior to transfection. Following 5 h incubation at 
37°C, the transfection mixture was replaced with relevant growth medium. Complete 
cell lysis after formation of viral plaques resulting from recombinant viral particle 
generation and spread was observed on day 10 to day 12. Cells were collected and 
recombinant virions were released from the cells by repeating three freeze/thaw 
cycles at-80°C and 37°C. Following centrifugation at 4°C for 15 min at 4000rpm, 
virions, situated in the supernatant, were used for large scale production of 
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recombinant viral particles. To amplify viruses, three further rounds of infection and 
virus preparation were performed using increasing numbers of cells (15-20 T175 cell 
culture flasks or 25 cell culture dishes (145cm2) in the last round of amplification). 
When complete lysis was observed in the last round of amplification, cells were 
collected, resuspended in 7ml medium and after three cycles of freezing/thawing, 
centrifuged at 4000rpm for 15 min (4°C). The supernatant (7ml), containing 
recombinant viral particles, was applied for purification of adenovirus. 
4.2.1.6.2. Caesium chloride gradient equilibrium density ultracentrifugation for 
the purification of viral particles 
For the purification of viral particles from culture supernatants (7ml) two rounds of 
caesium chloride equilibrium density ultracentrifugation was performed. Three ml 
CsCl 1.41 (1.41g/ml) was added to sterile ultracentrifugation tubes (Herolab, 
Wiesloch) and 5ml CsCl 1.27 (1.27g/ml) was carefully overlaid without destroying the 
border between phases. A volume of 3.5ml of viral cell lysate was pipetted onto the 
top of two tubes for each virus preparation. Following centrifugation at 4°C for 2 h at 
32.000rpm under vacuum infectious viral particles appeared as a white ring at the 
border of the two phases (Ad5 density: 1.34 g/ml), while empty particles lacking DNA 
genomes emerged as a ring located above. Virus was harvested by aspirating with a 
5ml syringe and a needle (0.4mm x 19mm, BD Microlance) punctured 1cm below the 
band, while an upper ring containing particles lacking DNA was not aspirated. After 
adjusting virus suspension to 7ml with 5mM Hepes a second caesium chloride 
gradient equilibrium density ultracentrifugation was carried out at 32.000rpm for 24 h 
at 4 °C under vacuum. The isolated virus suspension was adjusted to 2.5ml with PBS 
and PD 10 columns (Amersham, Munich) were used to remove CsCl following 
instruction manual. Elutions were performed with 0.5ml of PBS (discarded) and 2ml 
of PBS (virus stock). Subsequently, 10% glycerol was added to the purified virus and 
aliquots of 50μl were stored at -80°C.  
4.2.1.6.3. Determination of viral particle concentration 
4.2.1.6.3.1. Determination of infectious particle concentration using the Tissue 
Culture Infectious Dose 50 (TCID50)-assay 
To determine the concentration of infectious particles of purified recombinant 
adenovirus, TCID50 on 293 cells was performed. The principle of this method is the 
detection of plaques produced by the examined virus preparation applied in serial 
dilutions for infection. Ten thousand cells per well were seeded in 100μl infection 
medium (growth medium containing 2% FCS) into 96 well plates. The next day, virus 
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was serially diluted 10-fold (10-5-1012) and 100μl virus-dilution was used for infection 
each of 10 wells per dilution. As control, cells were mock infected using only infection 
medium. Following 10 days incubation at 37°C, cytopathic effect in each well was 
determined by microscopy analysis. Wells were evaluated as positive, one or more 
plaques were detected or complete cell lysis was observed. For each virus 
preparation two dilution series were carried out for precise definition of infectious 
particle concentration. The virus titer was calculated according to Kaerber’s statistical 
method and stated in TCID50/ml: 
Titer = 101 + 1(S-0.5) x 10 TCID50/ ml 
S = sum of positive wells (starting from the first 10-1 dilution) 
vp/TCID50 tissue culture infective dose ratio was between 15-20.  
 
4.2.1.6.3.2. Determination of physical viral particles by reading optical density 
To determine absolute concentration of adenoviral particles (vp/ml), optical 
adsorption of adenoviral DNA at λ= 260nm was quantified. Therefore purified virus 
was lysed by incubation in VLB buffer for 10 min at 56°C and different dilutions were 
measured. Viral particle concentration was calculated multiplying the absorbance by 
the appropriate dilution factor and the extinction coefficient (1.1 x 1011 vp/ml).  
4.2.1.6.3.3. Verification of recombinant adenoviral genomes 
For the verification of recombinant adenoviral genomes and the exclusion of Ad WT 
contamination, a PCR was performed. Purified virus was diluted 1:50 in H2O and 
incubated at 95°C for 10 min. Five μl was used as DNA template for PCR with a total 
volume of 25μl to control recombinant modified adenoviral genomes (see chapter 
4.1.6.1.4). 
4.2.1.6.4. Transduction and infections of cells with recombinant adenovirus 
4.2.1.6.4.1. Transduction with replication-deficient adenovirus for the analysis of 
luciferase activities 
Fifty-thousand cells were seeded per well into 24-well plates in 500μl medium 
(DMEM with 10% FCS). The following day, cells were infected in triplicates with titers 
dependent on their transduction efficiency (10-1000 TCID50/cell or vp/cell) in 250μl 
infection medium. Following 2 h incubation at 37°C, 500μl relevant growth medium 
was added to the cells. Forty-eight hours post infection cells were lysed for 
Luciferase assay.  
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4.2.1.6.4.2. Infection with replication-competent adenovirus with subsequent 
inhibition of virus genome replication by AraC 
For inhibition of virus genome replication, 50.000 cells were seeded in 24-well plates 
in 500µl growth media or 500.000 cells were seeded in 6-well plates in 3ml growth 
media containing 10 % FBS. The following day growth medium was removed and 
cells were infected with adenoviruses at 1-10 TCID50/cell in 250µl or 1ml growth 
medium containing 2 % FBS. To inhibit virus genome replication cells were incubated 
with AraC (Sigma-Aldrich) at 2µM, which was added at 1 h, 12 h, 24 h and 36 h post-
infection. 
4.2.1.6.4.3. Infection for cytotoxicity assay 
For the determination of virus-mediated cytotoxicity by crystal violet staining, 30.000 
cells per well were seeded in 48-plates. The following day, cells were infected in 
200µl of growth medium containing 2% FBS with adenoviruses at 10-fold increasing 
titers of 0.001-100TCID50/cell or 0.01–1000 vp/cell or were mock infected. Two hours 
post infection 500μl growth medium was added. Medium was replaced with growth 
medium every two or three days. When cell lysis was observed for virus at 0.01-0.1 
TCID50/cell or 0.1-1 vp/cell, cells were stained with crystal violet (see next chapter).  
4.2.1.6.4.4. Crystal violet staining of infected cells 
To document cell lysis, medium was removed from infected cells seeded into 48-well 
plates. For staining of living cells, approximately 50μl of 1% cystal violet/70% EtOH 
was added to the cells and incubated at RT for 20 min. Plates were rinsed with tap 
water to remove any excess colour. Afterwards, plates were dried and documented 
by digital photography. 
4.2.1.6.4.5. Infection for splicing analysis of the transgene FCU-1 by reverse 
transcription 
For the analysis of splicing by reverse transcription, 500.000 cells (SK-MEL-28) per 
well were seeded in 6-well-plates in 3ml growth medium. The following day, cells 
were infected with adenoviruses at 100 TCID50/cell in 1ml infection medium. Two 
hours post infection 2ml growth medium was added. One day post infection cells 
were washed once with PBS before and total cellular RNA was isolated using Qiagen 
RNeasy Mini RNA Extraction Kit (Qiagen) according to the manufacturer’s manual. 
To remove cell debris and shear genomic DNA from lysate, QIAshredder columns 
were utilized. Three µg of total RNA was reverse transcribed into single strand cDNA 
using SuperScript II Reverse Transcriptase Kit (Invitrogen) and oligo (dT) primers 
(Invitrogen) as described by the manufacturer. The FCU-1 gene was then amplified 
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from 2µl of cDNA in a final volume of 25µl, containing 1.5mM MgCl2, 0.2 mM dNTP 
mixture each, 1.25U taq polymerase (Invitrogen, Karlsruhe) and 10pmol  forward (5’-
CTG AGC GAG TCC GCA TCG) and reverse (5’-TAT CTG TCA CCA AAG TCA) 
primers. The amplicons were analyzed by agarose gel electrophoresis. 
4.2.1.6.4.6. Infection for quantification of adenoviral mRNA or adenoviral genomes 
by qPCR 
To quantify intracellular adenoviral mRNA or adenoviral genomes in proliferating 
cells, 50.000 cells were seeded in 24-well plates in 500μl growth medium (containing 
10 % FCS). Cells were infected the next day at 10vp/cell in 250μl infection medium. 
After 1 h of incubation at 37°C, 500µl of growth medium was added. Samples were 
harvested at indicated time points by removing the medium, adding 400µl of PBS (for 
genome copy numbers) or 350µl Buffer RLT (for adenoviral mRNA) and using cell 
scrapers (Sarstedt, Nümbrecht). Samples were stored at -20°C (genome copy 
numbers) or at -80°C (adenoviral mRNA). 
4.2.1.6.4.7. Infection for the analysis of protein-expression 
For the detection of adenoviral protein expression 500.000 cells were seeded in 6-
well-plates in 3ml of growth medium. The following day cells were infected at 10-
300TCID50/cell of adenovirus in 1ml infection medium. Two hours post infection 2ml 
growth medium was added. After indicated time points cells were harvested with cell 
scrapers and used for preparation of total cell lysates (see chapter 4.2.1.4.1 
Preparation of total cell lysates). 
4.2.1.6.4.8. Infection for the quantification of infectious particles of oncolytic 
adenoviruses  
To analyze the infectious particle production of oncolytic adenoviruses burst assays 
were performed. Therefore 50.000 cells were seeded per well in 24-well plates in 
500µl of growth medium. The day after, cells were infected at 10vp/cell of adenovirus 
in 250µl infection medium. Two hours post infection the medium was removed, cells 
were washed twice with PBS to remove all unbound adenoviruses and then 1ml of 
growth medium was added. After 2, 3 or 4 days supernatants and cells were 
harvested separately. Supernatants were collected in a 15ml tubes, spun down for 
5min at 1300rpm to remove residual cells and transferred into a fresh tube. After 
supernatants were removed 1ml of ice-cold PBS was added to the cells, cells were 
scraped off, transferred to a tube and lysates prepared by three cycles of freezing 
and thawing. Serial dilutions on the supernatants and lysates were titred on 293 cells 
using the TCID50 assay. 
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4.2.1.6.4.9. Infection for enzyme prodrug therapy 
For the determination of enzyme-produrg mediated cytotoxicity, cells were seeded in 
96-well-plates at a concentration of 10.000 cells / 100µl of growth medium 
(containing 2 % FCS) per well and grown overnight at 37°C. After 24 h, cells were 
infected with serial dilutions of the indicated viruses in 50µl of medium (containing 2 
% FCS). Two days post-infection either the prodrug FC at a final concentration at 
10mM (HaCat, A549 and SK-MEL-28) or 5mM (Mel624) or medium was added in a 
volume of 50µl to the cells. Five (A549) or six (HaCat, SK-MEL-28, Mel624) days 
post-infection, cells were fixed and stained with 1% crystal violet in 70% ethanol for 
10min, followed by washing with tap water to remove excess color. The plates were 
dried and images were captured with a LabsystemsMultiscanMS (Thermo, 
Braunschweig) at 595nm. The absorbance of control wells, which were exposed only 
to the medium, defined 100% viability and effect of the prodrug on cell survival was 
expressed as a percentage of cell viability relative to control cells.  
4.2.1.6.4.10. Infection for the analysis of bystander effect of the enzyme prodrug 
therapy 
For analysis of bystander effect, 50.000 cells (SK-MEL-28) were seeded in 24-well 
plates in 500µl growth media containing 2 % FBS. The following day, cells were 
infected at 10TCID50/cell in 500µl growth media containing 2 % FBS. Two days post-
infection, infection media was removed and cells were incubated with either 5-
fluorocytosine at a concentration of 10mM or with medium alone. The day after, 
collected supernatants and 5-fluorouracil (5-FU cat. no.: A13456, Alfa Aesar, 
Karlsruhe, Germany) at a concentration of 10mM were heated up for 10 min at 50°C. 
Serial dilutions of the supernatants and 5-FU were added to cells, which were plated 
for cytotoxicity assay.  
4.2.1.6.4.11. Infection for the analysis of effect of FC metabolites to viral life cycle 
For analysis of the influence of FC metabolites to viral life cycle, 50.000 cells (SK-
MEL-28) were seeded in 24-well plates in 500µl growth media containing 2 % FBS. 
The following day, cells were infected with Ad5TyrSsp_mFCU, Ad5TyrSL or 
Ad5CMVLUC at 1TCID50/cell in 250µl growth media containing 2 % FBS. Two hours 
post infection the medium was removed, cells were washed twice with PBS to 
remove all unbound adenoviruses and then 1ml of growth medium was added. One 
day post infection cells were incubated with 10mM FC. After two days supernatants 
and cells were harvested separately. Supernatants were collected in a 15ml tubes, 
spun down for 5min at 1300rpm to remove residual cells and transferred into a fresh 
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tube. After supernatants were removed 1ml of ice-cold PBS was added to the cells, 
cells were scraped off, transferred to a tube and lysates prepared by three cycles of 
freezing and thawing. Serial dilutions on the supernatants and lysates were titred on 
293 cells using the TCID50 assay. 
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5 RESULTS 
5.1 Late transgene expression by transcriptionally targeted 
oncolytic adenoviruses is dependent on the transgene 
insertion strategy 
Towards the goal to develop oncolytic adenoviruses (OAds) that feature expression 
of therapeutic genes in a tumour-specific manner, transgene expression by 
exploitation of the late viral gene expression machinery might be a promising tool. 
Promoter control of E1A could be used to indirectly control late transgene expression 
which should be replication-dependent. As the restriction of replication and 
cytotoxicity of the TyrE/P targeted OAds to melanoma cells was shown (Nettelbeck et 
al. 2002, Banerjee et al. 2004), the exceptionally high selectivity of TyrE/P offers a 
promising opportunity to combine transcriptional targeting of the E1A gene with the 
transgene expression to achieve indirectly melanoma selective transgene 
expression. 
 
5.1.1 Activity of optimized tyrosinase enhancer/promoter (TyrE/P) in 
replication-deficient adenoviral vectors 
To analyze the specificity of the TyrE/P promoter a tandem enhancer (2x203bp) and 
core promoter (260pb) of the human tyrosinase gene and an upstream 
polyadenylation signal (Nettelbeck et al. 2002) was cloned into a replication deficient, 
E1-and E3 deleted adenoviral vector.  
Fig.8: Activity of optimized tyrosinase enhancer/promoter (TyrE/P) in replication-deficient 
adenoviral vectors. (A) Schematic outline of replication deficient adenovirus vectors (Ad5CMVLuc, 
Ad5TyrE/PLuc) with either the Tyrosinase enhancer/promoter or the CMV promoter driving the 
luciferase gene. Luc, Luciferase reporter gene; pA, polyadenylation signal; ∆E1, E1 region deleted. (B) 
Cells were transduced with Ad5CMVLuc or Ad5TyrE/PLuc. Two days post transduction, luciferase 
activity was determined with a luminescence assay. Columns show mean RLU values of triplicate 
transductions; error bars show standard deviations; RLU, relative luminescence units. Background 
measurement readings from the lysis puffer were subtracted. One representative experiment out of at 
least three is shown. 
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In this regard, the TyrE/P controls the expression of the reporter gene luciferase, 
which was also placed into the E1 region of the viral genome. In addition, a viral 
vector that expresses the luciferase gene from the strong and constitutive CMV 
promoter (Reynolds et al. 2001) was also constructed (Fig. 8A). These viral vectors 
were used to analyze the selectivity of the TyrE/P measuring luciferase activity 48h 
post transduction of melanoma cell lines (Mel888, Mel624, SK-MEL-28) and control 
cells such as primary normal fibroblasts (HFF), immortalized keratinocytes (HaCat) 
and the lung adenocarcinoma epithelial cell line (A549). As shown in figure 8B, the 
luciferase gene expression level resulting form Ad5CMVLuc transduction yielded 
similar results of approximately 1.00E+05 relative light units (RLU) in melanoma and 
non-melanoma cells except in the HaCat cells. The luciferase expression in HaCat 
cells was approximately one order of magnitude reduced compared to the other cell 
types. The luciferase expression level resulting from AdTyrE/PLuc was 5.5-fold 
(Mel888), 22.6-fold (SK-MEL-28) and 26.4-fold (Mel624) less in comparison to 
Ad5CMVLuc. As expected, the luciferase activity resulting from the AdTyrE/PLuc was 
dramatically reduced in control cells. RLUs were 331-fold (HaCat), 2222-fold (A549) 
and 3968-fold (HFF) lower in these cells as compared with the Ad5CMVLuc. Still, the 
TyrE/P showed minimal basal activity after viral transduction, especially in A549 
cells. In summary, the TyrE/P allowed for strongly melanoma specific transgene 
expression by replication deficient adenoviral vectors. 
5.1.2 Adenovirus constructs used for investigation of melanoma selectivity 
of transgene expression by oncolytic adenoviruses 
Previously, Rivera et al. (2004) showed that the mode of transgene expression and 
the locale of transgene insertion into the virus genome of replication competent 
oncolytic adenoviruses critically determine the efficacy of their expression. Hence, 
the potency of the transgene, such as a therapeutic gene, is depended on the 
insertion strategy. Furthermore, it is important to note that timing of therapeutic gene 
expression are critical determinate of the outcome of the approach (see chapter 
2.4.3.3.). In light of these results, three different strategies for transgene insertion in 
the late transcription which might be resulting in replication-dependent expression 
pattern were analyzed. I chose an internal ribosomal entry site (IRES), a picornaviral 
2A sequences or an additional splice acceptor site to insert the reporter gene 
luciferase into the late transcription unit of Ad5 genome. For IL viruses, the 600 bp 
EMCV IRES sequence was used for bicistronic expression of the viral fiber and 
luciferase genes as described before (Rivera et al. 2004). TL viruses were generated 
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by fusion of the fiber and luciferase genes via the 54 bp 2A sequence of the insect 
virus Thosea asigna (Szymczak et al. 2004) for expression of both proteins from a 
single ORF by ribosomal skip (Fig. 9).  
 
 
Fig.9: Adenovirus constructs used for 
investigation of melanoma selectivity of 
transgene expression by OAds. Schematic 
outline of the genome of the 6 luciferase 
reporter viruses, of the parental E3-deleted 
recombinant adenoviruses without transgene 
(Ad5∆24E3-) and of the wild-type adenovirus 
serotype 5 (Ad5wt). ∆E3, E3 region deleted; 
E1A∆24; E1A mutant featuring a deletion of 
the pocket protein-binding conserved region 
two; IRES, internal ribosome entry site; SA, 
splice acceptor site (branch point, 
polypyrimidine tract, CAG); T2A, self-
cleaving motif of Thosea asigna virus (Asp-
Ile-Glu-X-Asn-Pro-Gly-Pro); Luc, luciferase 
gene; pA, polyadenylation signal for 
transcription termination; LITR/RITR, left/right 
inverted terminal repeat; ψ, packaging signal; 
black boxes in the left termini of the genomes 
highlight the optimized tyrosinase 
enhancer/promoter (TyrE/P) 
 
 
 
 
 
The SL viruses were generated by inserting the luciferase gene between E4 genes 
and RITR using a 26 bp artificial splice acceptor (SA) element consisting of 
branchpoint, polypyrimidine tract and splice acceptor element (Jin et al., 2005). The 
endogenous E1 is controlled by the highly pigment cell selective promoter TyrE/P 
aiming selective viral replication and indirect targeting of transgene expression to 
malignant melanoma. As shown in figure 9, the control viruses Ad5TL, Ad5IL, Ad5SL 
and Ad5∆24E3- encode the endogenous E1 promoter. Ad5TL, Ad5IL, Ad5SL, 
Ad5TyrTL, Ad5TyrIL and Ad5TyrSL were derived from parental virus Ad5∆24E3- 
carrying ∆24 and E3 deletion. Because of the size of the inserted DNA sequence all 
recombinant viruses are carrying deletion of E3 region and of the pRb-binding 
domain in the E1A gene.  
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5.1.3 Spread-dependent cell killing of recombinant oncolytic adenoviruses 
in different melanoma cell cultures and control cells 
First, cytolytic activity and specificity of cell lysis by Ad5TyrTL, Ad5TyrIL and 
Ad5TyrSL were analyzed after infection of melanoma (SK-MEL-28, Mel888) and non-
melanoma cells (HaCat, HFF). The different cell lines were infected with the total 
panel of recombinant adenoviruses (Ad5TL, Ad5IL, Ad5SL, Ad5TyrTL, Ad5TyrIL, 
Ad5TyrSL) and the parental virus Ad5∆24E3-, which offers the replicating control, at 
virus titer of 0.001 – 100 TCID50/cell in 10-fold dilutions. The replication-deficient 
Ad5CMVLuc served as a non-replicating control. Cell killing was detected by staining 
of viable, adherent cells with crystal violet (Fig. 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.10: Spread-dependent cell killing of recombinant oncolytic adenoviruses in different 
melanoma cell cultures and control cells. SK-MEL-28, Mel888, melanoma cell lines; HaCat, 
immortalized keratinocyte cell line; HFF, primary normal foreskin fibroblast; cell cultures were infected 
at 100TCID50/cell and 10-fold dilutions until 0.001TCID50/cell with indicated viruses carrying the 
adenoviral E1A gene under the transcriptional control of native E1A- or TyrE/P-promoter. Virus 
spread-dependent cytotoxicity was visualized by crystal violet staining of surviving cells. Therefore, 
staining was performed when cytotoxicity was observed for the most potent virus at 0.01 or 
0.001TCID50/cell for each cell type individually. TCID50, tissue culture infectious dose 50. One 
representative experiment out of at least three is shown. 
 
No cytotoxic effect was shown for replication-deficient Ad5CMVLuc. However, a 
replication dependent cytotoxicity in melanoma cells was observed for all 
recombinant oncolytic adenoviruses including the TyrE/P recombinant viruses 
(Ad5TyrTL, Ad5TyrIL, Ad5TyrSL) indicating that replacing the promoter of the E1A by 
the TyrE/P construct is feasible. After infection of the melanoma cell lines SK-MEL-28 
and Mel888, the total panel of recombinant viruses and Ad5∆24E3- showed similar 
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level of cytotoxicity. Almost identical cell killing by Ad5IL, Ad5SL and the 
corresponding Ad5TyrIL, Ad5TyrSL was observed in SK-MEL-28 and Mel888. One 
order of magnitude attenuated cell killing relative to the matching Ad5TyrTL was 
shown for Ad5TL in the tested melanoma cell lines. High cytolysis of all untargeted 
oncolytic viruses was detected in control cells HaCat and HFF, which were 
completely lysed at 10TCID50/cell (Ad5TL), 1TCID50/cell (Ad5IL) or 0.1TCID50/cell 
(Ad5SL). Importantly, in HaCat cells, the recombinant melanoma-targeted viruses, 
showed no (Ad5TyrSL) or only minimal (Ad5TyrTL, Ad5TyrIL) cell killing, even when 
infected with high virus titers. The cytolytic effect was 2 - 4 orders of magnitude 
attenuated compared to matching untargeted control viruses. Also in HFF the 
oncolytic potency of Ad5TyrTL, Ad5TyrIL and Ad5TyrSL was attenuated 10 – 1000 
fold when compared to Ad5TL, Ad5IL and Ad5SL. Thus, infection of Ad5TyrTL, 
Ad5TyrIL and Ad5TyrSL in melanoma cell lines resulted in potent cytotoxicity and is 
clearly attenuated in control cells. By comparison, highest selectivity of cytolysis was 
shown for Ad5TyrSL. Of note, insertion of the luciferase gene into the late 
transcription unit of the viral genome per se did reduce the oncolytic activity of Ad5TL 
in Mel888, SK-MEL-28, HaCat and HFF, and of Ad5IL in the control cells. In 
conclusion, melanoma-selectivity of cell lysis and spread by tyrosinase promoter-
regulated oncolytic adenoviruses was retained for viruses with transgene insertion 
into the late transcription unit via IRES and SA sequences, but less so when the 2A 
sequence was used.  
 
5.1.4 Investigation of dependence of transgene expression by oncolytic 
adenoviruses on the viral DNA replication 
My hypothesis was that transcriptional targeting of adenovirus replication indirectly 
confers specificity of the expression of transgenes inserted into the viral genome by 
targeted amplification of the transgene template. Besides regulation of virus genome 
numbers, indirect control should be achieved when transgenes are expressed from 
the major late promoter, which is activated only after virus genome replication. To 
further investigate whether the transgene expression by IRES, 2A or SA insertion 
strategies is restricted to the period after viral DNA replication, the melanoma cell line 
SK-MEL-28 was infected at 1TCID50/cell with the total panel of recombinant 
adenoviruses and the replication-deficient Ad5CMVLuc that served as a non-
replicating control. Cells were treated with cytosine arabinoside (AraC) to inhibit viral 
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replication. At 48 hours post infection, cells were harvested and luciferase activity 
was measured (Fig. 11).  
 
Fig.11: Investigation of dependence of transgene 
expression by OAds on the viral DNA replication. 
The melanoma cell line SK-MEL-28 was infected with 
indicated viruses. Cells were treated with 2 µM of 
AraC which was added 1 h, 12 h, 24 h and 36 h post 
infection or were mock treated. At 48 h after infection, 
luciferase activity was determined.  Columns show 
mean RLU values of triplicate infections; error bars 
show standard deviations; RLUs, relative 
luminescence units. This Experiment was performed 
three times and one representative result is shown. 
 
 
 
The measured luciferase activities showed that all recombinant oncolytic 
adenoviruses expressed luciferase independent from the insertion strategies, but the 
levels of luciferase expression differ. This demonstrated that the mode of transgene 
expression and the replacement of the viral E1 promoter with the TyrE/P obviously 
have an influence on the level of transgene expression. The luciferase expression 
resulting from the Ad5TyrSL was approximately 7-fold attenuated in comparison to 
Ad5TyrTL and Ad5TyrIL. However, only minimal differences between the Ad5TyrSL 
and Ad5SL were observed in comparison to Ad5TyrTL and Ad5TL (55.7-fold), 
Ad5TyrIL and Ad5IL (9.5-fold). Blocking viral replication by adding AraC clearly 
inhibited the transgene activity of all recombinant oncolytic viruses, showing that the 
luciferase behaves as late genes when inserted via IRES, 2A or SA site. The results 
of the replication-deficient Ad5CMVLuc demonstrate that AraC has no effect on 
expression of luciferase itself, which is independent of viral replication for 
Ad5CMVLuc. For Ad5TyrSL, repression of viral replication resulted in the strongest 
reduction of transgene activity by AraC.  
5.1.5 Efficacy and specificity of transgene activity of melanoma targeted 
OAds compared to untargeted viruses 
Having demonstrated that expression of the transgene by the recombinant viruses is 
efficient and replication-dependent in the melanoma cell line SK-MEL-28, the 
magnitude and the specificity of transgene expression was analyzed in two additional 
melanoma cell lines (Mel888, Mel624) and control cells such as HFF, HaCat and 
A549. For this purpose these cell lines were infected with Ad5TL, Ad5IL, Ad5SL, 
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Ad5TyrTL, Ad5TyrIL and Ad5TyrSL with a virus titer of 0.1TCID50/cell and luciferase 
activity was determined 48 hours post infection (Fig. 12A). 
 
Fig.12: Efficacy and 
kinetic of transgene 
expression by melanoma 
targeted OAds compared 
with untargeted viruses. 
(A/B) Cells were infected 
with the recombinant OAds 
expressing luciferase after 
transgene insertion into the 
late transcription unit of the 
viral genome. Two days 
post infection, luciferase 
activities were determined 
with a luminescence assay. 
(A) Luciferase activities in 
melanoma cell lines 
(Mel888, Mel624, SK-MEL-
28) and control cells (HFF, 
HaCat, A549). Cells were 
infected at 0.1TCID50/cell. 
Ratios, RLUs Ad5TyrT/I/SL 
/ RLUs Ad5T/I/SL. (B) 
Luciferase activities in 
control cells (HFF, HaCat, 
A549). Cells were infected 
at 1TCID50/cell and either 
treated with 2 µM of AraC 
which was added 1 h, 12 h, 
24 h and 36 h post infection 
or were mock treated. 
Columns show mean RLU 
values of triplicate 
infections; error bars show 
standard deviations; RLUs, 
relative luminescence units. 
One experiment out of at 
least three is shown. 
 
The values of luciferase activity for cells infected with TyrE/P recombinant viruses 
(Ad5TyrTL, Ad5TyrIL and Ad5TyrSL) were normalized with readings from the 
corresponding untargeted virus (Ad5TL, Ad5IL, and Ad5SL) to compare the efficacy 
and specificity of transgene expression. As shown in figure 12A for all melanoma cell 
lines the ratios of luciferase activity were positive indicating a higher level of 
luciferase activity was detectable for TyrE/P recombinant viruses in comparison to 
untargeted adenoviruses. In contrast, in control cells the ratios Ad5TyrIL / Ad5IL and 
Ad5TyrSL / Ad5SL revealed a significant reduction of luciferase activity resulting from 
a lower transgene expression by the TyrE/P recombinant viruses. This reduction of 
the luciferase ratios indicates a melanoma selective transgene expression depended 
on the TyrE/P. Of note, the ratio of luciferase activity for Ad5TyrSL / Ad5SL was 
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decreased 2.85-fold in HFF, 8-fold in HaCat and 9.8-fold in A549 when compared to 
Ad5TyrIL / Ad5IL, as well as in the melanoma cell lines Mel888 and Mel624 the ratio 
of luciferase expression Ad5TyrSL / Ad5SL was also reduced compared to Ad5TyrIL 
/ Ad5IL. Interestingly, the ratio of transgene activity by the Ad5TyrTL was in the 
control cells around one indicating a similar level of transgene expression for 
Ad5TyrTL and Ad5TL. In conclusion, the mode of transgene expression critically 
determines the specificity resulting in descending order of melanoma selective 
luciferase activity from Ad5TyrSL to Ad5TyrIL to Ad5TyrTL. Accordingly the minimal 
residual expression of luciferase by Ad5TyrSL in HFF and HaCat argued for a 
specifically “off” status of transgene expression indirectly regulated by TyrE/P in the 
context of the Ad5TyrSL genome. 
Furthermore, for detailed analysis of the specificity of transgene expression, HaCat, 
HFF and A549 cells were infected at 1TCID50/cell with the total panel of recombinant 
adenoviruses and genome replication was either blocked by adding AraC at a 
concentration of 2µM or cells were mock treated. Of note, this showed whether the 
targeting of adenoviral replication and indirectly the controlling of luciferase 
expression by the TyrE/P “mimic” the blocking of viral replication by adding the 
inhibitor AraC resulting in reduced luciferase activity in control cells. Cells were 
harvested 48 hours post infection and luciferase activity was determined (Fig. 12B). 
Efficient luciferase activity was detected for Ad5TL, Ad5IL and Ad5SL and 
surprisingly, for the melanoma targeted Ad5TyrTL and Ad5TyrIL. As depicted in 
figure 12B, no significant difference of transgene activity was observed for Ad5TyrTL 
and Ad5TL in the different cell types. Luciferase activity of Ad5TyrIL reaches nearly 
similar level when compared to Ad5IL in A549 cells, but decreased in the control cells 
yielding RLUs 47.1 (HaCat) - and 11.89 (HFF) -fold lower than for the Ad5IL. 
Depending on the cell line the level of transgene activity resulted from the Ad5TyrSL 
was 712.50-fold (HaCat), 199.17-fold (HFF) or 8.45-fold (A549) reduced in 
comparison to Ad5∆24SL. In addition, the inhibitor AraC blocked transgene activity of 
Ad5TL, Ad5IL and Ad5SL in HaCat, HFF and A549 (Fig 12B). Note, however, I 
observed that the AraC did not completely block adenovirus genome replication in 
HaCat cells (Fig. 13B). With the exception of Ad5TyrSL in HaCat cells, adding AraC 
led to lower levels of luciferase activity as the corresponding melanoma targeted 
adenoviruses. This tight control of transgene activity of Ad5TyrSL in comparison to 
Ad5SL inhibited by AraC showed the high selectivity of transgene activity. 
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5.1.6 Efficacy and kinetics of luciferase mRNA expression for the 
recombinant oncolytic viruses 
Next, magnitude and kinetics of luciferase mRNA expression by the recombinant 
oncolytic viruses were evaluated over the first 30h of the viral replication cycle. In 
addition, the specificity of transgene expression by the TyrE/P recombinant viruses 
was compared to the corresponding untargeted viruses in the control cell line HaCat. 
In this regard, HaCat cells were infected at 10TCID50/cell with the total panel of 
recombinant adenoviruses. Luciferase mRNA was quantified 6, 12, 18, 24, and 30 h 
post infection by real time PCR (Fig. 13A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.13: Efficacy and kinetics of mRNA expression from the transgene. (A/B/C) SK-MEL-28 and 
HaCat cells were infected with the indicated OAds at 10TCID50/cell. When indicated, viral replication in 
HaCat cells was inhibited by adding 2 µM of AraC 1 h, 12 h and 24 h post infection. Luciferase 
messenger RNA copies were quantified 6, 12, 18, 24, and 30 h after infection by Real Time PCR and 
are shown after normalization with mass of cellular RNAs determined by GAPDH messenger RNA 
copy numbers. One representative experiment out of at least three is shown. 
 
An increase of luciferase activity was determined from 6 to 30 h post infection for all 
recombinant viruses. However, for Ad5IL and Ad5SL, copy numbers for luciferase 
message were approximately 1500-fold or 2800-fold of those of the corresponding 
melanoma targeted adenoviruses Ad5TyrIL and Ad5TyrSL, respectively, over the 
time interval 18 – 30 h post infection in HaCat cells. This observation shows a TyrE/P 
dependent reduction of transgene expression in the control cells HaCat. On the 
contrary, after infection of HaCat cells with Ad5TyrTL and Ad5TL the same luciferase 
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expression pattern was observed for both viruses, representing an ineffective indirect 
transcriptional targeting. 
Due to the high specificity of luciferase activity by Ad5TyrSL evaluated in HaCat 
cells, in the following experiments I focused on the more detailed analysis of 
luciferase expression by Ad5TyrSL and the corresponding untargeted Ad5SL. Since, 
luciferase expression by Ad5TyrSL should be dependent on the transcriptional 
targeting of adenoviral replication by the TyrE/P, the levels of luciferase mRNA in 
Ad5TyrSL-, Ad5SL- and the parental virus Ad5∆24E3- infected cells were analyzed 
either after blocking viral replication by adding inhibitor AraC at a concentration of 
2µM or in untreated HaCaT cells (Fig. 13B). Luciferase mRNA was quantified 6, 12, 
18, 24, and 30 h post infection by real time PCR. For Ad5SL, expression of luciferase 
mRNA started 6 h later and was severely attenuated by the replication inhibitor AraC. 
Compared with the Ad5TyrSL, expression of luciferase messages by Ad5SL was still 
156.41-fold (with AraC) and 8041.80-fold (without AraC) increased 30 h post 
infection. Independent of AraC, luciferase expression by Ad5TyrSL and the control 
virus Ad5∆24E3-, which has no luciferase gene, was nearly similar in HaCat cells 
indicating background readings which cannot be attributed to transgene expression. 
To exclude that the high specificity of luciferase expression in HaCat cells by 
Ad5TyrSL results from a general reduction of transgene expression of Ad5TyrSL in 
comparison to Ad5SL, I evaluated luciferase mRNA expression after infection of the 
melanoma cell line SK-MEL-28 at 10TCID50/cell with Ad5TyrSL, Ad5SL and 
Ad5∆24E3-. In contrast to the parental virus Ad5∆24E3-, increasing mRNA copy 
numbers of luciferase were detected over the first 30 h post infection of Ad5TyrSL 
and Ad5SL in SK-MEL-28 (Fig. 13C). Of note, the same mRNA expression pattern 
for Ad5TyrSL and Ad5SL in SK-MEL-28 cells reflects that insertion of TyrE/P into the 
adenoviral genome of Ad5SL does not interfere with the luciferase expression.  
 
5.1.7 Efficacy and specificity of expression of the viral early E1A gene and 
the late fiber gene and quantification of virus genome copy numbers  
I could show that the specific cellular TyrE/P construct facilitated indirect 
transcriptional targeting of luciferase expression by the recombinant oncolytic 
adenoviruses Ad5TyrIL and Ad5TyrSL. Further, I investigated how the different 
insertion strategies of the luciferase gene influence the specificity of E1A expression 
controlled by the TyrE/P, the selective amplification of the viral genome as well as 
efficacy and specificity of the viral fiber gene expression.  
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In this regard, E1A mRNA expression was measured over the first 30h of the viral 
replication cycle (Fig. 14A).  
 
 
Fig.14: Kinetics and efficiency of messenger RNA expression form the viral early gene E1A of 
recombinant OAds (A) For quantification of E1A messenger RNA copy numbers in a period of 30 h, 
HaCat cells were infected with the indicated viruses at 10TCID50/cell. At 6, 12, 18, 24 and 30 h after 
infection the RNA copy numbers for viral E1A were determined by Real Time PCR and are shown 
after normalization with mass of cellular RNAs determined by GAPDH messenger RNA copy numbers. 
(B) The left panel shows the quantification of copy numbers of early E1A mRNA 24 h after infection of 
SK-MEL-28. Columns show mean values of triplicate infection and error bars show standard 
deviations. In the right panel is the quantification of E1A messenger RNA copy numbers in a period of 
30 h after infection of SK-MEL-28 cells with the indicated viruses at 10TCID50/cell shown. Data are 
presented as described in (A) One representative experiment out of at least three is shown. 
 
Therefore, HaCat cells were infected with the total panel of recombinant 
adenoviruses. Values were quantified 6, 12, 18, 24, and 30 h post infection by real 
time PCR. In HaCat cells a high E1A mRNA copy number for Ad5IL and Ad5SL were 
quantified 30 h after virus infection. However, E1A mRNA copy numbers were 
dramatically lower for Ad5TyrIL (21946.9-fold) and Ad5TyrSL (57582.3-fold) at late 
time points compared to the untargeted, recombinant adenoviruses (Ad5IL, Ad5SL). 
For Ad5TyrTL, the E1A mRNA level was only minimal attenuated in comparison to 
Ad5TL and still 29-fold higher as for Ad5TyrIL and Ad5TyrSL. Relative to the values 
of transgene expression (Fig. 13A), specificity of E1A expression by the melanoma 
targeted recombinant viruses correlated with the selectivity of luciferase expression 
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which is ordered from Ad5TyrSL > Ad5TyrIL > Ad5TyrTL. Of note, the mode of 
transgene expression has an influence on the specificity of the TyrE/P and therefore 
on E1A mRNA expression.  
As the expression of E1A mRNA reflected the highest selectivity of indirect 
transcriptional control by the TyrE/P within the context of Ad5TyrSL in HaCat cells, 
E1A expression was analyzed in SK-MEL-28 cells to investigate the efficacy of E1A 
mRNA expression resulting from Ad5TyrSL compared the corresponding unspecific 
Ad5SL and the parental virus, Ad5∆24E3-. E1A mRNA copy numbers were 
quantified 6, 12, 18, 24, and 30 h post infection of the melanoma cell line SK-MEL-28 
by real time PCR. The 30 h kinetics of E1A messages by Ad5TyrSL showed an 
almost similar increase compared to Ad5SL and Ad5∆24E3- early after adenoviral 
infection but was 3.2-fold reduced at the later time point (Fig. 14B).  
To analyze the E1A expression values by the Ad5TyrSL, Ad5SL and Ad5∆24E3- in 
comparison to Ad5TL, Ad5IL, Ad5TyrTL and Ad5TyrIL, SK-MEL-28 were additionally 
infected with the total panel of recombinant adenoviruses and E1A mRNA was 
measured 24 h post infection. E1A mRNA copy numbers were 26.7-fold (Ad5TyrTL), 
12-fold (Ad5TyrIL), 40.3-fold (Ad5IL), 4.1-fold (Ad5TyrSL), 10.5-fold (Ad5SL) 
increased and 3.3-fold (Ad5TL) attenuated relative to the parental virus Ad5∆24E3- 
in SK-MEL-28 (Fig. 14B). These results correlate with the oncolysis data of the 
recombinant viruses in SK-MEL-28 (Fig. 10). 
Next, the effect of the different strategies of transgene integration into the viral 
genome on viral replication was analyzed. Hence, amplification of the viral genome 
was measured over the first 30h of the viral replication cycle. Therefore, HaCat cells 
were infected with the total panel of recombinant viruses. Genome copy numbers 
were quantified 6, 12, 18, 24, and 30 h post infection by real time PCR. As expected, 
genome copy numbers of melanoma targeted adenoviruses Ad5TyrIL and Ad5TyrSL 
were approximately 2.5 orders of magnitude reduced 30h post infection in HaCat 
cells (Fig. 15A) compared with Ad5IL and Ad5SL, respectively. In contrast, at late 
time points genome copy numbers were almost identical for Ad5TyrTL and Ad5TL. 
Of note, the analysis of the genome copy number correlates with the E1A mRNA 
expression pattern indicating that viral genome replication is dependent on the 
expression of E1A and that the different transgene insertion strategies resulted in a 
downward order of selectivity of viral replication from Ad5TyrSL >  Ad5TyrIL > 
Ad5TyrTL. 
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Moreover, to further investigate the specificity of viral replication by the Ad5TyrSL, 
genome copy numbers of Ad5TyrSL, Ad5SL and Ad5∆24E3- were evaluated in 30 h 
kinetics in absence or presence of the viral replication inhibitor AraC. As depicted in 
figure 15B, viral replication of Ad5SL and Ad5∆24E3- could not be completely 
blocked by the inhibitor AraC. However, addition of AraC led to a reduction of 
genome copy numbers for Ad5SL and Ad5∆24E3- starting form 18 h after infection of 
HaCat cells. For Ad5TyrSL replication efficiency was severely attenuated compared 
with Ad5SL and Ad5∆24E3-. This observation was independent of the inhibitor AraC 
and indicates melanoma specific replication of Ad5TyrSL conditioned on the 
expression of E1A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15: Quantification of virus genome copy numbers of recombinant OAds in SK-MEL-28 and 
HaCat cells. (A/B/C) To analyze adenovirus genome copy numbers HaCat and SK-MEL-28 cells were 
infected with the indicated viruses at 10TCID50/cell. If indicated, viral replication in HaCat cells was 
inhibited by AraC added 1 h post infection. At 6, 12, 18, 24 and 30 h after infection genome copy 
numbers were determined by Real Time PCR and are shown after normalization with nanograms 
cellular genomic DNA determined by β-actin messenger DNA copy numbers. 
 
To underline that the reduction of genome copy numbers of Ad5TyrSL in HaCat cells 
comes from a high specificity of viral replication and is not a result of a generally 
lower replication rate of Ad5TyrSL, genome copy numbers of this recombinant virus 
was compared with Ad5SL and Ad5∆24E3- in melanoma cells. In this regard, SK-
MEL-28 was infected at 10TCID50/cell with Ad5TyrSL, Ad5SL and Ad5∆24E3- and 
genome copy numbers were quantified at different time points by real time PCR. The 
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genome copy numbers for Ad5TyrSL, Ad5SL and Ad5∆24E3- increased continuously 
over time with the sharpest increase from 18 – 30 h and ended up at the same level. 
This shows, that the transgene insertion by an additional splice acceptor site and the 
TyrE/P do not have an effect on the viral replication in SK-MEL-28. Consequently, all 
analyzed viruses showed the same efficacy of genome replication in melanoma cells. 
Next, it was analyzed whether the insertion of the transgene into the late transcription 
unit of the adenoviral genome interferes with the expression of the neighbouring late 
viral genes such as fiber. Therefore, expression of fiber mRNA was measured by real 
time PCR 6, 12, 18, 24 and 30 h after infection of HaCat cells with the total panel of 
recombinant viruses. 30 h after infection values of fiber messages were near four 
orders of magnitude increased compared to the early time point for Ad5IL and 
Ad5SL. According to the specific E1A expression, transgene expression and viral 
replication by Ad5TyrIL and Ad5TyrSL, fiber mRNA expression was reduced three 
orders of magnitudes 30 h post infection of HaCaT cells compared to cells infected 
with the corresponding, untargeted viruses. In contrast, the Ad5TyrTL and Ad5TL 
showed a similar level of fiber mRNA expression starting from 18 h after infection 
indicating that the late gene expression is independent of TyrE/P and not specific for 
melanoma cells. Furthermore, the expression of the structural protein fiber was 
analyzed by western blot (Fig. 16A).  
 
 
Fig.16: Kinetics and efficiency of expression of the viral late gene fiber by determination of fiber 
messenger RNA and protein. (A) For quantification of late fiber messenger RNA copy numbers, 
HaCat cells were infected with the indicated viruses at 10TCID50/cell. At 6, 12, 18, 24 and 30 h after 
infection mRNA copy numbers for the viral fiber gene were determined by Real Time PCR and are 
shown after normalization with mass of cellular RNA determined by GAPDH messenger RNA copy 
numbers. (B) SK-MEL-28 and HaCat cells were infected at 100TCID50/cell with the indicated viruses 
and were harvested one day post infection. Immunoblots were performed to detect viral Ad5 fiber or β-
actin. 
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HaCat cells were infected at 100 TCID50/cell with the total panel of recombinant 
viruses including Ad5∆24E3-. 24 h post infection total cell lysates were applied for 
SDS gel electrophoresis, followed by immunoblotting and detection of viral fiber 
protein. ß-actin was used as loading control. The results (Fig. 16B) demonstrated 
expression of fiber protein in HaCat cells infected with the recombinant viruses 
except the Ad5TyrSL. However, strongest protein expression was detectable after 
infection of Ad5TyrTL. Infection of HaCat cells yielded a high amount of fiber protein 
level by Ad5IL reducing in compare to Ad5SL. For Ad5TyrIL and Ad5TyrSL, fiber 
expression is clearly decreased or completely blocked compared to the Ad5IL and 
Ad5SL, whereas Ad5TyrTL and Ad5TL showed similar fiber expression. To 
determine the specificity of the protein expression in the context of recombinant 
viruses, fiber expression was analyzed 24 h post infection of the total panel of 
recombinant viruses as well as Ad5∆24E3- in the melanoma cell line SK-MEL-28. 
Western blot analysis demonstrated strong expression of fiber after infection with the 
recombinant viruses, except for Ad5TL and the parental virus Ad5∆24E3-. Of note, 
this observation implies that insertion of the luciferase-cassette per se does not 
reduce fiber expression by Ad5IL, Ad5SL, Ad5TyrTL, Ad5TyrIL and Ad5TyrSL in 
melanoma cells. As expected, infection with Ad5TyrSL resulted in highly specific 
expression of fiber in melanoma cells in comparison to control cells HaCat, reflecting 
the specificity of E1A and luciferase expression by Ad5TyrSL. In comparison to 
Ad5TyrSL the specificity of fiber expression by AdTyrIL and AdTyrTL was reduced or 
unregulated, respectively. 
 
5.1.8 Analysis of interference between splice acceptor site and E4 
expression in the context of Ad5SL  
Next, I analyzed whether insertion of the luciferase gene into the genome of Ad5SL 
interferes with expression of the neighbouring E4 genes, which are located between 
the fiber gene and the transgene (Fig. 9). This locale of transgene insertion differs 
from the other insertion strategies and could critically determine the efficacy of E4 
expression, depending on mRNA stability and splicing. For this purpose E4 mRNA 
expression by Ad5SL was compared to mRNA expression of the same genes in the 
parental virus Ad5∆24E3- in the SK-MEL-28 cell line by real time PCR (Fig. 17). E4 
mRNA copy numbers were similar for Ad5SL and Ad5∆24E3- over the whole time 
interval evaluated in this experiment. The increase in E4 messages from 6 to 30 h 
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was 26790-fold for both viruses indicating E4 mRNA expression was not affected by 
transgene insertion.  
 
 
Fig.17: Analysis of possible interference of 
splice acceptor site with E4 expression in 
the context of Ad5SL. SK-MEL-28 cells were 
infected with Ad5SL or Ad5D24E3- at 
10TCID50/cell and messenger RNA copy 
numbers were determined for the E4 genes at 
indicated time points. Values are shown after 
normalization with mass of cellular RNA 
determined by GAPDH messenger RNA copy 
numbers. One representative experiment out of 
at least two is shown. 
 
 
 
5.1.9 Expression of therapeutic genes by oncolytic adenoviruses via 
alternative splicing depends on the transgene 
My studies of the recombinant oncolytic adenoviruses have shown that the splice 
acceptor sequences can be used to achieve melanoma selective transgene 
expression in the context of Ad5TyrSL and Ad5TyrIL. AdTyrIL showed higher 
transgene expression level, however, transgene expression by AdTyrSL was more 
specific. Based on the required specificity of therapeutic gene expression for 
therapeutic application I decided to concentrate on Ad5TyrSL. This virus represents a 
genomically tool for arming oncolytic adenoviruses with therapeutic genes. 
 
 
Fig.18: Adenovirus constructs with CD-
FUR-1 fusion gene inserted into the late 
transcription unit via SA. Schematic outline 
of the genomes of the oncolytic viruses with 
insertion of FCU-1 gene encoding the yeast 
CD-FUR-1 fusion protein. Shown are the right 
termini of the genomes (see Fig. 9 for left 
termini of Ad5 and Ad5Tyr genomes). E4, 
early adenoviral gene; FCU_mut crypt. SA, 
FCU-1 gene with mutation of cryptic splice 
acceptor site; pA, polyadenylation signal; 
RITR, right inverted terminal repeat; SA, 
splice acceptor site.  
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Fig.19: Expression of the CD-FUR-1 fusion gene inserted into the late transcription unit via SA 
requires sequence optimization. (A) SK-MEL-28 cells were infected at 100TCID50/cell and 
expression of the CD-FUR-1 fusion protein was detected by Immunoblot two days post-infection. As 
loading control α-tubulin was detected. (B) SK-MEL-28 cells were infected at 10TCID50/cell in the 
absence or presence of AraC and fiber expression was detected by Immunoblot one day post-
infection. As loading control β-actin was detected. (C) Schematic outline of the FCU-1 gene insertion 
via SA into the late virus transcription unit and sequence optimization in 
Ad5Ssp_mFCU/Ad5TyrSsp_mFCU. Numbers indicate nucleotide positions in the Ad5 genome or 
FCU-1 gene. The non-coding spacer corresponds to nucleotides 4 to 54 of the luciferase 
gene.Nucleotide sequences indicate the cryptic splice acceptor site (FCU_cryp. SA) and the mutations 
we introduced (FCU_ mut cryp. SA). (D) RT-PCR analysis of FCU-1 mRNA expression by SK-MEL-28 
harvested one day post-infection with adenoviruses at 100TCID50/cell and using the primer pair 
indicated in C. The correct splice product is 1185bp. (E) qPCR analysis of FCU-1 mRNA expression in 
melanoma cells and keratinocytes harvested one day post-infection with adenoviruses at 
10TCID50/cell. 
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In this regard, the prodrug activating enzyme cytosine deaminase / uracil 
phosphoribosyltransferase fusion gene (FCU-1) from yeast (Erbs et al., 2000) was 
inserted into the late transcription unit of the Ad5TyrSL genome by replacing the 
luciferase gene (Ad5SFCU and Ad5TyrSFCU, Fig. 18). 
To my surprise, analysis of FCU-1 expression demonstrated that enzyme expression 
via alternative splicing was insufficient (Fig. 19A), even though the fiber gene was 
expressed (Fig. 19B) and lytic activity was not affected (Fig. 20). As their genomes 
outside the FCU-1 gene matched those of Ad5SL and Ad5TyrSL, I speculated that 
the different nucleotide sequence downstream of the SA in Ad5SFCU and 
Ad5TyrSFCU interfered with proper splicing. To optimize the splicing machinery a 
51bp long, non coding sequences of the luciferase gene were inserted as spacer 
between the splice acceptor sequence and the FCU-1 gene. These Ad5Ssp_FCU 
and AdTyrSsp_FCU viruses contain a SA nucleotide environment which is more 
similar to the surrounding sequences of the splice acceptor site of Ad5SL and 
AdTyrSL in comparison to Ad5SFCU and Ad5TyrSFCU (Fig. 18 and 19C). However, 
these viruses only showed marginal FCU-1 expression (Fig. 19A). I then analyzed 
FCU-1 mRNA expression and splicing in Ad5TyrSFCU-infected SK-MEL-28 cells. By 
RT-PCR using a forward primer binding in the tripartite leader and a reverse primer 
binding in the 3’ end of the FCU-1 gene a 1185 bp product was expected if splicing 
was correct, however we obtained a band of approximately 550bp (Fig. 19D). 
Sequencing of the PCR products revealed a cryptic splice acceptor site at position 
594 of the FCU-1 gene, that prevented synthesis of the proper fusion protein-
encoding mRNA. This position was also found in a search for splice sites using 
EMBnet / Scientific Computing Service software. In the light of these results I 
generated Ad5Ssp_mFCU and Ad5TyrSsp_mFCU by completely changing the 
sequence surrounding the cryptic splice acceptor site within the FCU-1 gene with 
silent mutations (Fig. 18, 19C).  
After infection of SK-MEL-28 cells, Ad5Ssp_mFCU and Ad5TyrSsp_mFCU 
expressed the CD-FUR-1 fusion protein (Fig. 19A). CD-FUR-1 expression was 
stronger for Ad5TyrSsp_mFCU than for Ad5Ssp_mFCU, which corresponded to the 
strength of luciferase expression observed for Ad5TyrSL and Ad5SL (Fig. 12). 
Viruses with mutated FCU-1 gene but without spacer (Ad5TyrS_mFCU and 
Ad5S_mFCU) showed lower CD-FUR-1 expression than Ad5TyrSsp_mFCU and 
Ad5Ssp_mFCU (not shown); indicating that the combination of cryptic splice site 
mutation and spacer ensured strongest transgene expression. As expected, 
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expression of fiber protein by Ad5TyrSsp_mFCU and Ad5Ssp_mFCU was dependent 
on virus replication and specific for melanoma cells (Fig. 19A and B). Immunoblot 
analysis was not sensitive enough to detect CD-FUR-1 protein in HaCat cells; 
however, I could demonstrate by qRT-PCR that FCU-1 mRNA expression by 
Ad5TyrSsp_mFCU was highly melanoma-specific (Fig. 19E). I conclude that insertion 
of the prodrug convertase fusion gene FCU-1 via SA into the late transcription unit of 
oncolytic adenovirus Ad5Tyr requires sequence optimization, but results in 
transcriptionally targeted FCU-1 expression.  
 
5.1.10 Lytic activity and specificity of armed oncolytic adenoviruses in 
melanoma and non-melanoma cells 
First, the lytic activity and specificity of the FCU1-armed oncolytic adenoviruses was 
determined by infection of melanoma and non melanoma cells. In this regard, cells 
were infected with the FCU1-armed oncolytic adenoviruses (Ad5TyrSFCU, 
Ad5TyrSsp_FCU, Ad5TyrSsp_mFCU and Ad5Ssp_mFCU) and the Ad5CMVFCU 
that served as a non-replicating control at virus titers of 0.001 to 100TCID50/cell in 
10-fold dilutions. Cell killing was detected by staining of surviving, adherent cells with 
crystal violet (Fig. 20). As expected, no cell killing was observed for all cells infected 
with Ad5CMVFCU regardless of which titer was used. Cytopathic effect of 
Ad5TyrSFCU, Ad5TyrSsp_FCU and Ad5TyrSsp_mFCU was similar to 
Ad5Ssp_mFCU in the melanoma cell lines Mel888 and SK-MEL-28. Of note, 
Ad5Ssp_mFCU and Ad5Ssp_mFCU were 10-fold superior to the melanoma targeted 
armed viruses Ad5TyrSFCU and Ad5TyrSsp_FCU in the cell killing of Mel624. 
Besides, Ad5Ssp_mFCU showed the most potent cytotoxicity in the tested control 
cell lines HaCat, A549 and HFF, which was approximately 2 to 3 orders of magnitude 
stronger compared to the melanoma targeted armed viruses. Importantly, the 
targeted armed viruses showed no cell killing of HaCat cells, even when infected at 
high titers. Minimal cell lysis by Ad5TyrSFCU, Ad5TyrSsp_FCU and 
Ad5TyrSsp_mFCU at 100TCID50/cell was observed in A549 and HFF. These results 
show that insertion of the mutated FCU-1 gene, SA and spacer did not interfere with 
selective replication of the virus. 
 
Results   67 
 
Fig.20: Oncolytic activity of adenovirus constructs with FCU-1 gene inserted via SA into the late 
transcription. Melanoma cells (SK-MEL-28, Mel624, Mel888), HaCat, HFF and A549 were infected 
with adenoviruses and cytotoxicity was determined by crystal violet staining of surviving cells when 
cytotoxicity was observed for the most potent virus at 1 or 0.1TCID50/cell for each cell type individually. 
Numbers are viral titers in TCID50/cell. Ad5CMVFCU is an E1/E3-deleted replication-deficient 
adenovirus with CMV-FCU-1 expression cassette.  
 
5.1.11 Combining of adenoviral oncolysis with suicide gene therapy by 
indirect transcriptional targeting of genetic prodrug activation 
In a virus burst assay, which over a single round of virus replication measure the 
infectious virus particles in a cell population, I first assessed the effect of 5-FC on 
virus production and release. For that purpose, SK-MEL-28 cells were infected at 
1TCID50/cell with Ad5TyrSsp_mFCU or Ad5Ssp_mFCU in the presence or absence 
of the prodrug 5-FC. Three days post infection supernatant and cells were harvested 
and amounts of total infectious virus particles were measured (Fig. 21). 
 
Fig.21: Progeny production of adenovirus 
constructs with FCU-1 gene inserted via SA into 
the late transcription. SK-MEL-28 cells were 
infected with the indicated viruses at 1TCID50/cell and 
one day post infection cells were incubated with 
10mM FC. Three days post infection, cells and 
supernatant were harvested separately and titers of 
infectious viral particles were determined by TCID50 
assay. Infections were performed in triplicates. 
Columns show mean titers, arrow bars show standard 
deviations.  
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The results showed that application of 5-FC was compatible with the production of 
infectious particles of Ad5TyrSsp_mFCU or Ad5Ssp_mFCU at high titers in 
melanoma cells, although virus yields were reduced 8.2- and 1.5-fold, respectively. I 
next investigated a combination therapy of viral oncolysis and tumour-targeted 
prodrug activation mediated by Ad5TyrSsp_mFCU. Therefore, I infected melanoma 
cells SK-MEL-28 and Mel624, and HaCat cells with dilutions of Ad5TyrSsp_mFCU, 
with Ad5Ssp_mFCU, Ad5SL or replication-deficient Ad5CMVFCU expressing FCU-1 
from the strong CMV enhancer/promoter. 
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Fig.22: Combined oncolysis and prodrug activation therapy by adenovirus constructs with 
FCU-1 gene inserted via SA into the late transcription unit. (A/B) Melanoma cells (SK-MEL-28, 
Mel624), and keratinocytes (HaCat) were infected with with adenoviruses at indicated titers or were 
mock-infected in triplicates. 5-FC or medium was added two day post-infection at 10mM (SK-MEL-28, 
HaCat) and at 5mM (Mel624) concentration. Cytotoxicity was determined six days post-infection by 
staining of surviving cells with crystal violet. (A) Cell content was determined by measuring OD595 and 
cell viability was plotted in % of mock-infected cells that did not obtain 5-FC. Mean values of triplicates 
are shown. For clarity of presentation, standard deviations are not shown and were below 16.6%. (B) 
Crystal violet-stained plates for the experiments with SK-MEL-28, Mel624 and HaCat cells. 
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The prodrug 5-FC or mock were added two days post-infection, thus before virus 
spread, and cytotoxicity was determined four days later (Fig. 20/21). As expected, 
the replication-competent adenoviruses Ad5Ssp_mFCU, Ad5TyrSsp_mFCU and 
Ad5SL showed similar dose-dependent cytotoxicity in melanoma cells, which was not 
observed for replication-deficient AdCMVFCU-1. Addition of 5-FC resulted in 
increased cytotoxicity for all FCU-1-encoding adenoviruses, but not for Ad5SL in 
melanoma cells. In both melanoma cells, the strongest cytotoxicity was observed for 
Ad5TyrSsp_mFCU in the presence of 5-FC, which reduced the viral IC50 dose 
approximately 10-fold. The stronger prodrug effect in comparison to Ad5Ssp_mFCU 
+ 5-FC corresponds with the higher expression of CD-FUR-1 by Ad5TyrSsp_mFCU 
(Fig. 22). In contrast to melanoma cells, the untargeted Ad5Ssp_mFCU + 5-FC 
showed the strongest cytotoxicity in HaCat cells. For Ad5TyrSsp_mFCU no 
cytotoxicity was observed in the absence of 5-FC and only at the highest virus titer 
we observed a prodrug effect. Note that in these cells 5-FC mediated also an 
increase in cytotoxicity of Ad5SL, which does not encode the prodrug convertase. I 
conclude that Ad5TyrSsp_mFCU induces melanoma-selective oncolysis and 
selectively enhanced cytotoxicity in combination with 5-FC.  
When combined with viral oncolysis, a bystander effect of genetic prodrug activation 
is essential in order to kill those tumour cells that the lytic virus cannot reach, for 
example due to connective tissue barriers in the tumour. We therefore investigated 
whether Ad5TyrSsp_mFCU + 5-FC has the potential to induce bystander killing in 
melanoma cells (Fig. 23).  
 
 
Fig. 23: Bystander effect of prodrug activation by 
adenovirus constructs with CD-FUR-1 fusion gene 
inserted via SA into the late transcription unit. SK-MEL-28 
cells were infected with Ad5TyrSsp_mFCU, Ad5CMVFCU or 
Ad5SL at 10 TCID50/cell. 5-FC at a concentration of 10mM 
was added two days post-infection; as control, 
Ad5TyrSsp_mFCU-infected cells were treated with media 
alone. Supernatants were harvested three days post-infection 
and were incubation for 10 min at 50°C for virus inactivation. 
Then, each heat-treated supernatant was added in a 3-fold 
dilution series to fresh SK-MEL-28 cell monolayer. In parallel, 
SK-MEL-28 cells were treated with a 3-fold dilution series of 
10 mM 5-FU or of 10 mM 5-FU after 10 min incubation at 
50°C. The arrow indicates increasing dilutions of 
supernatants/5-FU. Cytotoxicity was determined four days 
post-infection by staining of surviving cells with crystal violet. 
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Supernatants of Ad5TyrSsp_mFCU-infected and 5-FC-treated SK-MEL-28 cells 
showed a clear cytotoxicity for uninfected SK-MEL-28 cells when viruses in the 
supernatants were heat-inactivated. Cytotoxicity of supernatants was nearly as 
efficient as 10 mM of the drug 5-FU. As the prodrug 5-FC was added at 10 mM to the 
Ad5TyrSsp_mFCU-infected cells, these results demonstrate efficient activation of the 
prodrug and release of the drug into the media by Ad5TyrSsp_mFCU-infected SK-
MEL-28 cells. No bystander killing was observed for Ad5SL/5-FC or for 
Ad5TyrSsp_mFCU without 5-FC, indicating that virus particles in the supernatants 
were effectively inactivated by heat-treatment and that the detected cytotoxicity was 
dependent on prodrug-activation. 
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5.2 Targeting Oncolytic Adenoviruses based on Tumour Selective 
Cell Entry 
Recombinant adenoviruses have emerged as promising agents in therapeutic gene 
transfer, genetic vaccination and viral oncolysis. For therapeutic applications of 
adenoviruses cell type-selective viral cell entry, for example into cancer or immune 
cells, should be engineered. Such tropism-modification of adenoviruses requires the 
ablation of their natural cell binding properties and the incorporation of cell-binding 
ligands. The short fiber of subgroup F (F41s) adenoviruses has recently been 
suggested as a tool for genetic adenovirus detargeting based on the reduced liver 
infectivity of corresponding fiber chimeric adenovectors in vitro and in vivo. In regard 
to this, the aim of my project was to generate an oncolytic adenovirus that features 
the Ad41 short fiber to ablate the native tropism. To retarget the virus cell-binding 
ligands were inserted into the ablated Ad41 short fiber regaining cell-specific 
infectivity.  
 
 
Fig.24: Structure of the Ad41s fiber 
knob indicating the positions 
chosen for RGD insertion (Hesse et 
al., 2007). (left panel) knob monomer 
seen from the side (its position relative 
to the fiber shaft is indicated); (right 
panel) knob monomer seen from the 
top. 
 
 
 
 
 
Based on previous studies on functional insertion sites for a RGD model peptide into 
the Ad41 short fiber knob of replication-deficient adenovectors (Hesse et al. 2007; 
Fig. 24) I investigated (I) the F41s in context of oncolytic adenoviruses using a RGD 
model peptide and (ii) targeting cell entry by insertion of a described tumour cell-
binding peptide ligand into this fiber format. 
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5.2.1 F41s-pseudotyped recombinant adenoviruses as platform for 
insertion of RGD model peptide 
 
5.2.1.1 Generation of F41s-pseudotyped recombinant oncolytic 
adenoviruses  
Towards the goal to engineer the capsid of an oncolytic virus for optimal ablation of 
the native tropism and insertion of the RGD model peptide, I generated F41s-
pseudotyped oncolytic adenoviruses (Ad5/41sHI-RGD, Ad5/41sIJ-RGD, Ad5/41sEG-
RGD) with genetic insertion of the RGD peptide into the EG, HI and IJ loops of the 
41s knob domain. All recombinant adenoviruses code for chimeric F5/41s fiber 
constructs containing the tail domain of the Ad5 fiber fused to the shaft and knob 
domain of Ad41s fiber (Fig. 25). To investigate the role of the Ad41s shaft domain in 
context of oncolytic adenoviruses, a recombinant virus with a fiber construct matching 
Ad5/41sHI-RGD with the shaft domain of Ad5 fiber (Ad5ts41sHI-RGD) was 
generated. I hypothesize that both, length and flexibility of the shaft domain 
determines the efficiency and affinity of the interaction of ligands inserted into the 
fiber knob domain with their cellular receptors. The recombinant virus Ad5HI-RGD 
was produced as the corresponding control coding for the Ad5 fiber with the RGD 
model peptide insertion into the HI loop of the Ad5 knob domain. Concerning former 
reports that double mutants lacking both CAR- and integrin binding showed reduced 
liver tropism (Koizumi et al. 2003; Einfeld et al. 2001) I decided to mutate the integrin-
binding motif within the virus penton base of Ad5/41sHI-RGD. My focus was to 
analyze this Ad5RAE41sHI-RGD virus regarding the efficiency of viral cytotoxicity 
and as further steps, after replacing the RGD model peptide by a tumour cell-binding 
peptide ligand, to investigate the cell-specificity. All viruses could be produced in 293 
cells at high titers (Fig. 25C). However, the ratio of vp/ml versus TCID50/ml of 
Ad5/41sHI-RGD and Ad5/41sEG-RGD was approximately 10-fold higher in 
comparison to the other viruses indicating a higher concentration of non-functional 
virus particles in these virus preparations. After production of Ad5RAE41sHI-RGD no 
further detailed analysis was done. 
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Fig.25: Generation of F41s-pseudotyped recombinant oncolytic adenoviruses carrying the RGD 
peptide. (A) Schematic representation of adenovirus serotype 5 (F5), 41s (F41s) fiber and the 
chimeric fiber F5/41s and F5ts41s. To generate the chimeric fiber F5/41s the Ad5 fiber tail domain was 
fused to the Ad41s fiber shaft and knob domain. To generate the chimeric fiber F5ts41s the Ad5 fiber 
tail and shaft domain was fused to the Ad41s fiber knob domain. (B) Outline of RGD peptide insertions 
into various position of the Ad41s fiber knob. A CDCRGDCFC peptide with the indicated linkers (italic) 
was inserted into the EG, HI and IJ loop of Ad41s fiber knob (numbers in parenthesis refer to the 
amino acid positions of the Ad41s fiber that flank the insertion site; amino acid that flank the insertion 
site are shown in single letter code). (C) Tabular overview of the produced recombinant oncolytic 
viruses. 
 
5.2.1.2 Incorporation of the chimeric fiber F5/41s with RGD peptide insertion 
into the capsid of recombinant viruses 
For examination of chimeric fiber F5/41s incorporation into the viral capsid, 1010 virus 
particles of Ad5HI-RGD, Ad5/41sHI-RGD, Ad5/41sIJ-RGD, Ad5/41sEG-RGD, 
Ad5ts41sHI-RGD and Ad5RAE41sHI-RGD were boiled and analyzed by immunoblot 
analysis with mouse monoclonal antibody clone 4D2, which binds to the Ad5 fiber 
tail, and an anti-hexon antibody. As shown in Fig. 26, all recombinant fiber constructs 
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with the RGD peptide inserted into the HI, IJ or EG loop were incorporated into the 
viral capsid with similar efficiency.  
 
Fig.26: Incorporation of the chimeric F5/41s 
fibers with RGD peptide insertion into the 
viral capsid. 1010 purified particles of the 
indicated viruses were boiled and analyzed by 
SDS-polyacrylamide gel elcetrophoresis and 
western blotting with antibody 4D2 (lower 
panel) or with an anti-hexon antibody (upper 
panel) as a loading control. The calculated 
molecular mass of the F5/41s monomer is 
42kDa and the F5 and F5ts41s monomer are 
 
 
e different viruses 
ating that equal amount of virus particles were loaded.  
 
5.2.1.3 t cell killing of chimeric fiber F5/41s viruses in 
50kDa.
 
Notably, these results demonstrated that it is possible to insert peptides into Ad41s 
fiber knob in such a way that they face the top (IJ loop) or the side (EG and HI loop) 
without destroying the virus assembly including fiber incorporation. Almost similar 
amounts of the viral capsid protein hexon were detectable for th
indic
Spread-dependen
melanoma cells 
A cytotoxicity and spread assay was performed to analyze whether the chimeric fiber 
F5/41s has an influence on viral spread of the recombinant viruses in melanoma 
cells. Therefore, SK-MEL-28 and the CAR-negative cells C8161 and pMelL were 
infected with the total panel of recombinant viruses (Ad5HI-RGD, Ad5/41sHI-RGD, 
Ad5/41sIJ-RGD, Ad5/41sEG-RGD and Ad5ts41sHI-RGD) at virus titers of 0.01 to 
1000vp/cell in 10-fold dilutions. The parental Ad5wt was used as replication control 
virus and the Ad5RGDLuc represents a replication deficient control virus. When lysis 
of melanoma cells was observed for the most potent virus at 1-0.1vp/cell, surviving 
cells were fixed and stained with crystal violet (Fig. 27). As expected, no cell killing 
was detectable for all cells infected with the replication deficient AdRGDLuc. 
Cytotoxicity was observed for all chimeric fiber F5/41s viruses and for Ad5HI-RGD. 
Of note, in principle genetic insertion of the RGD model peptide into the Ad41s knob 
domain of recombinant viruses is feasible without loss of viral spread. However, 
efficiency of cytotoxicity of chimeric fiber F5/41s viruses was reduced. In comparison 
to Ad5HI-RGD, cytopathic effect of Ad5/41sHI-RGD, Ad5/41sIJ-RGD and 
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Ad5/41sEG-RGD was 10-100 fold attenuated depending on the cell line. Independent 
from the insertion loop of RGD into Ad41s knob, almost similar level of cytotoxicity 
was shown for Ad5/41sHI-RGD, Ad5/41sIJ-RGD and Ad5/41sEG-RGD in the 
different melanoma cells. Comparable or 10-fold increased cell killing to the chimeric 
fiber F5/41s viruses (Ad5/41sHI-RGD, Ad5/41sIJ-RGD and Ad5/41sEG-RGD) was 
hown for Ad5ts41sHI-RGD.  
 
s
 
Fig.27: Cytopathic effect of chimeric fiber F5/41s viruses in melanoma cells. C8161, SK-MEL-28, 
melanoma cell lines; pMelL, low passage melanoma culture; cell cultures were infected with the 
indicated viruses at 1000vp/cell and 10-fold dilutions until 0.01vp/cell. Attached cells were stained with 
cr
re
ystal violet when cell lysis was observed at 0.1vp/cell for each cell types individually. One 
presentative experiment out of at least three is shown. 
 activity is reduced, independent of the insertion site, in comparison 
 Ad5HI-RGD.  
 
 
 
Low or no cytotoxicity of Ad5wt was detected in C8161 and pMelL due to the lack of 
the Adenovirus serotype 5 primary receptor CAR. Notably, cell entry of the total panel 
of recombinant viruses is mediated by the RGD motive inserted into the knob 
domain. In this case, viral cell entry is independent of the CAR receptor. As expected, 
potent cell killing of SK-MEL-28 was observed by Ad5wt resulting in a 10-fold 
stronger cytopathic effect than obtained with the chimeric fiber F5/41s viruses. Taken 
together, oncolysis by chimeric fiber F5/41s viruses is feasible in all tested cell lines. 
However, the lytic
to
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5.2.1.4 Efficacy of replication of chimeric fiber F5/41s viruses in melanoma 
cells 
To analyze the reason for the attenuation of viral spread by the recombinant oncolytic 
viruses cytotoxicity assay was performed. Therefore, viral replication of the 
recombinant viruses was studied over a time period of 7 days in melanoma cells. In 
this regard, the melanoma cell line C8161 was infected with the total panel of 
recombinant viruses (Ad5HI-RGD, Ad5/41sHI-RGD, Ad5/41sIJ-RGD, Ad5/41sEG-
RGD and Ad5ts41sHI-RGD), the parental Ad5wt and a replication deficient virus 
Ad5RGDLuc at virus titers of 10vp/cell. Cells were harvested 3 h and 7 days post 
infection, DNA was purified and virus genome numbers were quantified by real time 
PCR.  
 
 
Fig.28: Efficacy of replication of chimeric fiber F5/41s viruses in melanoma cells. (A) To analyze 
adenovirus genome replication, C8161 cells were infected with the indicated viruses at 10vp/cell in 
triplicates. Three hours and seven days post infection DNA was purified and ratio of adenovirus 
genome copy numbers to nanograms cellular genomic DNA was determined by real time PCR. 
Columns show mean values. Error bars show standard deviation. One representative experiment out 
of three is shown. (B) For quantification of adenovirus genome copy numbers during the first 
replication cycle C8161 and SK-MEL-28 cells were infected with Ad5HI-RGD, Ad5/41sHI-RGD and 
Ad5/41sIJ-RGD at 10vp/cell. At 8, 12, 16, 20, 24, 28 and 32 h post infection genome copy numbers 
were determined by real time PCR and are shown after normalization with mass of cellular DNA. 
Experiments were repeated at least three times; one representative experiment is shown. p.i., post 
infection; h, hours. 
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As shown in Fig. 28A, genome copy numbers of the replication-deficient Ad5RGDLuc 
were nearly constant within one week revealing replication-independent background 
of virus genomes. As expected, genome copy numbers of all recombinant viruses 
dramatically increased from 3 h to 7 days post infection. Due to the lack of the 
primary receptor CAR on the surface of C8161 genome copy numbers for Ad5wt was 
16-fold lower than for Ad5HI-RGD at day 7 indicating a lower genome amplification 
rate. Genome copy numbers of chimeric fiber F5/41s viruses (Ad5/41sHI-RGD, 
Ad5/41sIJ-RGD and Ad5/41sEG-RGD) were similar at day 7, which was lower than 
the genome copy numbers of Ad5HI-RGD but higher than Ad5wt. Of note, highest 
genome copy numbers were observed for Ad5HI-RGD and Ad5ts41sHI-RGD 7 days 
post infection.  
To further investigate the cause for the fiber-dependent differences in virus spread, 
the amplification of the genome copy numbers during the first replication cycle was 
analyzed in more detail (Fig. 28B). Therefore, C8161 and SK-MEL-28 were infected 
with Ad5HI-RGD, Ad5/41sHI-RGD and Ad5/41sIJ-RGD at 10vp/cell. Values were 
quantified 8, 12, 16, 20, 24, 28 and 32 h post infection by real time PCR. 
Amplification of adenovirus genomes for Ad5HI-RGD, Ad5/41sHI-RGD and 
Ad5/41sIJ-RGD was detected in both melanoma cell lines. Genome copy numbers by 
Ad5/41sHI-RGD increased continuously over time with the sharpest increase 
between 12 and 28 h post infection resulting surprisingly in the highest genome copy 
numbers at all time points in both cell lines. The increase in genome copy numbers 
from 8 to 32 h was 1306-fold (Ad5/41sHI-RGD), 21-fold (Ad5HI-RGD) and 7-fold 
(Ad5/41sIJ-RGD) in C8161 and 531-fold (Ad5/41sHI-RGD), 187-fold (Ad5HI-RGD) 
and 13-fold (Ad5/41sIJ-RGD) in SK-MEL-28. Genome copy numbers of viruses 
Ad5HI-RGD and Ad5/41sIJ-RGD were nearly similar among each other from 8 to 20 
h post infection in C8161 and showed the same level of genome copy numbers 20 h 
post infection in SK-MEL-28 indicating same input of genome copy numbers after 
viral cell entry. Genome copy numbers for Ad5HI-RGD increased significantly from 
20 to 32 h post infection in comparison to Ad5/41sIJ-RGD. Notably, the differences of 
the efficacy of viral replication are dependent on the fiber format, but also the 
insertion loop of RGD into the Ad41s knob domain seems to play a critical role. 
Referring to this, the recombinant virus Ad5/41sHI-RGD showed the highest efficacy 
of genome replication whereas genome copy numbers increased only slightly for 
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Ad5/41sIJ-RGD coding both for the chimeric fiber F5/41s, but with different insertion 
sites for the RGD peptide. 
 
5.2.1.5 Efficacy of late viral genes expression by chimeric fiber F5/41s 
viruses in melanoma cells 
For Ad5/41sHI-RGD and Ad5/41sIJ-RGD, representing exemplary two varied 
chimeric fiber F5/41s viruses, efficacy of late genes expression was analyzed in 
comparison with Ad5HI-RGD over an extended time interval of 7 days after infection 
(Fig. 29A). For this purpose, C8161 were infected with Ad5/41sHI-RGD, Ad5/41sIJ-
RGD and Ad5HI-RDG at 10vp/cell. 8 h and 7 days post infection cells were 
harvested; RNA was isolated and quantified by real time PCR. Expression of hexon 
mRNA of Ad5/41sHI-RGD, Ad5/41sIJ-RGD and Ad5HI-RDG increased from 8 h to 7 
days post infection 80976, 263711, and 1472566-fold, respectively. Highest hexon 
messages were detected for Ad5HI-RGD at day 7 compared to Ad5/41sHI-RGD and 
Ad5/41sIJ-RGD. In regard to the investigation of cytotoxicity and viral replication, this 
result confirmed that chimeric fiber F5/41s influenced viral spread and consequently, 
led to the attenuation of cell killing, viral genome copies and late gene expression 
independently of the RGD insertion loop. Furthermore, I analyzed at what step of the 
viral replication cycle chimeric fiber F5/41s viruses were attenuated in comparison to 
Ad5HI-RGD. I quantified the level of late gene expression during the initial replication 
cycle. Therefore, SK-MEL-28 and C8161 were infected with Ad5/41sHI-RGD, 
Ad5/41sIJ-RGD and Ad5HI-RDG at 10vp/cell. Values were quantified 8, 12, 16, 20, 
24, 28 and 32 h post infection by real time PCR. Hexon mRNA expression of the 
chimeric fiber F5/41s viruses was weak early after infection, as expected for a late 
gene, and from 8 to 20 h post infection almost similar to Ad5HI-RGD. However, 
expression of hexon messages by Ad5/41sHI-RGD increased dramatically from 20 to 
32 h post infection resulting in the highest hexon expression over the total time 
period. The increase between 8 and 32 h was 241-fold or 15618-fold for Ad5/41sHI-
RGD after infection of C8161 or SK-MEL-28, respectively. Increase in copy numbers 
of hexon mRNA by Ad5HI-RGD started 24 (C8161) or 28 h (SK-MEL-28) post 
infection. Nevertheless, they were significant attenuated 32 h post infection 
compared to Ad5/41sHI-RGD. This observation demonstrated a delayed onset of 4 or 
8 h, depending on the cell line, of hexon expression from Ad5HI-RGD relative to 
Ad5/41sHI-RGD. Surprisingly, expression of hexon mRNA by Ad5/41sIJ-RGD was 
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only slightly higher as background measurement over the total time period. Overall, 
these patterns resembled the kinetic and efficacy of viral DNA replication by 
Ad5/41sHI-RGD, Ad5/41sIJ-RGD and Ad5HI-RDG. 
 
 
Fig.29: Efficacy of late viral genes expression by chimeric fiber F5/41s viruses in melanoma 
cells. (A) For quantification of messenger RNA copy numbers of hexon gene C8161 cells were 
infected with Ad5HI-RGD, Ad5/41sHI-RGD and Ad5/41sIJ-RGD at 10vp/cell. Eight hours and seven 
days post infection RNA was purified and ratio of RNA copy numbers to nanograms cellular RNA was 
determined by real time PCR. Experiments were repeated at least three times; one representative 
experiment is shown. (B) Melanoma cell lines were infected with indicated viruses at 10vp/cell. At 8, 
12, 16, 20, 24, 28 and 32 h post infection cells were harvested for RNA purification to determine hexon 
mRNA numbers by real time PCR. Data are presented as hexon mRNA copy numbers / ng cellular 
RNA. Experiments were repeated at least three times; one representative experiment is shown. (C) 
C8161 and SK-MEL-28 were infected with Ad5HI-RGD, Ad5/41sHI-RGD and Ad5/41sIJ-RGD at 
100vp/cell. 30, 40 and 50 hours after infection, cells were harvested and total cell lysate was used to 
perform immunoblots for hexon and fiber detection. The calculated molecular mass of the F5/41s 
monomer is 42kDa, the F5 monomer is 50kDa and the hexon monomer is 105kDa. 
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Next, I assessed the efficiency of late viral gene expression by detection of fiber and 
hexon protein by immunoblotting (Fig. 29C). In this regard, SK-MEL-28 and C8161 
were infected with Ad5/41sHI-RGD, Ad5/41sIJ-RGD and Ad5HI-RDG at 100vp/cell. 
30, 40 and 50 h post infection cells were harvested, total cell lysates were applied for 
SDS gel electrophoresis, followed by immunoblotting and detection of viral fiber and 
hexon proteins. The results demonstrated strong expression of fiber for Ad5/41sHI-
RGD at all time points. Delayed fiber protein expression levels compared to 
Ad5/41sHI-RGD were observed for Ad5HI-RGD and Ad5/41sIJ-RGD. 30 h post 
infection only weak or no expression of fiber was detectable for Ad5HI-RGD and 
Ad5/41sIJ-RGD. At later time points expression of fiber protein was similar when 
infected with Ad5HI-RGD and Ad5/41sHI-RGD. Low fiber expression was observed 
at 40 and 50 h post infected for Ad5/41sIJ-RGD in SK-MEL-28. Expression of hexon 
protein of Ad5/41sHI-RGD, Ad5/41sIJ-RGD and Ad5HI-RDG at all 3 time points 
matched those of the expression of fiber protein.  
In summary, I concluded that late viral gene expression was affected by the fiber 
format and the RGD model peptide insertion site. However, the expression of hexon 
and fiber by Ad5/41sHI-RGD was still expressed with earlier kinetics compared to 
Ad5HI-RGD and Ad5/41sIJ-RGD. Therefore, reduced viral spread and toxicity could 
not be explained by reduced / delayed genome replication or gene expression for 
Ad5/41sHI-RGD.  
5.2.1.6 Effect of chimeric fiber F5/41s on progeny production and viral 
release  
Next, I investigated whether the observed effects of chimeric fiber F5/41s on viral 
spread and cell killing were the result of a reduction of viral progeny production or 
release after infection of chimeric fiber F5/41s viruses (Fig. 30). For this purpose, SK-
MEL-28 cells were infected with Ad5/41sHI-RGD and Ad5HI-RDG. 2, 3 and 4 days 
post infection supernatants and cells were harvested separately and cell lysates were 
prepared by three cycles of freezing and thawing. Serial dilutions of the lysates were 
then titered on 293 cells using the TCID50 assay. Surprisingly, production of total 
infectious particles for Ad5HI-RGD was significantly higher compared to Ad5/41sHI-
RGD at day 2, 3 and 4 post infections. The Ad5HI-RGD infection resulted in an 
approximately 10-fold increase in total virus particle production and an earlier onset 
of viral release concluding from the lower ratio TCID50/ml_cells / 
TCID50/ml_supernatant of Ad5HI-RGD in comparison to Ad5/41sHI-RGD at day 2 
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and 3 post infection. These results argue that the fiber format has an influence on 
production of infectious virus particles and viral release. Finally, this observation 
could be an explanation for the attenuation of viral spread and cell killing by chimeric 
fiber F5/41s viruses.  
 
 
 
Fig.30: Effect of chimeric fiber F5/41s on viral progeny production and release. SK-MEL-28 cells 
were infected with Ad5HI-RGD and Ad5/41sHI-RGD at 10vp/cell. Two, three and four days post 
infection, supernatants and cells were harvested separately and titers of infectious viral particles were 
determined by TCID50 assay. Left panel shows total infectious viral particles (cells + supernatants). 
Right panel shows the ratio of infectious viral particles in cells to infectious viral particles in 
supernatants to indicate virus release. Experiments were repeated at least two times; one 
representative experiment is shown. p.i., post infection. 
 
 
5.2.1.7 Thermal stability of chimeric fiber F5/41s viral capsids 
To assess the thermal stability of the chimeric fiber viruses as a potential cause of 
reduced virus titers of Ad5/41sHI-RGD in comparison to Ad5HI-RGD and to 
investigated the relation of stability of viral capsid and viral spread, Ad5/41sHI-RGD 
and Ad5HI-RGD were incubated for 0, 12 or 24 minutes at 45°C.  
 
Fig.31: Thermal stability of 
chimeric fiber F5/41s viral capsids. 
To determine the thermal stability of 
chimeric fiber F5/41s, 1000vp/cell of 
Ad5HI-RGD and Ad5/41sHI-RGD 
were preincubated for 0, 12, or 24 
minutes at 45°C. Subsequently, SK-
MEL-28 cells were infected with the 
heat-treated viruses. 12 h post 
infection cells were harvested for 
RNA purification to determine E1A 
mRNA numbers by real time PCR. 
Data are presented as E1A mRNA 
copy numbers / ng cellular RNA and 
obtained values are normalized with 
readings for untreated. Experiment 
was repeated at least two times.  
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Afterwards, SK-MEL-28 cells were infected with these viruses and 12 h post infection 
5.2.2 F41s-pseudotyped recombinant adenoviruses as platform for 
cells were harvested, RNA was purified and expression of the E1A gene was 
analysed by quantitative real time PCR. The ability of the virus to enter the cell and 
express the early gene E1A required a functional viral capsid structure. 
Consequently, the efficacy of E1A expression correlates with the stability and viability 
of the heat-treated virus particles. The level of E1A copy numbers correlated 
inversely with time of treatment. However, only minor differences of E1A expression 
by Ad5/41sHI-RGD and Ad5HI-RGD were shown. In conclusion, the fiber format has 
no major influence on the thermal stability of the virus particles. 
 
insertion of a tumour cell-binding peptide ligand that binds to the 
EphA2 receptor 
 
5.2.2.1 Generation of F41s-pseudotyped recombinant adenoviruses 
d41s 
This work was based on results of our lab that a highly affinitive peptide that binds to 
incorporated an EphA2 ligand peptide into the HI loop of the A
knob domain 
EphA2 receptor (Zelinski et al. 2001) could be used for specific transduction of 
replication-deficient adenovirus vectors. In the light of these results, I investigated the 
lytic efficiency and specificity of oncolytic adenoviruses engineered with an EphA2 
ligand peptide inserted into the HI loop of the Ad41 fiber knob (Fig. 32).  
 
Fig.32: Generation of F41s-pseudotyped recombinant oncolytic adenoviruses carrying an 
EphA2 peptide ligand. Outline of EphA2 peptide ligand insertions into the Ad41s fiber knob. An 
YSAPDSVPMMS peptide was inserted into the HI loop of Ad41s fiber knob (numbers in parenthesis 
refer to the amino acid positions of the Ad41s fiber that flank the insertion site; amino acid that flank 
the insertion site are shown in single letter code).  
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In this regard, the model peptide RGD was replaced by a tumour cell-binding EphA2 
ligand peptide generating the oncolytic adenovirus Ad5/41sHI-ephA2. Additional, I 
investigated whether the native cellular tropism could be further ablated, beside the 
F5/41s fiber format, by mutation of the integrin-binding motifs in the penton base 
(double-ablated virus Ad5RAE/41sHI-ephA2). To generate the F41s-pseudotyped 
oncolytic adenoviruses as tool for viro- and gene therapy the E3 region was already 
deleted to obtain space for future transgene insertion.  
 
5.2.2.2 Spread-dependent cell killing by the EphA2-targeted chimeric fiber 
F5/41s viruses  
Due to former surface expression analysis of the EphA2 receptor on human 
melanoma cell lines, the CAR-negative cell line C8161 were suitable as a model to 
study viral targeting. Since the EphA2 receptor is absent on SK-MEL-28, I used these 
as negative control cells. For the analysis of the cytolytic activity and the specificity of 
cell lysis of the targeted chimeric fiber F5/41s viruses, C8161 and SK-MEL-28 were 
infected with Ad5/41sHI-ephA2 and Ad5RAE/41sHI-ephA2 at virus titer of 1000-
0.01vp/cell in 10-fold dilutions. Ad5wt, Ad5∆24E3-, Ad5/41sHI-RGD and the 
replication-deficient virus Ad5CMVLuc served as control viruses. Cell killing was 
detected by staining of viable cells with crystal violet (Fig. 33).  
 
 
 
 
 
 
 
 
 
 
Fig.33: Spread-dependent cell killing by the targeted chimeric fiber F5/41s viruses. SK-MEL-28 
and C8161 cells were infected with the indicated viruses at 1000-0.01vp/cells. Virus spread-dependent 
cytotoxicity was visualized by crystal violet staining of surviving cells. Therefore, staining was 
performed when cytotoxicity was observed for the most potent virus at 0.1vp/cell (SK-MEL-28) or 
1vp/cell (C8161). Experiments were repeated at least two times; one representative experiment is 
shown. 
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Cytotoxicity by Ad5/41sHI-ephA2 was observed in C8161. However, Ad5RAE41sHI-
ephA2 showed no cell killing of C8161 indicating that penton-integrin interaction is 
needed. Most potent cytotoxicity in C8161 cells was observed for Ad5/41sHI-RGD, 
which was approximately 10 to 100 fold enhanced when compared to Ad5/41sHI-
ephA2. Of note, Ad5wt and Ad5∆24E3- were 10-fold superior or identical to 
Ad5/41sHI-ephA2 in cell killing of C8161. This was not expected due to the low 
expression of the CAR-receptor on C8161. As expected, cell killing was observed for 
SK-MEL-28 infected with Ad5wt, Ad5∆24E3- and Ad5/41sHI-RGD confirming my 
analysis of spread-dependent cell killing of chimeric fiber F5/41s viruses (see chapter 
5.2.1.3). Of note, EphA2 receptor-deficient SK-MEL-28 cells showed no lysis by 
Ad5/41sHI-ephA2 and Ad5RAE/41sHI-ephA2 indicating specific cell lysis of EphA2 
positive cells. Taken together, targeted chimeric fiber F5/41s virus Ad5/41sHI-ephA2 
clearly demonstrated specific cell killing, though attenuated compared to Ad5/41sHI-
RGD. For Ad5RAE/41sHI-ephA2 even no cell killing of C8161 was observed. 
 
5.2.2.3 Efficacy and specificity of the late fiber gene expression by the 
EphA2-targeted chimeric fiber F5/41s viruses  
Towards the goal to engineer highly potent and tumour specific viruses, the efficacy 
and specificity of the late fiber gene expression by the targeted chimeric fiber F5/41s 
viruses were analyzed. For this purpose, SK-MEL-28 and C8161 were infected with 
Ad5/41sHI-ephA2, Ad5RAE/41sHI-ephA2, Ad5/41sHI-RGD and Ad5∆24E3-. 40 h 
post infection cells were harvested, total cell lysates were applied for SDS gel 
electrophoresis, followed by immunoblotting and detection of viral fiber (Fig. 34). 
 
 
Fig.34: Efficacy and specificity of late fiber gene 
expression by the targeted chimeric fiber F5/41s 
viruses. Melanoma cells were infected with the indicated 
viruses at 100vp/cell. Cells were lysed at 40 h post 
infection and were analyzed for fiber expression by SDS-
polyacrylamide gel electrophoresis and western blotting 
using monoclonal antibody clone 4D2, which binds to the 
Ad5 fiber tail. Lysates with 30µg of protein were boiled 
before being loaded. The calculated molecular mass of the 
F5/41s monomer is 42kDa and the F5 monomer is 50kDa. 
 
 
 
 
Results   86 
For all chimeric fiber F5/41s viruses (Ad5/41sHI-ephA2, Ad5RAE/41sHI-ephA2 and 
Ad5/41sHI-RGD), infection of C8161 cells resulted in fiber expression. However, the 
efficacy of fiber scaled down from Ad5/41sHI-RGD to Ad5/41sHI-ephA2 to 
Ad5RAE/41sHI-ephA2. Consequently, merely low fiber expression was observed for 
Ad5RAE/41sHI-ephA2 in C8161. As expected, no fiber expression was found for 
CAR-negative C8161 cells infected with Ad5∆24E3-, which binds to cells via CAR 
receptor. Furthermore, the results demonstrated strong expression of fiber in SK-
MEL-28 infected with Ad5∆24E3- and Ad5/41sHI-RGD. In contrast, no fiber 
expression was detected after infection of the EphA2-negative cell line SK-MEL-28 
by Ad5/41sHI-ephA2 and Ad5RAE/41sHI-ephA2 confirming the analysis of 
cytotoxicity in SK-MEL-28 (see chapter 5.2.2.2). To conclude, these data 
demonstrated an efficient and specific fiber expression mediated by Ad5/41sHI-
ephA2 EphA2-positive C8161 cells. Late fiber gene expression by the targeted 
Ad5RAE/41sHI-ephA2 was selective for C8161 but less efficient than for Ad5/41sHI-
ephA2. 
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6 DISCUSSION 
6.1 Combination of oncolysis with targeted prodrug activation 
therapy of melanoma 
The development of tumour-specific drugs and the implementation of potent 
multimodal treatment regimens are of critical importance for cancer therapy. 
Oncolytic adenoviruses have the potential to realize both tumour-specificity and 
multimodality by restricting virus replication to tumour cells and by insertion of 
therapeutic genes into the virus genome, respectively. Using the luciferase gene as a 
sensitive reporter for monitoring transgene expression, I showed in this study that 
expression of E1A from a cell-type-specific promoter not only mediates targeted virus 
replication, but also facilitates the expression of transgenes inserted in the late 
transcription unit with remarkable selectivity (selectivity up to 1500-fold). Notably, I 
revealed that selectivity and efficiency of transgene expression depend on the 
strategy of transgene insertion into the late transcription unit and might require 
optimization for individual transgenes. Specifically, my results demonstrated that both 
the IRES and SA strategies of transgene insertion facilitate indirect transcriptional 
targeting of transgene expression by tyrosinase promoter-dependent expression of 
E1A without interfering with virus replication. When comparing melanoma cells with 
fibroblasts and keratinocytes, the SA strategy showed highest selectivity of up to 
1500-fold (Fig. 12); for the IRES strategy selectivity was up to 450-fold. However, the 
IRES strategy mediated approx. 10-fold stronger transgene expression. In 
consequence, I suggest the IRES strategy for expression of therapeutic genes for 
which high expression levels are necessary in order to reach therapeutic efficacy, 
whereas the SA strategy is especially advantageous whenever side effects of 
therapeutic genes are limiting. These “add-in” strategies for transgene insertion into 
the adenoviral genome, in contrast to replacing late viral genes with transgenes 
(Nettelbeck 2009), in principle allow for retaining all viral genes – at least if transgene 
sequences are short (the viruses used in this study were E3-deleted due to the large 
size of the luciferase gene). Both the EMCV IRES and different splice acceptor 
sequences have been previously used for late therapeutic gene expression (Sauthoff 
et al. 2002 and 2006; Fuerer and Iggo 2004; Lukashev et al. 2005; Carette et al. 
2005; Robinson et al. 2007; Cascante et al. 2007). My results suggest that comparing 
both strategies in therapeutic studies might indeed be of interest to improve a given 
therapeutic approach.  
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Lower transgene expression by the SA strategy (Fig. 11/13) observed in my study 
might reflect the locale of transgene insertion between the E4 genes and right ITR of 
the adenovirus genome. Other groups have inserted transgenes with different splice 
acceptor sites directly downstream of the fiber gene (Fuerer and Iggo 2004; 
Cascante et al. 2007). Fuerer and Iggo reported that therapeutic gene expression by 
the EMCV IRES resulted in stronger gene expression than the splice acceptor 
sequence of the Ad41 long fiber, when both were inserted at the end of the L5 
transcript (Fuerer and Iggo 2004). It remains to be investigated in direct comparisons 
whether this fiber locale results in more efficient transgene expression than the E4 
site and whether the selectivity I reported in the present study is dependent on the 
specific splice acceptor sequence used. However, in a transposon-based scan for 
insertion sites for SA-transgene cassettes in the adenovirus genome, Hermiston and 
colleagues reported that an E4 insertion site, similar to the one I used, afforded 
strongest transgene expression and reflected late transgene expression kinetics best 
(Jin et al. 2005).  
An additional important finding of my study with respect to the necessity to optimize 
transgene insertion into oncolytic adenovirus genomes was that transgenes can 
interfere in a sequence-specific manner with splicing (Fig. 19A). Thus, efficient 
transgene expression was lost by replacing the luciferase cDNA of SL viruses with 
the FCU-1 gene or the therapeutic gene purine nucleoside phosphorylase (data not 
shown). Interestingly, this was not only due to insufficient activity of the inserted SA 
sequence (caused by a different sequence downstream of the SA site), but was also 
resulting from usage of a cryptic splice acceptor site within the transgene (Fig. 19B). 
In this regard it is important to note that the SA sequence used in my study, 
containing branch point and polypyrimidine tract elements, was already optimized for 
more “tight” splicing than shorter sequences (Jin et al. 2005). Having revealed the 
reasons for ineffective splicing, I could restore FCU-1 expression by insertion of a 
luciferase gene-derived spacer downstream of the SA sequence in combination with 
switching codons in and around the identified cryptic splice site. The former might 
restore a favourable sequence environment around the SA site. One could envision 
that cryptic splicing of transgenes could also interfere with viral gene expression and 
thus with virus replication, although this was not the case for the viruses generated in 
this study (Fig. 17). These results suggest that, when “arming” viruses with 
therapeutic genes, it is advisable to perform splicing analyses.  
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To optimize transgene insertion into oncolytic adenovirus genomes, I also 
investigated a viral 2A sequence as a tool for co-expression of two or more proteins 
from one transcription unit (Szymczak et al. 2004). I showed that the short 2A 
sequence of the Thosea asigna virus facilitates replication-dependent co-expression 
of adenoviral fiber and luciferase proteins as observed via inhibition of virus 
replication with AraC, with no fusion protein detectable (data not shown). However, 
my data also revealed that indirect promoter control was not effective using the 2A 
strategy, as Ad5TyrTL, in contrast to Ad5TyrIL and Ad5TyrSL, showed strong 
luciferase expression in fibroblasts and keratinocytes (Fig. 12). Thus, an important 
result of my study is that replication-dependence of transgene expression, as 
demonstrated using for example by AraC block, does not always correctly predict 
selectivity of transgene expression by targeted oncolytic adenoviruses. In 
consequence, it is necessary to investigate selectivity of armed oncolytic 
adenoviruses in a biologically relevant system, e.g. in both target and non-target 
cells, with an appropriate control of a matching but non-targeted, transgene-encoding 
virus. This was often not done in previous studies. For reasons that remain to be 
determined, the 2A strategy also resulted in reduced E1A expression, replication and 
transgene expression for the Ad5TL virus, but not the Ad5TyrTL virus. Iggo and co-
workers recently reported feasibility of 2A sequences derived from the foot-and-
mouth disease virus (F2A) and from the porcine teschovirus-1 (P2A) for co-
expression of GFP with the adenoviral pIX (Funston et al. 2008). They also observed 
reduced replication and spread for the 2A viruses, which they attributed to 
interference with pIX activity of the 2A-derived amino acids that remain in the pIX 
protein. In our study both Ad5TL and Ad5TyrTL feature the same fiber modification 
but a different replication phenotype. Thus, interference of the 2A-derived amino 
acids with capsid stability or virus entry into cells is unlikely. I conclude that the 2A 
strategy, facilitating efficient co-expression in other systems (Szymczak et al. 2004; 
Fang et al. 2005), can affect both replication and targeted transgene expression in 
armed oncolytic adenoviruses. 
Iggo and co-workers previously investigated selective expression of therapeutic 
genes inserted via IRES or splice site into the viral late transcription unit of an 
adenovirus transcriptionally targeted to colon cancer via TCF4 transcription factor 
binding sites in E1 and E4 promoters (Fuerer and Iggo, 2004; Lukashev et al. 2005). 
Comparing tumour and normal cells, they could also demonstrate tumour-selective 
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expression of the therapeutic protein by immunoblot; however, they did not quantify 
the level of specificity. Other studies reporting late therapeutic gene insertion into 
transcriptionally targeted oncolytic adenoviruses frequently lacked a proof of indirect 
promoter regulation of transgene expression. 
I reported that the SA strategy, after optimizing splice-dependent FCU-1 expression, 
facilitates the transcriptionally targeted combination therapy of efficient oncolysis and 
molecular chemotherapy. When the prodrug 5-FC was added during the first virus 
replication cycle after infection with Ad5TyrSsp_mFCU, production of infectious virus 
particles was only modestly reduced by less than 10-fold (Fig. 21), showing that late 
expression of CD-FUR-1 in the presence of 5-FC is compatible with virus replication, 
which is in agreement with previous reports in other tumour cells (Fuerrer and Iggo, 
2004). Importantly, cytotoxicity of the oncolytic virus was strongly increased by 5-FC 
in a melanoma-specific manner and was superior to Ad5CMVFCU treatment in 
melanoma cells; for Mel624 cells this difference was quite remarkable, more than 30-
fold (Fig. 22). Interestingly, I observed that Ad5TyrSsp_mFCU showed higher CD-
FUR-1 fusion protein expression in melanoma cells than Ad5Ssp_mFCU (Fig. 19A), 
which translated in stronger sensitization to the prodrug 5-FC. This was in agreement 
with the results of luciferase reporter assays for IL and SL viruses, that also showed 
stronger luciferase expression when E1A was expressed from the tyrosinase 
promoter (Fig. 11). E1A expression kinetics of Ad5SL and Ad5TyrSL were similar 
during the first 30 h after infection of melanoma cells, the reason for this difference is 
not clear and might be due to different expression kinetics at later times. Whereas my 
results clearly establish the efficacy and specificity of the Ad5TyrSsp_mFCU/5-FC 
therapy for melanoma, there is further opportunity for improvement. I always added 
the prodrug during the first virus replication cycle after infection in order to show the 
selectivity of the system. However, an important advantage of the genetic prodrug 
activation therapy is that kinetics of gene transfer and prodrug application can be 
optimized. This is especially of interest for armed oncolytic viruses: both efficacy and 
selectivity of oncolytic virus-delivered genetic prodrug therapy can be improved by 
adding the prodrug later after infection, allowing for (tumour-specific) virus spread 
and thus more widespread expression of the prodrug convertase. My observation 
that supernatants of Ad5TyrSsp_mFCU/5-FC-treated melanoma cells, after virus-
inactivation, can efficiently kill uninfected melanoma cells demonstrated the potential 
of the system for effective prodrug conversion and for killing of uninfected “bystander” 
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tumour cells. Again, this is of critical importance for combination therapies with 
“armed” oncolytic adenovirus, as the killing of uninfected cells is the goal of the 
arming strategy. Previous studies investigated oncolytic adenoviruses expressing E. 
coli CD directly from tyrosinase promoters, either by expressing E1A and CD from 
two identical copies of the promoter (Liu and Deisseroth, 2006) or by expressing a 
CD-IRES-E1A fusion gene (Liu et al. 2006). In agreement with my results, these 
studies also reported synergy between adenoviral oncolysis and CD/5-FC therapy. 
However, the virus described in the present study possesses qualities that differ from 
these viruses in several aspects. It encodes the yeast CD-FUR-1 fusion protein, 
which has been reported to be a more effective prodrug convertase (Erbs et al. 
2000), which goes along with the efficient bystander effect we observed. This protein 
is expressed with late kinetics, which is advantageous to prevent interference with 
viral replication. A single copy of the tyrosinase promoter ensures stability of the virus 
genome by avoiding homologous recombination. Direct control and thus strong 
expression of E1A ensures efficient virus replication and oncolysis, in contrast to the 
CD-IRES-E1A strategy, while indirect control of late gene expression still facilitates 
melanoma-specific expression of the CD-FUR-1 fusion protein.  
5-FU is not used in clinical routine for chemotherapy of malignant melanoma. 
However, I believe that local application of the drug at high doses, as I proposed by 
targeted prodrug activation after infection with “armed” oncolytic adenoviruses, holds 
promise as a novel regimen for targeted treatment of malignant melanoma. This is in 
agreement with previous reports on CD/5-FC gene therapy by non-viral, viral, 
bacterial or cellular vectors (Szala et al. 1996; Cao et al. 1998; Aboody et al. 2006; 
Stritzker et al. 2008; Kucerova et al. 2008). Moreover, several studies indicate that 
treatment of melanoma with 5-FU improves cellular natural or therapeutic immune 
responses to the tumour (Ryan et al. 1988; Neefe and Glass, 1991; Gazit et al. 1992; 
Cao et al. 1998; Yang and Haluska, 2004). In this regard, activation of prolonged 
anti-tumour immunity by oncolytic adenoviruses is considered a promising strategy to 
complement viral tumour cell lysis for increased therapeutic potency. 
In summary, my study established Ad5TyrSsp_mFCU/5-FC as an effective strategy 
for targeted killing of melanoma cells by combined viral oncolysis and molecular 
chemotherapy. I reported several steps for genetic engineering of the therapeutic 
virus that were required to optimize late therapeutic gene expression. This, in turn, 
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facilitated targeting of both viral replication and therapeutic gene expression to 
melanoma cells from the cellular tyrosinase promoter. 
6.2 Peptide-dependent cell entry for targeted oncolysis 
6.2.1 Ad41 short fiber as platform for insertion of RGD model peptide in 
context of oncolytic adenoviruses 
Recombinant adenoviruses have emerged as promising agents in therapeutic gene 
transfer, genetic vaccination, and viral oncolysis (Alemany and Curiel et al. 2000; 
Basak et al. 2004; McConnell et al. 2004; Zang et al. 1999). However, therapeutic 
applications of adenoviruses would benefit substantially from targeted virus cell entry. 
Notably, all oncolytic adenoviruses described to date are based on post-entry 
restriction of adenoviral life cycle. To target viral oncolysis by a specific cell entry 
genetic modification is needed. Such modification of the natural adenoviral tropism 
requires the deletion of the natural cell binding properties and achievement of tumour 
specific targeting for example by incorporation of cancer cell binding ligands. 
Recently, the replacement of the Ad5 fiber with the short fiber of subgroup F 
adenovirus Ad40 and Ad41 has been shown to achieve substantially reduced 
transduction of the liver and other organs after intravenous injection into mice and 
rats (Nakamura et al. 2003; Nicol et al. 2004). Therefore, the short fiber of Ad40 and 
Ad41 represent promising “detargeted” platforms for retargeting of adenovirus cell 
entry by insertion of specific peptide ligands. It was previously shown by our group 
that peptide ligand insertions into various positions of the Ad41s knob domain is 
feasible resulting in molecules that retain both fiber / capsid integrity and the potency 
of the inserted peptide to bind to its cellular receptor (Hesse et al. 2007). Of note, this 
was the first study that reported the feasibility of internal ligand insertions into a short-
shafted adenovirus fiber. In this regard, I investigated the short fiber of Ad41 (F41s) 
in context of oncolytic adenoviruses by using the integrin-binding motif RGD as a 
prototype of the cell binding ligand. I inserted the model peptide RGD into the Ad41s 
fiber knob in such a way that they face the top (IJ loop) or the side (EG and HI loop) 
of the fiber molecule (Fig. 24). The production and amplification of the recombinant 
viruses represents a critical step towards the implementation of viral targeting. 
Referring to this, I retained that the conservation of the Ad5 fiber tail in my 
recombinant adenoviruses might lead to a more efficient incorporation of the fiber 
chimera with Ad5 tail fused to Ad41 shaft and knob domains into the Ad5 capsid 
(Hesse et al. 2007). All recombinant viruses were able to be produced at high titers 
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(Fig. 25C). According to the successful viral production, the chimeric fiber retains the 
fiber’s essential properties of trimerization, incorporation into adenovirus capsids and 
binding to its cellular receptor which is important for viral spread and amplification. 
Together with the western blot data (Fig. 26) my results indicate that all fibers can be 
incorporated into the viral capsid with efficiency comparable to Ad5wt. 
It was shown previously (de Jong et al. 1983) that the subgroup F adenoviruses grow 
poorly in cell cultures that are highly permissive to other human adenoviruses. It is 
possible that the unique property of enteric adenoviruses missing the RGD motif in 
the penton base (Albinsson et al. 1999) might be related to the special ability of these 
viruses to mainly infect cells in the human gastric system with high efficiency. In my 
study, all recombinant viruses code for the chimeric fiber F5/41 containing an RGD 
motif in the Ad5 tail and in addition in the Ad41s knob domain. Though, the 
cytotoxicity of all chimeric fiber F5/41s viruses was 10-100 fold attenuated in 
comparison to the corresponding virus Ad5HI-RGD with the same ligand inserted into 
the Ad5 fiber in the tested melanoma cells (Fig. 27). This finding suggests that the 
presence of the Ad41s shaft and knob domain irrespective of the RGD insertion site 
has a negative effect on the lytic potency and spread of the chimeric fiber F5/41s 
viruses. At which step of the viral replication cycle this effect could take place needs 
to be further characterized. My results argue that the reduced lytic potency of the 
chimeric fiber F5/41s viruses is independent from the insertion site of the model 
ligand RGD into the Ad41s fiber knob. The analysis of viral gene expression and 
replication of the viral genome during the first replication cycle demonstrated that 
infection by Ad5/41sHI-RGD resulted in the earliest onset of viral replication and in 
the sharpest increase of genome copy numbers over the time period (Fig. 28B). In 
this regard, an attenuated transactivation capacity of the E1A proteins resulting from 
reduced replication efficiency was not observed for Ad5/41sHI-RGD in comparison to 
Ad5HI-RGD. In contrast, genome copy numbers of Ad5/41sIJ-RGD showed only a 
slightly increase from 8 to 32 h post infection and in comparison to Ad5/41sHI-RGD 
and Ad5HI-RGD the lowest replication rate (Fig. 28B). This is surprising, especially in 
consideration of the fiber format F5/41s which is used by both viruses, Ad5/41sHI-
RGD and Ad5/41sIJ-RGD, for cell entry. I conclude that the efficacy of viral 
replication is dependent on the fiber format, but also the insertion site of RGD into the 
Ad41s knob domain seems to play a critical role. Note that the HI loop is located on 
the side and the IJ loop face the top of the Ad41s fiber knob. I hypothesize that the 
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insertion of the model peptide RGD into different orientated loops of the Ad41s fiber 
knob domain might influence the binding behaviour and / or the cellular signalling 
which could affect viral replication. In previous study it was shown that loops located 
on the side (HI and EG loop) might be a favourable location for insertion of targeting 
ligands resulting in high transduction efficiency (Hesse et al. 2007). It has been 
reported that enteric adenoviruses Ad40 and Ad41 do not use integrins for cell entry 
and may use an alternative, unknown mechanism for facilitating endocytosis 
(Albinsson et al. 1999). It is possible that due to the different orientation of the RGD 
motif Ad5/41sHI-RGD could infect the cell via integrin-mediated cell entry. However, 
Ad5/41sIJ-RGD could show a different manner of binding in comparison to 
Ad5/41sHI-RGD using the alternative mechanism for endocytosis of the enteric 
adenoviruses.  
Further studies of the expression of the late viral genes (Fig. 29) underline the data of 
the viral replication experiments. In accord with the high efficiency of viral replication 
by Ad5/41sHI-RGD, this recombinant viruses resulted in higher expression of hexon 
mRNA and the late viral proteins hexon and fiber compared to Ad5HI-RGD and 
Ad5/41sIJ-RGD. However, in contrast to the analysis of viral replication and late gene 
expression during the first replication cycle, genome copy numbers and late gene 
expression by the chimeric fiber F5/41s viruses was reduced in comparison to Ad5HI-
RGD 7 days post infection (Fig. 28A/29A). These observations might indicate that 
some steps following late gene expression are influenced by the chimeric fiber 
F5/41s. In addition to cellular binding, the fiber and its knob domain have been 
suggested to have several functions important for intracellular trafficking, membrane 
lysis and virus maturation (Legrand et al. 1999; Miyazawa et al. 2001; Gaden et al. 
2004). In regard to this, the analysis of viral release and progenies production 
demonstrated a significant reduction of the amount of infectious viral particles 2, 3, 
and 4 days post infection of Ad5/41sHI-RGD compared to Ad5HI-RGD (Fig. 30). I 
could also show a delayed release of Ad5/41sHI-RGD viral particles from the cell into 
the supernatant. This low titer of infectious particles of Ad5/41sHI-RGD might be 
explained by the absence of the Ad5 fiber shaft and knob domain. As discussed 
above, this domain can be involved in some additional steps of viral life cycle beside 
cell binding and entry which cannot be adopted by Ad41s fiber shaft and knob 
domain. For example, it has been suggested that the deletion of the knob domain of 
serotype 5 fiber might have a negative effect on the intracellular concentration of the 
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fiber protein (Henning et al. 2006) resulting either in a delayed viral assembly or in a 
delayed encapsidation. Importantly, it was also shown that glycosylation of the fiber 
shaft might play a role in the stabilization of the fiber and may also protect it from 
proteolytic degradation (Mullis et al. 1990). This aspect could have an influence on 
the kinetic of the intracellular accumulation of the fiber protein. Note that only the 
central shaft domains of serotype 2 and 5 fibers are glycosylated by O-linked N-
acetylglucosamine (Mullis et al. 1990). In the light of our results for thermal stability of 
chimeric fiber F5/41s viral capsids, I could not detect an influence of the fiber format 
on the thermal stability of the virus capsid (Fig. 31). However, the lytic potency of the 
chimeric fiber F5/41s was increased when the fiber shaft domain of the Ad41s was 
replaced by the Ad5 shaft (Fig. 27). This could be explained either by stabilization of 
the fiber due to the Ad5 shaft glycosylation or by optimized length and flexibility of the 
longer Ad5 shaft which have been shown to be of importance for efficient virus entry 
(Shayakhmetov and Lieber, 2000; Wu et al. 2003). I also explored that ectopic 
expression of Ad5 fiber by the host cell could not restore the negative effect of the 
chimeric fiber F5/41s on viral assembly and spread levels (data not shown). This 
result suggests that this negative effect could not be compensated by Ad5 fiber 
protein provided from the host cell.  
In summary, Ad5/41sHI-RGD showed an early onset of gene expression, but lower 
infectious particles production in comparison to Ad5HI-RGD. I conclude that the fiber 
format and the precise position of the model peptide RGD in the knob domain of the 
serotype 41 short fiber, as well as the position of the modified knob in the virus 
capsid, and the length or structure of the fiber shaft, are critical determinants for the 
efficiency of the viral life cycle, especially for receptor binding capacity and virus 
assembly.  
 
6.2.2 Targeting of F41s-pseudotyped recombinant oncolytic adenovirus by 
insertion of an EphA2 peptide ligand  
During malignant transformation, many cells start to express surface antigens which 
are normally absent or down-regulated on normal cells. Tumour antigens can either 
be tumour-specific like MAGE (Farina and van der Bruggen 1996) or tissue-specific 
like prostate-specific membrane antigen (Israeli et al. 1994). These tumour-specific 
cell markers are the most attractive targets in cancer therapy. One advantage of 
tumour-specific markers is that their use has already been proven to be safe in 
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clinical trials. For example, therapy of breast cancer with HER2/neu antibodies 
resulted in a positive antitumor response in patient (Weiner et al. 1999).  
 
I suggested recombinant adenoviruses carrying the chimeric fiber F5/41s which 
consists of the Ad5 tail, Ad41s fiber shaft and knob domain as a novel platform for 
genetic targeting of adenovirus cell entry. This platform can be exploited for insertion 
of targeting peptides into the HI loop of the Ad41s fiber knob. My used model peptide 
RGD which binds to cellular integrins is a well known example to overcome the poor 
transduction of human cancers caused by low expression of CAR (Wesseling et al. 
2001; Sandovici et al. 2006; Dmitriev et al. 1998). Although integrins are highly 
expressed on cancer cells, the specificity of RGD targeting in vivo is questionable 
because of integrin expression on other tissues.  
Previous studies showed that a small, highly affinitive peptide that binds the EphA2 
receptor could be a promising candidate peptide ligand used for transductional 
targeting of cancer therapy. EphA2 is a receptor tyrosine kinase, which is over 
expressed on a number of solid tumours (Abraham et al. 2006, Muldali et al. 2006, 
Miyazaki et al. 2003, Zelinski et al. 2001) and is often associated with poor prognosis. 
Targeting EphA2 showed decrease of tumour growth in multiple preclinical models of 
ovarian, breast and pancreatic cancer (Landen et al. 2005). Based on these studies, I 
inserted a small EphA2 peptide ligand into the HI loop of the chimeric fiber F5/41s 
virus. Since ablation of the native binding reduces liver transduction and improves 
specific targeting in vivo (Einfeld et al. 2001), I combined EphA2-targeting with 
deletion of the natural cell binding properties. Previously, ablation of the native 
tropism by chimeric fiber F5/41s via transduction experiments in melanoma cells was 
shown (Hesse et al. 2007). Consequently, I used the recombinant adenovirus 
carrying the chimeric fiber F5/41s as platform for detargeting the native tropism. I 
hypothesized that cell entry of Ad5/41s might be also mediated by binding of the 
penton base via its RGD motif to cellular integrins. Thus, to further improve the 
detargeting of the Ad5-derived Ad5/41s viruses the penton base RGD motif was 
mutated. The recombinant oncolytic EphA2-targeted viruses showed no cell lysis and 
viral spread by F5/41s-detargeting in melanoma cells that do not express the EphA2 
receptor. In addition, I could not detect expression of late viral gene by immunoblot 
after infection of EphA2-negative cells. Furthermore, the lytic potency of the Ad5/41s 
was restored by insertion of the EphA2 peptide into the HI loop for EphA2-positive 
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melanoma cells (Fig. 33). However, the efficiency of cell killing by Ad5/41sHI-ephA2 
was reduced in comparison to Ad5/41sHI-RGD. The “double-ablated” Ad5RAE41sHI-
ephA2 did not show efficient cell lysis in these cells indicating that penton-integrin 
interaction is required. In this regard, it was already known that not all retargeted 
viruses do provide efficient transduction which would explain the lack of cytotoxicity 
of Ad5RAE41sHI-ephA2. For example, insertion of RGD into a vector in which the 
CAR binding site was ablated did not result in integrin-mediated uptake (Kritz et al. 
2007). However, weak expression of the late fiber protein by Ad5RAE41sHI-ephA2 
was shown in targeted cells (Fig. 34). Thus, it seems that the cell binding and entry of 
the “double-ablated” virus is not completely inefficient. Nevertheless, this virus is not 
able to lyse EphA2-positive cells and spread (Fig. 33). My data shows that the CAR-
negative cell line C8161 was lysed by Ad5wt and Ad5∆24E3- which is a novel and 
striking finding. It might be explained by a CAR independent uptake of the virus which 
could occur during the extended time interval of approximately three weeks of the 
cytotoxicity assay. In contrast, fiber gene expression was not detectable for Ad5wt 
and Ad5∆24E3- in C8161 by immunoblot (Fig. 34), which was performed 40 h post 
infection, indicating a reduced cell entry of these viruses.  
An important result of this study was that I generated a virus ablated for CAR-binding 
which targets EphA2 receptor expressing melanoma cells via an inserted EphA2 
peptide ligand and shows specific cell lysis. However, the lytic potency of the 
chimeric fiber F5/41s viruses, especially the EphA2-trageted virus, was significantly 
reduced referring to Ad5HI-RGD. In consequence, for future application of these 
adenoviruses the loss in lytic activity by chimeric fiber F5/41s has to be 
complemented without sacrificing their specificity. Notably, this work established the 
basis for entry-targeted oncolytic adenoviruses and open new ways for future 
development of improved recombinant adenoviruses for targeted viral oncolysis. 
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8 ABBREVIATIONS 
 
aa  aminoacid 
Ad adenovirus 
Ad3 adenovirus serotype 3 
Ad5 adenovirus serotype 5 
amp ampicillin 
approx approximately 
APS ammonium persulfate 
AT annealing temperature 
bp basepair 
β beta 
β-gal β-galactosidase 
β-me β-mercaptoethanol 
BSA bovine serum albumin 
C° degree celcius 
cDNA complementary DNA 
CMV cytomegalovirus 
CsCl caesium chloride 
CRAd conditionally replicative Adenovirus 
∆ delta 
DNA deoxyribonucleic acid 
DMSO dimethylsulfoxide 
dNTP deoxyribonucleic acid triphosphate 
DTT 1,4 dithiothreitol 
ECL enhanced chemiluminescence 
E.coli Escherichia coli 
EDTA ethylendiamin N,N,N,N-tetraacetat 
EtBr ethidiumbromide 
EtOH ethanol 
FACS fluorescence-activated cell sorting 
FITC fluorescein isothiocyanate 
fig figure 
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FCS fetal calf serum 
for forward 
g gram 
G glutamine 
h hour 
HRP horseradish peroxidase 
IgG immunoglobulin G 
k kilo 
kan kanamycin 
kD kilo dalton 
l liter 
LB Luria-Broth 
m milli  
M molar 
mA milli ampere 
MCS multiple cloning site 
min minute 
MMP powdered milk  
MoAb monoclonal antibody 
MOI multiplicity of infection 
n nano 
NEAA non essential amino acids 
OD optical density 
P penicillin 
PBS Phosphate buffer saline 
PCR polymerase chain reaction 
PE phycoerythrin 
pH potentia hydrogen 
PMSF Phenyl-methyl-sulfonyl-fluorid 
rdAd Replication-deficient adenovirus 
rev reverse 
RLU relative light unit 
RNA ribonucleic acid 
Abbreviations   114 
rpm rounds per minute 
RT room temperature 
RT-PCR Reverse transcriptase-PCR 
S streptomycin 
s.c. subcutane 
SD standard deviation 
SDS sodium dodecyl sulfate 
sec second 
SV40 Simian virus 40 
TCID50 tissue culture infectious dose 50 
TEMED N,N,N',N'-Tetramethylethylenediamine 
Tyr tyrosinase 
U unit 
V volt 
vp virus particle 
WT wild type 
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